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Abstract 
Background: Reduced fertility is a common and multifaceted medical and social 
problem affecting about 10-15% of couples in Western countries. Differences in 
prevalence of infertility have previously been published by age and socio-
demographic factors. Infertility treatments are currently widely used to help couples 
suffering from infertility. However, the use of infertility treatments also varies by 
age, education, household income and in some countries ethnicity. For most couples 
infertility is a serious crisis causing significant negative emotional responses. 
Among many patients participating in infertility treatments diagnostic criteria of 
psychiatric disorders, usually anxiety disorder or depression are also fulfilled. For 
some couples the cause of infertility remains unexplained but many females with 
reduced fertility have gynaecological disease such as endometriosis or polycystic 
ovary syndrome causing significant alterations to the body’s hormonal or 
inflammatory balance. During infertility treatments exogenous drugs affecting 
hormone balance are administered. Thus it is important to know whether these 
infertility-causing conditions or hormonal infertility treatments predispose women 
to increased risk for cancer. 
 
Objective:  The purpose of this study was to investigate the prevalence of infertility 
and use of infertility treatments by socio-demographic determinants in Finland. The 
increase of in vitro ferilizations (IVF), intra cytoplasmic sperm injections (ICSI) and 
frozen embryo transfers (FET) over time and the changes in causes of infertility 
behind these treatments were also ascertained. Success of infertility treatments was 
calculated over time using different indicators and success rates by numbers of 
embryos transferred and by care site were compared. The health of a cohort of 
women who received IVF, ICSI or FET was also studied from two perspectives: 
psychiatric disorders leading to hospitalizations were studied both before and after 
infertility treatments and incidence of cancer was studied after treatments. 
  
Materials and Methods: In this study two population surveys FINRISK 1997 and 
2002, Aggregate IVF Statistics and a cohort of women (N=9175) who received IVF, 
ICSI or FET 1996-1998 and their age and residence matched controls were used. 
The cohort was identified through the drug reimbursement records from the Social 
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Insurance Institution. Hospitalizations due to psychiatric diagnoses were obtained 
from the Hospital Discharge Register and cancers from the Finnish Cancer Register.  
 
Results: Self-reported life-time prevalence of infertility was 16%. Prevalence of 
infertility differed significantly by age and education: among the youngest women it 
was more often reported among the least educated, but in older age groups among 
the more educated. Infertility treatment seeking was more common among urban, 
highly educated and affluent women. Number of IVF, ICSI and FET treatments 
provided more than tripled 1992-2004 and the causes of infertility changed 
significantly as tubal infertility became less frequent and male infertility more 
common.  
Clinical pregnancy rates and live birth rates after IVF, ICSI and FET treatments 
remained stable (21-25%) 1994-2005 despite a huge increase in single embryo 
transfers (from 14% to 51%). The proportions of term singletons and singletons 
weighting at least 2500 grams increased from 9% to 14%. Especially at the 
beginning of the follow-up period success rates were better in the private sector than 
in the public sector among women younger than 35 years of age. 
The cohort of IVF, ICSI or FET treated women had fewer hospitalizations for all 
psychiatric diagnoses before infertility treatments than did the controls but the 
difference was statistically significant only for psychotic disorders. After treatments 
during the 8 to 10-year follow-up differences were mainly similar but the women in 
the cohort had statistically significantly more hospitalizations due to adjustment 
disorders and statistically significantly fewer hospitalizations due to alcohol and 
other intoxicant abuse. Those infertile women who gave birth after infertility 
treatments had fewer hospitalizations for all psychiatric diagnoses than those 
infertile women who did not have a baby. 
The general incidence of cancer was similar among the women treated with IVF, 
ICSI or FET and controls. In the cohort of treated women statistically fewer cervical 
cancers and more skin cancers other than melanoma were diagnosed. All lung 
cancer cases occurred among the controls. Ovarian cancer incidence was greater 
among infertile women but the difference was not statistically significant. 
 
Conclusions: The prevalence of infertility differed by age and education and there 
were also socio-demographic differences in the use of infertility treatments. Success 
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rates of IVF, ICSI and FET treatments have remained stable in spite of a significant 
increase of single embryo transfers. There have been differences in success rates by 
care site but this has diminished over time. Women who received IVF, ICSI or FET 
treatments had in general fewer hospitalizations due to psychiatric diagnoses than 
did the controls. Hospitalizations after treatments were also significantly fewer 
among those infertile women who had a baby. General cancer incidence among the 
cohort of infertile women and controls did not differ significantly. There were, 
however, differences in the incidence of cervical cancer, lung cancer and skin 
cancers other than melanoma that suggested a healthy patient effect. 
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Tiivistelmä 
Tutkimuksen taustaa: Heikentynyt hedelmällisyys on yleinen ja moniulotteinen 
lääketieteellinen ja sosiaalinen ongelma, joka länsimaissa koskettaa noin 10-15 
prosenttia pariskunnista. Lapsettomuuden yleisyys vaihtelee aikaisemmin 
julkaistujen tutkimusten perusteella iän ja sosioekonomisten tekijöiden suhteen. 
Nykyään lapsettomuushoitoja käytetään laajasti auttamaan lapsettomuudesta 
kärsiviä pariskuntia. Näiden hoitojen käytön yleisyys kuitenkin vaihtelee iän, 
koulutustason, tulotason ja joissain maissa etnisyyden suhteen. Valtaosalle 
pariskunnista lapsettomuus on vakava kriisi, joka aiheuttaa merkittävästi negatiivisia 
tunteita. Monilla lapsettomuushoitoihin osallistuvilla täyttyvät myös psykiatrisen 
sairauden, useimmiten ahdistuneisuushäiriön tai masennuksen, diagnostiset kriteerit. 
Joidenkin parien lapsettomuuden syy jää epäselväksi, mutta monilla naisilla, jotka 
kärsivät heikentyneestä hedelmällisyydestä, on gynekologinen sairaus - kuten 
esimerkiksi endometrioosi tai munasarjojen monirakkulaoireyhtymä – joka aiheuttaa 
merkittäviä muutoksia elimistön hormonaaliseen tai tulehdukselliseen tasapainoon. 
Lapsettomuushoidoissa myös käytetään lääkkeitä, jotka vaikuttavat 
hormonitasapainoon. Niinpä on tärkeää tietää, altistavatko lapsettomuutta 
aiheuttavat sairaudet tai hormonaaliset lapsettomuushoidot syöpäriskin 
lisääntymiselle. 
 
Tutkimuksen tarkoitus: Tämän tutkimuksen tarkoituksena oli selvittää 
lapsettomuuden ja lapsettomuushoitojen käytön yleisyyttä Suomessa 
sosiodemografisten tekijöiden valossa. Lisäksi kuvataan koeputkihedelmöitysten 
(IVF), siittiön mikroinjektio hoitojen (ICSI) and pakastetun alkion siirtojen (FET) 
määrän lisäystä ajan myötä ja muutoksia lapsettomuutta aiheuttavien diagnoosien 
yleisyydessä. Lapsettomuushoitojen onnistumisaste laskettiin useilla indikaattoreilla 
ja onnistumisastetta suhteessa siirrettyjen alkioiden määrään ja hoitopaikkaan 
verrattiin. IVF-, ICSI- tai FET- hoidoissa olleen kohortin terveyttä tukittiin kahdesta 
näkökulmasta: sairaalahoitoon johtaneiden psykiatristen sairauksien yleisyyttä 
tutkittiin ennen ja jälkeen lapsettomuushoitojen ja syöpätapausten määrää hoitojen 
jälkeen. 
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Aineisto ja menetelmät: Tässä tutkimuksessa käytettiin aineistona kahta 
väestötutkimusta, FINRISKI 1997 ja 2002, IVF Tilastoa, kohorttia naisia (N=9175), 
jotka saivat IVF-, ICSI-, tai FET-hoitoja vuosina 1996-1998 sekä näiden naisten iän 
ja paikkakunnan suhteen vakioituja verrokkeja. Kohortti luotiin käyttämällä 
Kansaneläkelaitoksen lääkekorvausrekisteriä. Sairaalahoitojaksot psykiatrisista 
syistä saatiin Terveyden ja Hyvinvoinnin Laitoksen Hoitoilmoitusrekisteristä ja 
syöpätapaukset Syöpärekisteristä. 
 
Tulokset: Itse raportoituna lapsettomuuden elinaikainen esiintyvyys oli 16 %. Se 
vaihteli merkitsevästi iän ja koulutustason suhteen: nuorimmista naisista vähiten 
koulutetut olivat yleisemmin kokeneet lapsettomuutta, mutta vanhemmissa 
ikäryhmissä lapsettomuus oli yleisempää korkeammin koulutetuilla naisilla. 
Lapsettomuushoitoihin hakeutuminen oli yleisempää kaupunkilaisilla, korkeasti 
koulutetuilla ja varakkailla naisilla. Annettujen IVF-, ICSI- ja FET-hoitojen määrä 
yli kolminkertaistui 1992-2004 ja taustalla olevat lapsettomuuden syyt muuttuivat 
merkittävästi, kun munajohdinperäinen lapsettomuus harvinaistui ja miehestä 
johtuva lapsettomuus yleistyi. 
Kliinisten raskauksien ja elävän lapsen syntymään johtaneiden raskauksien osuus 
IVF-, ICSI- tai FET-hoitojen tuloksena pysyi vakaana (21-25 %) 1994-2005 vaikka 
yhden alkion siirtojen osuus lisääntyi suuresti (14 %:sta 51 %:iin). Täysiaikaisten 
yksisikiöisten raskauksien ja vähintään 2500 grammaa painavien yhden lapsen 
syntymään johtavien raskauksien osuus hoitojen tuloksena kasvoi 9 %:sta 14 %:iin. 
Erityisesti seurantajakson alussa hoitojen onnistumisprosentti oli parempi 
yksityisellä kuin julkisella sektorilla hoidettaessa alle 35-vuotiaita naisia. 
IVF-, ICSI- tai FET-hoitoja saaneiden naisten kohortissa oli ennen 
lapsettomuushoitoja vähemmän sairaalahoitojaksoja kaikkien psykiatristen 
diagnoosien takia, mutta ero oli tilastollisesti merkitsevä vain psykoottisten 
häiriöiden suhteen. Hoitojen jälkeen 8-10 vuoden seurantajaksolla erot pysyivät 
pääsääntöisesti samanlaisina paitsi että lapsettomilla naisilla oli tilastollisesti 
merkitsevästi enemmän sairaalahoitojaksoja sopeutumishäiriöiden takia ja 
tilastollisesti merkitsevästi vähemmän hoitojaksoja alkoholin tai muiden päihteiden 
väärinkäytön takia. Niillä lapsettomilla naisilla, jotka saivat lapsen hoitojen jälkeen, 
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oli kaikkien psykiatristen diagnoosien takia vähemmän sairaalahoitojaksoja kuin 
niillä lapsettomilla, jotka eivät hoitojen jälkeen lasta saaneet. 
Syöpien kokonaisilmaantuvuus oli samansuuruinen IVF-, ICSI tai FET-hoidoissa 
olleilla naisilla ja kontrolleilla. Hoidettujen naisten kohortissa oli tilastollisesti 
merkitsevästi vähemmän kohdunkaulan syöpää ja enemmän muita ihosyöpiä kuin 
melanoomaa. Kaikki keuhkosyövät diagnosoitiin kontrollinaisilla. Munasarjasyövän 
ilmaantuvuus oli suurempaa lapsettomilla naisilla, mutta ero ei ollut tilastollisesti 
merkitsevä. 
 
Johtopäätökset: Lapsettomuuden esiintyvyys vaihtelee iän ja koulutustason 
suhteen ja myös lapsettomuushoitoihin hakeutumisessa on sosioekonomisia eroja. 
IVF-, ICSI- ja FET-hoitojen onnistumisprosentti on pysynyt vakaana vaikka yhden 
alkion siirrot ovat merkittävästi lisääntyneet. Onnistumistuloksissa on ollut 
hoitopaikan suhteen eroja, jotka ovat ajan myötä pienentyneet. IVF-, ICSI- tai FET-
hoitoja saaneilla naisilla oli yleisesti ottaen vähemmän sairaalahoitojaksoja 
psykiatrisista syistä kuin kontrollinaisilla. Hoitojen jälkeen lapsen saaneilla oli myös 
merkittävästi vähemmän hoitojaksoja. Syövän kokonaisilmaantuvuudessa ei 
lapsettomilla naisilla ja kontrolleilla ollut merkitsevää eroa. Kohdunkaulan syövän, 
keuhkosyövän ja muiden ihosyöpien kuin melanooman ilmaantuvuudessa havaitut 
erot kuitenkin viittaavat niin sanottuun ”terve potilas” –ilmiöön. 
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1. Introduction  
The European Society on Human Reproduction and Embryology (ESHRE) has 
defined infertility as a serious handicap preventing people from realizing an 
important life goal. Infertility treatments in turn allow these people to express their 
autonomy by realizing their reproductive choices thus increasing their well-being 
(Pennings et al. 2008).  
 
Infertility directly affects about one out of six couples (Evers 2002, Gnoth 2005) 
and indirectly affects a much larger group of family members, friends and in many 
cases also colleagues and supervisors at work. To people suffering from infertility 
the experience is likely to cause a significant amount of stress and grief and even 
expose to mental problems. Conditions causing infertility and infertility treatments 
may also, fortunately seldom, cause potentially serious somatic side-effects and later 
probably expose to some types of cancer. 
 
This study aimed to investigate many different aspects of reduced fertility and the 
use of infertility treatments.  The prevalence of infertility and the use of infertility 
treatments were studied and the success of infertility treatments was evaluated. 
 
The health of a cohort of women who received IVF, ICSI or FET treatments 1996-
1998 was studied from two different perspectives. Firstly, severe psychiatric 
morbidity of these women was evaluated before and after the need for infertility 
treatments comparing the number of hospitalizations due to psychiatric diagnoses to 
that of control women. Secondly it was studied whether this cohort of IVF, ICSI or 
FET treated women had more cancers than did control women. 
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2. Review of literature 
2.1 Infertility 
2.1.1 Definitions and prevalence of infertility 
Europe is the continent with the lowest fertility rate. The total fertility rate, TFR, 
which is calculated as a sum of age-specific fertility rates of a current year, is the 
lowest (less than 1.54) in the Eastern European countries such as Belarus, Ukraine 
and Russia and in Southern European countries Greece, Italy and Spain. The highest 
TFRs exceeding 2.0 needed to approach the population replacement levels are in 
Northern European countries Norway, Iceland and Denmark and in Ireland, France 
and Turkey (The ESHRE Capri Workshop Group 2010). In Finland the current TFR 
is 1.84 (Miettinen & Rotkirch 2008).  This decline in total fertility rate is a result of 
numerous socio-cultural, political, economical, educational, religious and medical 
factors. The increase in actual incidence of infertility explains this decline less. 
However, as more and more couples postpone childbearing, the risk of infertility 
increases as a result of natural decline in fertility (The ESHRE Capri Workshop 
Group 2010). 
 
According to the most widely used definition, a couple is considered infertile when 
a pregnancy has not begun after one year of unprotected sexual intercourse (Evers 
2002, Gnoth 2005). For each couple the monthly fecundity rate varies. However, it 
has been estimated that 80% of couples conceive within 6 months and 50% of the 
remaining couples within the following 6 months (Gnoth 2003, Wang 2003). Even 
among couples regarded as infertile by definition, the spontaneous pregnancy rate 
within the following 12 months is up to 50% (Evers 2002).  
 
The prevalence of infertility is most often studied as current prevalence or as life-
time prevalence, which is a cumulative prevalence until the time of the study 
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(Schmidt & Münster 1995). Worldwide the current prevalence of infertility is over 
70 million couples (Boivin 2007, Ombelet 2008). Infertility is particularly common 
in Sub-Saharan Africa, where the prevalence is up to 30% mainly due to sexually 
transmitted diseases, poor health care and female genital mutilation (Pennings 
2009). Infertility can be divided into primary or secondary infertility depending on 
whether a couple has had a previous pregnancy (Nguyen & Wilcox, 2005) 
 
In a meta-analysis consisting of studies published 1970-1992 Schmidt and Münster 
concluded that the current prevalence of infertility was 3.6-14.3% and life-time 
prevalence in turn 12.5-32.6%. A more recent meta-analysis included data from 25 
population studies published since 1990 (Boivin 2007). According to this study the 
current prevalence of infertility was in developed countries 3.5-16.7% and in less 
developed countries 6.9-9.3%. Life-time prevalence varied in developed countries 
between 6.6-26.4% and in less developed countries between 1.3-25.7%. According 
to a Finnish population survey that was not included in the meta-analysis by Boivin 
et al. (2007) life-time prevalence of infertility was 16% (Malin et al. 2001). This 
variation can at least partly be explained by differences in the populations studied 
(entire study population regardless of desire to become pregnant, married women, 
women, who have given birth etc.) 
 
A woman’s age and the duration of childlessness are the most significant factors 
determining fertility (Evers 2002). A Swedish study estimated factors affecting time 
to pregnancy. The age of a woman, prior use of oral contraceptives, parity and 
length of menstrual cycle were significant affective factors and explained 14% of 
variation in time to pregnancy (Axmon 2006). Woman’s age is estimated to start to 
have a negative effect on fertility from the late 20’s onward. A study investigating 
the day-specific probability of pregnancy found that the probability of pregnancy 
was twice as high for women aged 19-26 years compared to that of women aged 35-
39 years (Dunson 2002). 
 
There have been contradictory reports about changes in the prevalence of infertility 
over time. According to a study conducted in Scotland, the prevalence of infertility 
had not increased in 20 years (Bhattacharya et al. 2009). Another study in Iran 
(Safarinejad et al 2008) in turn found that the prevalence of infertility had risen from 
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2.6% to 5.5% in the period 1985-2000. Chandra and Stephen (1998) reported that in 
the United States impaired fecundity rose from 8% to 10% 1982-1995. The same 
authors, however, found out that among married women prevalence of infertility 
declined from 8.5% to 7.4% in the period 1982-2002 (Stephen & Chandra 2006). 
This study has, however, been criticized because of methodological and definitional 
weaknesses (Thorton & Goldman 2006, Guzick & Swan 2006, Olive & Pritts 2006) 
 
A Swedish population survey suggests that infertile women are less educated than 
women with no fertility problems (Wulff et al. 1997). Similar data has been reported 
from the United States (Jain & Hornstein 2005, Bitter et al. 2006) where infertility is 
significantly more common among women with little education as well as among 
African Americans and Hispanic women compared with Caucasian women. 
However, opposite results have been published - according to a Norwegian 
population study infertility was more common among highly educated women 
(Rostad et al. 2006) 
2.1.2 Causes of reduced fertility 
The most common conditions causing impaired fertility among females are 
ovulation and menstrual cycle disturbances, tubal obstruction, pelvic adhesions and 
endometriosis. In ovulation and menstrual cycle disturbances the problem may be 
central: either low follicle stimulating hormone (FSH) secretion which in turn 
causes low oestrogen secretion or elevated prolactin secretion that down regulates 
FSH and oestrogen secretion. Decreased ovarian reserve also causes infertility: this 
state is hypergonadotrophic but hypo-oestrogenic. If a problem in turn is on the 
hypothalamo-pituitary-ovarian axis, the hormone status may be 
normogonadotrophic, normo-oestrogenic and normoprolactenemic (Evers 2002).  
 
Poor semen quality and hormonal disturbances are the most important reasons 
causing reduced fertility among men. The semen analysis gives information on the 
concentration, motility, morphology and viability of sperm. Other factors such as 
antisperm antibodies can also be studied (Agarwal et al. 2008). Other reasons for 
male infertility are anatomical disturbances such as absence of vas deferens and 
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seminal vesicles, varicocele, obstruction of vas deferens or genetic disorders such as 
Klinefelter syndrome or chromosome Y microdeletions (Bhasin 2007, Jarow 2007, 
Sarkar et al. 2007, Sussman et al. 2008). Hormonal states causing male infertility 
may be gonadotrophin deficiency (characterized by low testosterone concentration 
and low or normal gonadotrophin concentration), primary testicular failure (low 
testosterone and elevated gonadotrophin concentration), sertoli cell only syndrome 
(normal testosterone and LH, but elevated FSH concentration) or partial androgen 
resistance (high testosterone and LH concentration) (Bhasin 2007). 
 
Among both males and females many chronic diseases and lifestyle factors may 
impair fertility. Women with diabetes mellitus may suffer from oligomenorrhea or 
secondary amenorrhea when glycaemic control is bad (Livshits & Seidman 2009). 
Among diabetic men in turn the risk for sexual disorders such as impotence, 
retrograde ejaculation, low serum testosterone levels and poor semen quality are 
increased (Amaral et al. 2008). Hypothyroidism and hyperthyroidism cause 
alteration in serum sex hormone binding hormone (SHBH) and thus in sex hormone 
levels in both sexes. Hypothyroidism may cause abnormalities in sperm morphology 
and among females causes oligomenorrhea. Hyperthyroidism in turn may impair 
sperm motility and predispose women to hypomenorrhea or polymenorrhea. 
Autoimmune thyroid disease is more common among females attending infertility 
clinics (Krassas et la. 2010). A recent meta-analysis suggests that the presence of 
thyroid antibodies was associated with increased risk for unexplained infertility 
(Van der Boogard et al. 2011). 
 
Chronic gastroenterological illnesses may cause fertility problems. Population 
studies indicate that general fertility rates among females with inflammatory bowel 
disease (Crohn’s disease or colitis ulcerosa) is similar to that in general population. 
However, among those patients who have undergone surgery fertility rates are 
poorer (Moscandrew & Kane 2009). Untreated coeliac disease may cause impaired 
fertility (Soni & Badawry 2010, Ozgor & Selimoglu 2010). 
 
Common lifestyle factors impairing fertility are obesity and smoking. Obese women 
are at risk of developing insulin resistance that causes ovulation problems and other 
indirect fertility problems probably via metabolic, inflammatory and immunological 
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changes. Among obese men serum testosterone levels may be lower which may 
affect sperm production. Underweight women may have FSH and LH deficiency 
leading to ovulation problems. Smoking has negative effects on fertility. It decreases 
sperm count and motility and among women accelerates dissipation of eggs and 
may have negative effects on the zona pellucida around the egg as well as on the 
endometrium (Anttila 2008, Dondorp et al. 2010). 
2.2 Infertility treatments 
2.2.1 Definitions and details of the methods 
The most common infertility treatments are ovulation induction with or without 
insemination, in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI) 
and frozen embryo transfer (FET). Fertility can sometimes be improved surgically 
when for example varicocele, leiomyoma or endometriosis is operated. Weight 
reduction or cessation of smoking may reduce the need of infertility treatments and 
improve the outcomes of these treatments (Luke et al. 2011, Waylen et al. 2009, 
Dondorp et al. 2010).  
 
Ovulation induction with drugs can be used alone to treat women suffering from 
ovulation problems or it can be combined with insemination. Clomiphene citrate is 
the most commonly used drug to induce ovulation. Clomiphene citrate is an anti-
oestrogenic compound that induces follicle growth by preventing negative feedback 
caused by oestrogen to production of gonadotrophins. Thus the secretion of FSH, 
LH and oestrogen increases and the peak of LH secretion induces ovulation. 
 
A more novel class of drugs used to induce ovulation is so called aromatase 
inhibitors. These drugs prevent the natural conversion of androgens to oestrogens by 
aromatase enzymes thus decreasing body’s oestrogen levels. Clomiphene citrate and 
aromatase inhibitors are administered orally. 
 
Ovulation can also be induced by drugs that are injected subcutaneously or 
intramusculary. Exogenous FSH or human menopausal hormone, HMG, can be used 
20 
to mature single follicles or to cause hyperstimulation for IVF or ICSI cycles. 
Human chorionic gonadotrophin, hCG, is usually used in combination with FSH or 
HMG and it mimics the effects of the endogenous LH (Pharmaca Fennica, 2011).  
 
In intra uterine insemination procedure (IUI) the semen is inserted into the uterus 
using a catheter. Before the procedure the semen is washed i.e. the un-motile 
spermatozoa and most other components of the seminal fluid are removed.  
 
In IVF and ICSI protocol woman’s menstrual cycle is regulated by drugs and the 
goal is to achieve regulated ovarian hyperstimulation to produce multiple follicles. 
The normal, endogenous function of the ovaries is inhibited by administering either 
gonadotrophin releasing hormone, GnRH, agonists or antagonists. Exogenous FSH 
is usually used to stimulate the growth of follicles. The maturation of eggs is 
regularly monitored using ultrasonography and when the desired maturation of the 
follicles is achieved, hCG is injected to complete the ovulation process. After hCG 
injection follicles are harvested from the ovaries before spontaneous ovulation 
occurs. 
 
In IVF procedure the eggs are separated and fertilized in a petri dish by washed 
semen. In ICSI procedure a single sperm is injected into the egg. Normally the 
fertilized embryos are cultured until 4-8 cell stage but longer cultivation time until 
blastocyst phase can also be used. Thereafter the embryo or two embryos are 
transferred into the uterus with a catheter. Vaginal progesterone is used as support 
treatment usually until gestational weeks 9-11. (Pharmaca Fennica). 
 
Normally IVF or ICSI cycles produce more good quality embryos that are 
transferred. These embryos are frozen and used in later treatment cycles (FET). FET 
can be done on a woman’s natural menstrual cycle or after administration of 
oestrogen and progesterone. 
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2.2.2 Use of infertility services 
In Western countries 44-73% of infertile couples seek medical help (Schmidt et al 
1995, Buckett & Bernstick 1997, Chandra & Stephen 1998, Stephen & Chandra 
2000, Moreau et al. 2008, Bhattacharya et al. 2009). According to a meta-analysis 
by Boivin et al. (2007) the proportion of infertile couples seeking medical help in 
less developed countries varies between 27-74%. The proportion of couples actually 
receiving infertility treatments, however, is smaller, in Western countries 43-74% of 
help seeking couples (Buckett & Bernstick 1997, Stephen & Chandra 2000, Moreau 
et al. 2008). The reasons why infertile couples do not seek medical help can be 
classified as financial, medical, psychosocial, moral or ethical (Dawson et al. 2005). 
 
Research indicates that the use of infertility treatments is affected by socio-
demographic factors. Participation is more common among older, more educated, 
wealthier and married women (Schmidt et al. 1995, Wulff et al. 1997, Stephen & 
Chandra 2000, Bitter et al. 2006, Moreau et al. 2008). Studies from the United 
States indicate that participation is significantly more common among Caucasian 
women than among African American or Hispanic women (Stephen & Chandra 
2000, Jain & Hornstern 2005, Chandra & Stephen 2008) as well as among those 
who have private health insurance (Chandra & Stephen 2008). A population based 
survey on the lifetime prevalence of infertility and infertility treatments among 
women aged 40-55 conducted in the United Kingdom demonstrated that the 
youngest women had statistically more infertility treatments than the older ones 
even though the prevalence of infertility itself was similar (Oakley et al. 2008). 
 
In Finland differences in seeking medical help for infertility have been reported. 
One study found that women who did not seek help were younger, had fewer years 
of formal education and had tried to become pregnant for a shorter time period than 
the treatment-seeking women (Malin et al. 2001). In two other studies a higher ratio 
of seeking of medical help was found among more educated women (Gissler et al. 
1995) and among those with a better socio-economic position (Silverio et al. 1996). 
The utilization of infertility services varies by residence: the age-standardized IVF 
incidence per thousand women aged 20 to 49 was 7.3 in rural and 8.8 in urban areas 
(Klemetti et al. 2004).  
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2.2.3 Practices of infertility treatments in Finland 
It is recommended that a couple suffering from fertility problems first visit a 
primary care physician or a private gynaecologist who interviews and examines 
them. Important patient history includes general health, chronic illnesses and 
medications, surgeries, possible previous pregnancies, history of sexually 
transmitted diseases, frequency of sexual intercourse, smoking, intoxicant use, 
weight, physical activity and nutrition. Gynaecological examination should be 
performed and blood pressure and height, weight and waistline circumference 
should be measured. The first line medical tests for possible causes of fertility 
problems include papanicolaou smear, a test to detect Chlamydia trachomatis, blood 
haemoglobin, prolactin and thyreotrophin (TSH). Sperm analysis and a test for 
Chlamydia trachomatis are performed on males. HIV and hepatitis B and C 
antibodies are evaluated in both partners. 
 
Prior possible infertility treatments gynaecological ultrasound and, if semen quality 
is good, hysterosalpingo-sonography should be performed. With gynaecological 
ultrasound, for example, uterine leiomyomata, polyps, adhesions or uterine septi 
may be detected. Ovaries are studied and possible cysts, endometriomas and 
tumours may be diagnosed. The size of the ovaries and the number of growing 
follicles (antral follicle count) can be estimated. Possible hydrosalpinx may also be 
detectable. With hysterosalpingo-sonography in turn the openness of the tubes can 
be ensured. 
 
There are a few possible ways to estimate the occurrence of ovulation. The peak in 
LH secretion can be detected from urine 1 or 2 days prior to ovulation. The elevated 
serum progesterone level is an indicator of ovulation having occurred. Estimates can 
be made with gynaecological ultrasound. Typical follicle is about two centimetres in 
diameter before ovulation. The structure of the endometrium changes after ovulation 
and this can be detected with ultrasound (Nuojua-Huttunen & Anttila 2009). 
 
The World Health Organization (WHO) has published a manual on examining of 
semen samples. According to this manual, in normal sperm sample the number of 
sperm should exceed 39 million per ejaculate and total volume of ejaculate should 
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be at least 1.5 millilitres. At least 40% of sperm should be motile and 32% of sperm 
should move progressively. The proportion of viable sperm should exceed 58% and 
at least 4% of sperm should have normal morphology (WHO Manual for the 
Examination and Processing of Human Semen, 2010). The most important factor 
predicting male fertility is the number of motile sperm. However, it has been 
demonstrated that sperm analysis alone has poor power to predict future fertility 
(Lewis, 2007). 
 
Other indicators are also studied in a semen sample. The agglutination of the sample 
may be an indication of antisperm antibodies that can impair fertility. The presence 
of excess white blood cells may explain fertility problems due to chronic infection 
such as chronic prostatitis (Nuojua-Huttunen & Anttila 2009). After the preliminary 
examinations and tests the need for infertility treatments can be estimated in a public 
or private infertility clinic if a couple wants to receive infertility treatments. 
 
In Finland infertility treatments are given in seven public hospitals (in all five 
university hospitals and in central hospitals in Jyväskylä and Joensuu). In addition 
there are thirteen private clinics: four in Helsinki, two in Turku and Tampere and 
one in Kuopio, Oulu, Lappeenranta, Kotka and Jyväskylä. 
 
Infertility treatments were given in Finland without legislation for over twenty 
years. An act on assisted fertility treatments came into force on 1 September 2007. It 
stipulates that infertility treatments can be given to married couples, to unmarried 
cohabitants, to female couples and to single women. All clinics that provide 
infertility services and store gametes or embryos have to have a permission granted 
by The National Supervisory Authority for Welfare and Health (Valvira). Another 
permit from the National Agency for Medicines is also required. A written and 
signed consent form (hoitosuostumus) must be completed before treatments. It is not 
allowed to provide infertility treatments if a pregnancy would be a significant risk to 
the health of either the mother or the child or if it is evident that the parents could 
not offer a safe childhood.  
 
The law requires that all donors of gametes must give their identification to a 
register maintained by Valvira. If a child born after the use of these gametes so 
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wishes, s/he can obtain information on the donor after turning 18 years 
(22.12.2006/1237, Finlex, http://www.finlex.fi/fi/laki/ajantasa/2006/20061237) 
 
In 2009 Ministry of Social Affairs and Health published guideline on how to 
provide infertility services. The guideline emphasize that only effective treatments 
should be provided in public infertility clinics and thus the success rate should be 
estimated to be at least 10%. In given conditions such as poor ovarian response to 
gonadotrophins or severe uterine malformation infertility treatments should not be 
provided in the public sector. A woman’s age (39 years or more) or three or more 
unsuccessful prior IVF or ICSI treatments are exclusion criteria. The guidelines also 
recommend that if a couple suffering from secondary infertility has already two or 
more common children or has undergone sterilization infertility treatments should 
not be offered in the public sector (Uniform criteria for access to non-emergency 
treatment, 
http://www.stm.fi/c/document_library/get_file?folderId=2593921&name=DLFE-
13802.pdf) 
2.2.4 Data collection on infertility treatments 
In Finland statistics on the use of infertility treatments have been compiled since 
1992. The data was first gathered by Helsinki University Central Hospital and since 
1994 by the National Institute for Health and Welfare (THL, formerly the National 
Research and Development Centre for Welfare and Health, STAKES). The statistics 
consist of aggregate data on all IVF, ICSI and FET treatments and since 2006 of 
inseminations and since 2001 about donor gamete cycles (THL, 
http://www.stakes.fi/FI/tilastot/aiheittain/Lisaantyminen/hoidot/index.htm). 
 
The European Society on Human Reproduction and Embryology (ESHRE) was 
founded in 1985 to stimulate the research on reproductive medicine. ESHRE 
currently promotes clinical practices and develops and maintains data registries 
(ESHRE, http://www.eshre.eu/home/page.aspx/2). The European IVF monitoring 
program (EIM) was founded in 1997 and since 1999 thirty European countries have 
reported data about IVF treatments. The number and outcomes of treatment cycles 
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and side-effects of treatments, availability of services and well-being of children are 
recorded. Reports on the results of this data collection have been published since 
2001 (ESHRE, http://www.eshre.eu/ESHRE/English/Specialty-Groups/Data-
collection-Consortia/European-IVF-Monitoring-EIM-/page.aspx/281 ) 
 
In the United States Centers for Disease Control and Prevention (CDC) has a 
division concentrating on reproductive health. It has been mandatory since 1992 for 
all infertility clinics to report all procedures conducted to CDC, which publishes 
reports annually. Unlike, for example, in Finland in these US reports clinic-specific 
success rates are published (CDC, http://www.cdc.gov/art/ARTReports.htm). 
2.2.5 Infertility treatments worldwide 
The uses and practices of infertility treatments vary between different countries. The 
European Society of Human Reproduction and Embryology has published ten 
reports on the use and success of infertility treatments in Europe. The most recent 
study reporting data from 2006 was published in 2010. According to this report the 
proportion of infants born as a result of infertility treatments was lowest in 
Montenegro (0.8%), Italy and Latvia (1.0%) and highest in Denmark (4.1%), 
Slovenia (3.6%) and Iceland (3.4%). In total 850 cycles were performed per 1 
million inhabitants (de Mouzon et al. 2010). 
 
The overall clinical pregnancy rate per embryo transfer was 32-33% after IVF and 
ICSI. After IVF and ICSI the distribution on transfers of one, two, three and four or 
more embryos was 22.1, 57.3, 19.0 and 1.6% respectively, but there is wide 
variation between countries. In general in Northern Europe countries and in 
Belgium single embryo transfers are common (35-69% of all transfers). In Eastern 
and Southern Europe transfers of three or four embryos are still commonly used (up 
to 85% of all transfers in Albania). Understandably the proportion of multiple 
pregnancies varies. The proportion of twin deliveries is between 5.7% (in Sweden) 
and 38.3% (in Serbia) and the proportion of triplet deliveries between 0% (in 
Finland and Montenegro) and 14% (in Albania). The general trend was however the 
small decrease in number of embryos transferred (de Mouzon et al. 2010).  
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Comparisons between the use of IVF, ICSI and FET between the United States and 
Europe have been made (Gleicher et al. 2006, Gleicher et al. 2007). The problem 
with these comparisons is that Europe is analysed as a whole despite the variation 
between countries. In 2001 the aggregate clinical pregnancy rate for all European 
countries was 24% and live birth rate 17%. In the United States clinical pregnancy 
rate in 2001 was 33% and live birth rate 27% (Gleicher et al. 2006). In 2002 the 
difference was even larger as clinical pregnancy rate was 29% in Europe and 42% in 
the United States. However, during those years, the treatment protocols were 
different between the United States and Europe as whole. In Europe in 2002 single 
embryo transfers were quite rare but conducted anyway in 13.7% of cycles 
compared to 6.7% in the United States. The proportion of two embryo transfers was 
54.8% in Europe and 31.6% in the United States. Three embryos were transferred in 
26.8% of cycles in Europe and 33.6% in the United States. The proportion of four 
embryo transfers in the United States was in 2002 still huge: 28.1% compared to 
4.7% in Europe (Gleicher et al. 2007). Also, during those years it was more 
common in the United States to select embryos, conduct oocyte donation cycles and 
perform genetic diagnosis prior to implantation (Gleicher et al. 2006). The 
proportion of multiple pregnancies was significantly higher in the United States 
(36.2%) than in Europe (24.9%) (Gleicher et al 2007). 
 
One recent study (Baker et al. 2009) aimed to compare success rates between 
infertility clinics in the United States and Europe that participated in clinical trials 
with similar protocols and inclusion criteria. One obvious problem with the 
interpretation of this comparison was the fact that Europe was represented by France 
and Hungary alone. In any case, the number of embryos transferred was similar and 
the patients were slightly older in the United States. However, both clinical 
pregnancy rate (43.4% in the United States and 29.7% in France and Hungary) and 
live birth rate (38.2% in the United States and 30.4% in France and Hungary) were 
significantly better in American clinics. The only difference between protocols was 
larger starting dose of gonadotrophins in the United States and significantly greater 
number of embryos transferred in blastocyst phase (26% in the United States and 
2.2% in Europe).  
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2.2.6 Costs and funding of infertility treatments 
The costs of infertility treatments consists of direct costs including physician’s and 
nurse’s services, medications, laboratory tests, ultrasound scans, the ART procedure 
itself, hospital charges and administrative costs. Immediate indirect costs are losses 
of working hours and travel costs and are generally regarded as low. However, 
much more significant possible indirect costs come from hospitalization fees of 
pregnant women and their premature infants in case of multiple pregnancies as a 
result of infertility treatments (Ata & Seli 2010).  
 
The direct costs of infertility treatments in different countries have been compared. 
Chambers et al. (2009) studied the costs of IVF treatments in the United States, 
Canada, the United Kingdom, Japan, Australia and Scandinavia as whole in 2003. 
They found that there was a vast variation in both prices of treatment cycles and in 
expenditure per live birth. The standard IVF cycle was most expensive in the United 
States, more than 12,500 dollars (in 2006 US dollars), and the cheapest in Japan 
about 3,950 US dollars. In the United States the costs of a single IVF cycle 
amounted to 44% of annual income of a single worker earning 100% of average 
earnings after taking account of average insurance coverage. In Japan this relative 
cost for a patient was the lowest, 14%. Costs per live birth were also highest in the 
United States and the United Kingdom, exceeding 40,000 US dollars and lowest in 
Scandinavia and Japan, exceeding 24,000 US dollars. The writers concluded that the 
costs of infertility treatments reflect the costliness of the entire healthcare system 
rather than the regulatory or funding policies and that only in countries with the 
smallest patient out-of-pocket expense the demand for infertility treatments met the 
need of these treatments (Chambers et al. 2009).  
 
German researchers studied opinions on fair payment policies for infertility 
treatments among infertile patients, the general public and professionals working in 
infertility clinics. According to this study in all groups studied most of respondents 
were in favour of public coverage of infertility treatments. Opinions about patient’s 
co-payment differed between groups: only around 30% of infertile patients 
supported this but the proportion was substantially larger among professionals 
(around 70%) and the general public (around 75%). Generally the respondents 
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thought that the amount of appropriate patient co-payment should be 15-25% 
instead of the actual 50% in Germany (Rauprich et al. 2010). 
 
The costs of infertility treatments may be partially or completely funded by a public 
health care service or private insurer or paid completely by the patient. Comparisons 
of the use and results of infertility treatments in different funding environments have 
been published. One study (Navarro et al. 2008) compared funding strategies in the 
United States and in certain European countries (Belgium, Denmark, Finland, 
France, Germany, the Netherlands, Norway, Sweden, Switzerland, and the United 
Kingdom). This paper concluded that the states with either partial or complete 
public coverage for infertility treatments had statistically significantly more 
infertility clinics per million inhabitants and significantly more treatment cycles 
were also performed. The number of ART pregnancies per million inhabitants was 
almost threefold in the states with complete public funding compared to states with 
no funding. On the other hand the funding system has the opposite effect on the 
number of treatment cycles needed to achieve a live birth as in the states with partial 
or complete public coverage systems significantly more treatment cycles were 
needed. As expected from this, the number of embryos transferred as well as the 
proportion of multiple pregnancies, were substantially larger in the states with no 
public funding. The results from the states with private coverage were in between of 
those from states with no coverage and those with public coverage (Navarro et al. 
2008). 
 
In these comparisons, however, the costs caused by hospitalizations of premature 
neonates have not been taken into consideration. A study conducted in Belgium 
compared costs after single and double embryo transfer (DET) and clearly 
demonstrated that average neonate costs were significantly (p<0.001) higher after 
DET (Gerris et al. 2004). According to a recent American study 48% of neonates 
born after infertility treatments were born as a part of multiple infant delivery and 
62% of twins and 97% of triplets were delivered preterm. A mean cost of one 
preterm infant was 51,600 US dollars and the authors estimated total financial 
burden caused by these preterm neonates is 1 billion US dollars annually (Bromer et 
al. 2011) 
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Studies from different states in the United States indicate that the availability and 
utilization of infertility treatments are higher in the states with private insurance 
coverage (Henne & Bundorf 2008, Hammound et al. 2009). A report from Germany 
studying the effects of a law increasing patient’s out-of-pocket payment clearly 
demonstrates that the utilization of infertility treatments is partly dependent on 
financial accessibility. The reduction in use of infertility treatments was statistically 
significantly greater in economically weaker areas (Griesinger et al. 2007). 
 
The European Society on Human Reproduction and Embryology recommends that 
in affluent societies infertility treatments should be at least partly publicly funded. 
This funding should be considered in a structural way including efficiency, safety 
and equality and it is just to fund a fixed number of treatment cycles. They also 
conclude that the practitioners providing infertility treatments have a moral 
obligation towards both their patients and the entire health care system to reduce the 
costs of infertility treatments as far as reasonably possible (Pennings et al. 2008) 
2.2.7 Measurement of success of infertility treatments 
It is naturally important to have reliable estimates of success with infertility 
treatments. However, there is still debate about the most accurate indicators. 
Traditionally used indicators are implantation rate, clinical pregnancies per cycle 
and live birth delivery rate (Davies et al. 2004, Schieve et al. 2004). The problem 
with these indicators is that they emphasize the effectiveness of treatments but do 
not take safety aspects into the consideration.  
 
Two quite similar indicators emphasizing the importance of the durations of 
pregnancies and preference for singleton pregnancies have been suggested. Min et 
al. (2004) introduced the concept of BESST (Birth Emphasizing a Successful 
Singleton at Term) and The European IVF Monitoring Consortium suggested as an 
indicator “singleton delivery rate per embryo transfer” (Nyboe Andersen et al. 
2004). 
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It has also been recommended that instead of one indicator several endpoints should 
be considered simultaneously (Davies et al. 2004, Schieve et al. 2004, Pinborg et al. 
2004). Pinborg et al. (2004) suggested the use of three parameters to measure the 
success of infertility treatments: number of oocytes per aspiration is a pre-in vitro 
parameter, number of ongoing implantations per embryo transfer is an in vitro 
parameter and number of deliveries per embryo transfer is a post-in vitro parameter. 
 
As the proportion and number of elective single embryo transfers has increased 
significantly, the importance of indicators concentrating on cumulative probability 
of pregnancies has also risen. Tiitinen et al. (2004) and Lundin & Bergh (2007) have 
suggested utilization of cumulative delivery rate per stimulated cycle after all fresh 
or frozen embryo transfers from the same oocyte retrieval and Veleva et al. (2009) 
cumulative birth rate per woman. 
 
In recent years relatively large studies investigating elective single embryo transfers 
(eSET) compared to two embryo transfers have been published. These studies 
indicate that cumulative pregnancy rate after elective single embryo transfers is 
comparable to that of two embryo transfer and that the multiple pregnancy rate is 
largely decreased (Vilska et al. 1999, Thurin et al. 2004, Lundin & Bergh 2007, 
Bechoua et al. 2009, Fauque et al. 2009, Veleva et al. 2009, Stillman et al. 2009). A 
Finnish study by Vilska et al. (1999) compared success rates after elective single 
embryo transfers, single embryo transfers when only one embryo was available and 
two embryo transfers. Pregnancy rates were similar in the elective single embryo 
transfer group (29.7%) and the two-embryo transfer group (29.4%) and poorer in 
single embryo transfer group with only one embryo available (20.2%). Pregnancy 
rates among younger women (under 35 years) in the elective single embryo transfer 
group were significantly higher than among women aged over 35 years (32.5% 
versus 18.8%). The quality of embryos significantly affected on pregnancy rates 
(Vilska et al. 1999). 
 
Thurin et al. (2004) studied cumulative pregnancy rates among women under 36 
years old with at least two good quality embryos. The pregnancy rate after fresh 
single embryo transfer was 27.6% and after two embryo transfer 42.9%. After 
possible frozen embryo transfer the cumulative pregnancy rate in the single embryo 
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group was 38.3% and did not differ significantly from the pregnancy rate after fresh 
two-embryo transfers. Multiple pregnancy rate was evaluated and it was, as 
expected, vastly decreased in the single embryo transfer group (0.8% versus 33.1%) 
(Thurin et al. 2004).  
 
In the study by Lundin and Bergh (2007) cumulative pregnancy rate was similar: 
34.8% in the elective single embryo transfer group and 33.5% if two embryos were 
transferred. A recent French study reports similar findings: among women aged 
under 35 years with at least three high quality embryos participating in their first 
treatment cumulative cycle live birth rate after fresh and frozen embryo transfers 
was 60.8% in the single and 60.5% in the double embryo transfer groups (Bechoua 
et al. 2009). 
 
In another French study on elective single embryo transfers cumulative pregnancy 
rate was even higher among women with single embryo transfers (54.7%) than 
among women with double embryo transfers (49.0%) but this difference was not 
statistically significant. The participants of this study were under 36 years old, 
participating in their first or second IVF or ICSI treatments and had adequate 
ovarian function and at least two top embryos (Fauque et al. 2009). 
 
A recent Finnish study aimed to compare success rates in 1995-1999 when elective 
single embryo transfers were rarely used (4.2% of all) and in 1999-2004 when their 
proportion was 42.6% of all transfers. During the period 2000-2004 all indicators 
studied - the cumulative pregnancy rate per oocytes pickup (38.2 versus 33.1%), 
cumulative live birth rate per oocytes pickup (28.0 versus 22.5%) and cumulative 
live birth rate/woman (41.7 versus 36.6%) - were better than in 1995-1999. All 
differences were statistically significant. Multiple birth rate also decreased 
significantly (8.9% in 2000-2004 and 19.6% in 1995-1999) (Veleva et al. 2009). 
 
The European Society on Human Reproduction and Embryology has recommended 
wider used of single embryo transfers since 2001 and The American Society for 
Reproductive Medicine since 2006. Despite this, elective single embryo transfers 
are commonly used only in some European countries, on the largest scale in 
Finland, Sweden and Belgium (Veleva 2008). In Sweden and Belgium preference 
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for elective single embryo transfers is recommended in law (Nyboe Andersen et al. 
2007). In Finland this change in treatment protocols has been made by clinics. 
 
In Finland elective single embryo transfers (eSETs) are particularly common when 
performing frozen embryo transfers. According to the latest data from 2009, the 
share of eSETs was 61.7% of all frozen embryo transfers. In fresh IVF and ICSI 
cycles the share is smaller but significant: 46.5% in 2009. Especially in the case of 
fresh IVF or ICSI cycles there are, however, some differences in the treatment 
protocols between the public and the private clinics: in 2009 single embryo was 
electively transferred in 51.8% of cycles in the public sector and 43.3% of cycles in 
the private sector. For frozen embryo transfers the difference was significantly 
smaller: 63.2% and 60.6%, respectively (THL, Statistics on Assisted Fertility 
Treatments, unpublished statistics, 2011). 
 
Strategies using elective single embryo transfers have been criticized as well. 
Gleicher and Barad (2006) wrote that elective single embryo transfers are suitable 
for only a small minority of IVF patients and arguments favouring eSETs appear 
unrealistic and should be reconsidered. 
2.3 Health of women before and after infertility 
treatments 
2.3.1 Psychiatric disorders and fertility  
The effects of long-term psychiatric disorders, especially mood and psychotic 
disorders, on fertility and number of children have been widely studied. Fertility 
among women with psychotic disorders may be affected by the disorder itself, 
medications or social factors like the probability of a stable relationship. 
Epidemiological studies indicate that fertility among women with schizophrenia is 
lower than in controls or unaffected siblings of patients (Fananas et al. 1995, 
Howard et al. 2002, Haukka et al. 2003, Howard 2005, MacCabe et al. 2009) and 
the number of children among parous patients is reduced (Nimgaonkar et al. 1997, 
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McGrath et 1999). However this difference has diminished over time as a greater 
proportion of patients is treated on an outpatient basis (Howard 2005).  
 
It is not known whether nulliparous women with schizophrenia do not want to have 
children or are actually infertile. A person may become ill with a psychotic disorder 
at any age but, for example, incidence of schizophrenia peaks among women 
between 25-35 years (Rajji et al. 2009). Thus many patients have to struggle with 
the fact that they have not yet become parents and the decision to try to become 
pregnant has to be made knowing that they will be afflicted with a serious illness for 
the rest of their lives. Fertility may be affected by drugs as many neuroleptics cause 
hyperprolactinemia and inhibit ovulation (Dickson et al. 2000). Patients with 
chronic psychotic illness may well face more prejudice than other women and they 
need to justify more to other people that they “are allowed” to become pregnant or 
to participate in infertility treatments.   
 
Mood disorders have effects on fertility and number of children. Williams et al. 
(2007) concluded in their review article that women with mood disorders had fewer 
observed number of children than the expected number. However, for mood 
disorders as well this may be due to social factors. A study by Harlow et al. (2003) 
namely suggests that depressive women have an increased risk for divorce and 
widowhood. 
 
In addition to social factors, biological and pharmacological factors in individuals 
with mood disorders may affect fertility (Williams et al. 2007). According to two 
studies, women suffering from bipolar disorder may have menstrual problems even 
before taking mood stabilizors (Rasgon et al. 2005, Joffe et al. 2006). For unipolar 
depression the evidence is inconsistent (Harlow et al. 2004, Rowland et al. 2002, 
Joffe et al. 2006). However, the use of selective serotonin reuptake inhibitors may 
potentially influence fertility as the medication can decrease libido and increase the 
risk of spontaneous abortions (Williams et al. 2007). 
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2.3.2 Psychiatric disorders among women participating in 
infertility treatments 
Negative emotions are typical and anxiety disorders and depression are common 
among infertile women participating in infertility treatments. Many couples have 
found infertility the most distressing experience of their lives (Guerra et al. 1998). 
Thus grief and emotional distress are understandable and even expected responses to 
infertility, as infertility can be considered a loss to the couple. The most common 
reactions are shock, anger, guilt, marital distress, impaired self-esteem, sexual 
dysfunction, and social isolation (Burns 2007). It may also be difficult to decide 
whether to start infertility treatments and this may cause anxiety. Typically, when a 
couple has decided to start infertility treatments, negative emotions and stress 
fluctuate during the course of treatment procedures (Hammarberg et al. 2001, 
Verhaak et al. 2007).  
 
The prevalence of depression and anxiety disorders among women participating in 
infertility treatments is high but estimates have varied widely. This can be explained 
by variation in diagnostic criteria of the disorders, data collection methods and 
differences in the backgrounds of infertile couples regarding, for example, duration 
of childlessness or number of prior treatments. These varied in the studies as well as 
between the studies.  
 
Domar et al. (1992) used the Beck Depression Inventory and the Center for 
Epidemiological Studies Depression Scale to compare prevalence of depressive 
symptoms among 338 women seeking help for infertility and 39 control women 
who visited physician for routine gynaecological examinations. The prevalence of 
depression was twofold among the infertile women and highest among those women 
who had tried to become pregnant for 2-3 years.  
 
Matsubayashi et al. (2001) compared treatment-seeking Japanese infertile women 
(N=101) to healthy pregnant women (N=81): Emotional distress was estimated by 
using the hospital anxiety and depression scale (HADS) and the profile of mood 
states (POMS). They found that the depression/dejection score of infertile women 
was twice that of pregnant women. Other scores studied with the exception of 
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fatigue were higher among infertile women suggesting that they had more anxiety, 
aggression, hostility, lack of vigour, tension, anxiety and confusion. 
 
In a study by Guerra et al. (1998) the prevalence of psychiatric symptoms was 
evaluated among 110 infertile patients in an infertility clinic. As diagnostic criteria 
they used DSM-III-R (axis 1). Psychiatric morbidity was found among 61% female 
and 21% male patients. The most common problem was anxiety disorder. A 
significant proportion of infertile patients also had significant psychological 
dysfunction even though they did not fulfill the diagnostic criteria for any specific 
disorder (Guerra at al. 1998). 
 
Lok et al. (2002) found that 30% of 372 Chinese patients attending for infertility 
treatments had impaired psychological well-being and 8% were diagnosed with 
moderate or severe depression. Even more significant psychiatric morbidity was 
reported among Taiwanese infertile treatment-seeking patients of whom 23% had 
generalized anxiety disorder, 17% had major depression and 10% dysthymia (Chen 
et al. 2004). 
 
Sbaragli et al. (2008) compared the prevalence of psychiatric disorders among 81 
Italian couples participating in infertility treatment and 70 fertile controls recruited 
from an obstetrics and gynaecology clinic. Their results demonstrated that the 
infertile women had significantly more morbidity especially because of adjustment 
disorders and binge eating disorders (Sbaragli et al. 2008). 
 
Volgsten et al. (2008) evaluated the presence of psychiatric diagnoses among 
couples being treated for infertility. Their study population consisted of 545 
Swedish couples. Of infertile women 26% and of infertile men 9% suffered from 
mood disorders and 15% of women and 5% of men had anxiety disorder (Volgsten 
et al. 2008). 
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2.3.3 Infertility and cancer - possible mechanisms   
Among Finnish female population 13,874 cancer cases were diagnosed 2009. The 
most common cancer was breast cancer (4,474) cases, followed by basalioma (4,007 
cases), colon cancer (827 cases) and uterine cancer (806 cases) (Finnish Cancer 
Registry, 2011). 
 
Although the development of cancer is a complex network of different mutations 
caused by various endogenous and exogenous factors, it is known that hormonal 
stimuli promote the development of common cancer types. For breast cancer early 
age at menarche, low parity, late menopause and late age at first birth increase the 
risk for cancer development. Risk for ovarian cancer is linked to hormonal factors as 
high parity and oral contraceptive use are significant protective factors. It is 
considered that repeated ovulations that disrupt the ovarian epithelium might 
predispose epithelial cells to malignant transformations. Another explanation is 
ovarian stimulation of gonadotrophins that directly or via increased oestrogen levels 
could be carcinogenic. A third hypothesis suggests that inflammatory reactions 
caused by endometriosis can promote the development of ovarian cancer. The role 
of androgen secretion has been considered as it has been proposed that excessive 
androgen secretion may be carcinogenic (Klip et al. 2000) 
 
A risk for uterine cancer is influenced by endogenous and exogenous hormonal 
factors. Well recognized risk factors for this cancer are nulliparity, polycystic 
ovarian syndrome (PCOS), late age at menopause, obesity and oestrogen-secreting 
tumours. The risk is significantly increased in hormone replacement therapy 
containing only oestrogen. However, when progesterone is combined with the 
therapy the risk for uterine cancer is no longer increased. Oral contraceptive pills 
containing both oestrogen and progesterone even decrease the risk for this cancer 
type. The increased uterine cancer risk in conditions when oestrogen secretion or 
levels are increased can be explained by high mitogenic activity in the endometrial 
tissue. The decrease in oestrogen levels and / or increase in progesterone levels in 
turn decreases mitogenesis and promotes maturation of the endometrium thus 
lowering the risk for cancer promoting mutations in the tissue (Klip et al. 2000). 
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The risk for thyroid cancer and melanoma being related to hormonal factors has 
been studied. Some studies suggest that low parity and late age at delivery are risk 
factors for the development of melanoma but others have not confirmed this finding. 
For thyroid cancer the risk is significantly greater among females than among males 
suggesting that sex hormones have a role in cancer development. It has also been 
shown that women who have ever been pregnant have increased risk for this cancer 
compared to nulliparous women. A possible explanation for this risk increase is the 
higher secretion of thyroid stimulation hormone (TSH) caused by high female sex 
hormone levels promoting hyperplasia in thyroid tissue exposing the tissue to 
mutations (Klip at al. 2000). 
 
Researching whether infertility and hormonal infertility treatments increase cancer 
risk or not is reasonable as in many infertility-causing conditions the secretion or 
levels of sex hormones are disturbed and during hormonal infertility treatments 
exogenous drugs affecting hormone balance are administered. For example women 
with polycystic ovary syndrome  suffer from hyperandrogenism and insulin 
resistance leading to compensatory hyperinsulinemia. Androgen excess in turn 
increases gonadotrohpin releasing hormone (GnRH) levels which causes luteinizing 
hormone (LH) hypersecretion altering normal LH/FSH (follicle stimulating 
hormone) levels. Women with PCOS have severe ovulation dysfunction marked by 
high oestrogen secretion that is not followed by normal progesterone secretion. This 
is a risk for developing uterine cancer (Goodarzi et al. 2011). 
 
Endometriosis is another common disease that typically causes impaired fertility 
and may increase cancer risk. Although this condition is benign, it is marked by 
numerous immunological changes suggesting the role of chronic intraperitoneal 
inflammatory process in endometriosis pathogenesis. This inflammation is in turn 
characterized by increased macrophage activity and increased secretion of 
cytokines, other growth factors and angiogenic factors (Brosens & Benagiano, 
2011). 
 
A recent review article concludes that present data indicate that women with 
endometriosis are at increased risk for ovarian cancer. Breast cancer risk may be 
modestly elevated but the findings are inconsistent. Uterine cancer risk is not 
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elevated and cervical cancer risk is even reduced. Ovarian cancer diagnosed among 
endometriosis patients, however, is usually clinically somewhat different from 
“typical” ovarian cancer as patients are younger, diagnosed in earlier stages and 
have lower grade tumours and thus better survival rate (Munksgaard & Blaakaer, 
2011). The suggested pathogenesis for this type of endometriosis-associated ovarian 
endometroid cancer is related retrograde menstruation causing increased oxidative 
stress, activation of anti-apoptotic pathways and aberrant activation of stress 
signalling pathways (Kobayashi et al. 2011). 
2.3.4 Infertility and the risk of uterine, ovarian and breast cancer 
The risk of cancer among infertile women with or without undergoing infertility 
treatments has been studied in various cohort and case-control studies. Reviews of 
the topic have also been published. Despite significant research activity, the results 
are still at least partly inconsistent.  
 
Overall cancer risk among infertile women was statistically significantly increased 
compared to general population according to three relatively large cohort studies. 
Standardized incidence ratio (SIR) for all cancers was reported to be 1.20 (95% CI 
1.0-1.5) among 2,496 Israeli infertile women (Modan et al. 1998). According to an 
American study among 12 193 infertile women SIR was 1.23 (95% CI 1.1-1.3) 
(Brinton et al. 2005) and in a large Danish cohort study among 54,362 infertile 
women parity-specific SIR for all cancers was 1.04 (95% CI 1.00-1.09) (Jensen et 
al. 2008). However not all cohort studies (population size 1,082-5,556 women) have 
confirmed these results (Doyle et al. 2002, Dor et al. 2002, Lerner-Geva et al. 2003). 
 
The risk of uterine cancer among infertile women has been estimated in several 
studies, some of which report significantly elevated risk while others do not. 
Statistically significantly increased uterine cancer incidences were found in a cohort 
study by Venn et al. (1995), SIR 2.84 (95% CI 1.18-6.8), Modan et al. (1998), SIR 
4.85 (95% Cl 3.0–7.4) and by dos Santos Silva et al. (2009), RR 2.02 (95 % CI 
1.37-2.87). According to two studies by Venn et al. (1995, 1999) uterine cancer risk 
was especially increased among women suffering from unexplained infertility. 
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However in case control studies by Benshushan et al. (2001) and Brinton et al. 
(2007) infertility was not observed as a risk factor for uterine cancer, nor was the 
cancer risk increased in the cohort studies by Venn at al. (1999), Doyle at al. (2002) 
and Jensen et al. (2008) (Table 1) 
 
Table 1. Uterine cancer incidence among infertile women according to previous studies 
STUDY STUDY TYPE N RESULT 
Venn et al. 1995 cohort  10,358 infertile 
women, 5564 exposed 
to infertility drugs and 
4,794 unexposed 
SIR 2.84  95% CI 1.18-
6.8, for women with 
unexplained infertility 
RR 6.64, 95% CI 1.06-
38 
Modan et al. 1998 cohort 2,496 infertile women SIR 4.85, 95% Cl 3.0–
7.4 
Venn et al. 1999 cohort 29,700 women infertile 
women: 20,656 
exposed to fertility 
drugs and 9,044 
unexposed 
SIR (exposed) 1.09, 
95% CI 0.45-2.61 and 
SIR (unexposed) 2.47, 
95 % CI 1.18-5.18. For 
women with 
unexplained infertility 
SIR 4.59, 95% CI 1.91-
11.0 
Benshushan et al. 2001 case-control 128 women with 
uterine cancer and 255 
controls 
OR 1.82, 95% CI 0.99-
3.32 
Doyle et al. 2002 cohort 5,556 infertile women 
of whom 75% exposed 
to infertility drugs 
SIR 1.27, 95% CI 0.35–
3.25 
Brinton et al. 2007 case control 551 endometrial cancer 
patients and 1,925 
controls 
OR 1.03, 95 % CI 0.7-
1.5 
Jensen et al. 2008 cohort 54,362 infertile women SIR 1.08, 95% CI 0.83-
1.38 
dos Santos Silva et al. 
2009 
cohort 7,355 infertile women 
of whom 43% exposed 
to ovarian stimulating 
drugs 
RR 2.02, 95 % CI 1.37-
2.87 
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Some previous studies suggest that infertility increases the risk for ovarian cancer. 
The risk for ovarian cancer was statistically significantly increased according to 
cohort studies by Rossing et al. (1994), Brinton et al. (2004) and Jensen et al. 
(2008), in a case control study by Mosgaard et al. (1997) and in a survey by 
Tworoger et al. (2007). The risk for ovarian cancer was not elevated among infertile 
women according to the cohort studies by Venn et al (1995, 1999), Doyle et al. 
(2002) and dos Santos Silva et al. (2009) and case control study by Shushan et al. 
(1996). However, in the studies by Venn et al. (1995, 1999) ovarian cancer risk was 
elevated among those infertile women whose infertility remained unexplained 
(Table 2).  
 
Table 2. Ovarian cancer incidence among infertile women according to previous studies 
STUDY STUDY TYPE N RESULT 
Rossing et al. 1994 cohort 3,837 infertile women SIR 2.5 (1.3-4.5) 
Venn et al. 1995 cohort  10,358 infertile 
women, 5,564 exposed 
to infertility drugs and 
4,794 unexposed 
SIR (exposed) 1.70, 
95% CI 
 0-55-5.27 
SIR (unexposed) 1.62, 
95% CI 0.52-5.02, for 
women with 
unexplained infertility 
RR (19.19, 95% CI 
2.23-165 
Shushan et al. 1996 case-control 200 women with 
ovarian cancer and 408 
controls 
SIR 1.31, 95% CI 0.63-
2.74 
Mosgaard et al. 1997 case-control 684 women with 
ovarian cancer and 
1,721 controls 
OR for infertile non-
treated nulliparous 
women compared to 
noninfertile nulliparous 
women 2.7, 95% CI 1.3-
5.5 
Modan et al. 1998 cohort 2,496 infertile women SIR 1.6, 95% CI 0.8-2.9 
Venn et al. 1999 cohort 2,9700 women infertile 
women: 20,656 
exposed to fertility 
drugs and 9,044 
unexposed 
SIR (exposed) 0.88, 
95% CI 0.42-1.84 and 
SIR (unexposed) 1.16, 
95% CI 0.52-2.59. For 
women with 
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unexplained infertility 
SIR 2.64, 95% CI 1.10-
6.35 
Doyle et al. 2002 cohort 5,556 infertile women 
of whom 75% exposed 
to infertility drugs 
SIR 0.98, 95% CI 0.36-
2.14 
Brinton et al. 2004 cohort  12,193 infertile women SIR 1.98, 95% CI 1.4-
2.6 
Tworoger et al. 2007 survey 107,900 women SIR 1.36, 95% CI 1.07-
1.75 
Jensen et al. 2008 cohort 54,362 infertile women  SIR 1.46,  95% CI 1.24- 
1.71 
dos Santos Silva et al. 
2009 
cohort 7,355 infertile women 
of whom 43% exposed 
to ovarian stimulating 
drugs 
SIR 0.97, 95 % CI 0.6-
1.48 
 
Two large cohort studies report increased breast cancer incidence among infertile 
women. In a study by Brinton et al. (2004) SIR was 1.29 (95% CI 1.1-1.4) among 
12,193 infertile women. SIR 1.08, 95% CI 1.01-1.16 was found in a study by Jensen 
et al. (2009) among 54,362 infertile women. However, other cohort and case control 
studies do not report increased risk for this cancer type among infertile women 
compared to general population (Venn et al. 1995, Braga et al. 1996, Rossing et al. 
1996, Modan et al. 1998, Ricci et al. 1999, Dor et al. 2002, Doyle et al. 2002, 
Lerner-Geva et al. 2006, Pappo et al. 2008, dos Santos Silva et al. 2009) (Table 3) 
  
Table 3. Breast cancer incidence among infertile women according to previous studies 
STUDY STUDY TYPE N RESULT 
Venn et al. 1995 cohort  10,358 infertile women, 
5,564 exposed to 
infertility drugs and 
4,794 unexposed 
SIR (exposed) 0.89, 
95% CI 0-55-1.46 
SIR (unexposed) 0.98, 
95% CI 0.62-1.56 
Braga et al. 1996 case-control 2,569 women with 
breast cancer and 2,588 
controls 
OR 1.08, 95% CI 0.8-
1.5 
Rossing et al. 1996 cohort 3,837 infertile women SIR 0.9, 95% CI 0.6–1.4 
Modan et al. 1998 cohort 2,469 infertile women  SIR 1.30, 95% CI 0.96-
1.60 
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Ricci et al. 1999 case-control 3,415 women with 
breast cancer and 2,916 
controls 
OR 0.8, 95% CI 0.5-1.1 
Dor et al. 2002 cohort 5,026 infertile women SIR 0.69, 95% CI 0.46-
1.66 
Doyle et al. 2002 cohort 5,556 infertile women 
of whom 75% exposed 
to infertility drugs 
SIR 1.15, 95% CI 0.86-
1.49 
Brinton et al. 2004 cohort  12,193 infertile women SIR 1.29, 95% CI 1.1-
1.4 
Lerner-Geva et al. 
2006 
cohort and nested 
case–control study 
cohort of 5,788 infertile 
women, 61 cases of 
women with breast 
cancer and 120 controls  
SIR 1.1, 95% CI 0.9–1.4 
Jensen et al. 2008 cohort 54,362 infertile women  SIR 1.08, 95% CI 1.01-
1.16 
Pappo et al. 2008 cohort 3,375 infertile women SIR 1.4, 95% CI 0.98-
1.96 
dos Santos Silva et al. 
2009 
cohort 7,355 infertile women 
of whom 43% exposed 
to ovarian stimulating 
drugs 
SIR 1.13, 95 % CI 0.97-
1.30 
 
The risk for other cancers among infertile women has been studied although not as 
intensively as the risk for breast or gynaecological cancers. Studies indicate that the 
risk for cervical cancer is statistically significantly lower among infertile women 
compared to general population (Doyle et al. 2002, Jensen et al. 2008, dos Santos 
Silva et al. 2009). Thyroid cancer risk according to earlier studies was evaluated in a 
review by Klip et al. (2000) and no statistically significantly increased risk was 
found. Similar results have also been reported in two cohort studies published later 
(Jensen et al. 2008, dos Santos Silva et al. 2009). These studies indicate that the risk 
for melanoma among infertile women is not elevated (Jensen et al. 2008, dos Santos 
Silva et al. 2009). 
 
Even though the results are still inconsistent, it seems that in medical conditions 
causing infertility the risk for some cancers may be slightly increased compared to 
that in general population. Another important question is whether hormonal 
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treatments used to help couples suffering from infertility increase cancer risk. 
Results from large cohort studies on the risk for uterine cancer after infertility drugs 
are inconsistent. Statistically significantly increased uterine cancer risk among 
parous women exposed to treatments for ovulation induction compared to other 
parous women was reported in a recent cohort study (Calderon-Margalit et al. 
2009). According to a study by Jensen et al. (2008) the risk after taking any 
infertility drug was not statistically significantly elevated but after exposure to 
gonadotrophins and more than six cycles of clomiphene citrate the risk for uterine 
cancer was statistically significantly increased. However, in the cohort studies by 
Venn et al. (1999), Doyle et al. (2002) and Althuis et al. (2009), dos Santos Silva et 
al. (2009) uterine cancer risk after infertility drug treatment was not elevated (Table 
4). 
 
Table 4. Uterine cancer risk after infertility drug use according to previous studies 
STUDY STYDY TYPE N RESULT 
Venn et al. 1999 cohort 29,700 women 
infertile women: 
20,656 exposed to 
fertility drugs and 
9,044 unexposed 
SIR (exposed) 1.09, 95% CI 
0.45-2.61 and SIR 
(unexposed) 2.47, 95% CI 
1.18-5.18 
Doyle et al. 2002 cohort 5,556 infertile women 
of whom 75% 
exposed to infertility 
drugs 
RR (exposed/unexposed) 
0.72, 95% CI 0.06–8.62 
Althuis et al. 2005 cohort 8,431 infertile women for clomiphene RR 1.79, 
95% CI 0.9-3.4 
Jensen et al 2009 cohort 54,362 infertile 
women 
For any drug RR1.10, 95% 
CI 0.69-1.76. for 
gonadotrophins RR 2.21, 
95% CI 1.08-4.50) for 
clomiphene after 6 or more 
cycles RR 1.96, 95% CI 
1.03-3.72 
Calderon-Margalit 
et al. 2009 
cohort 15,030 women who 
gave birth 1974-1976 
HR 3.39, 95% CI 1.28- 8.97 
dos Santos Silva et 
al. 2009 
Cohort 7355 infertile women 
of whom 43% 
SIR (exposed) 2.31, 95% CI 
1.37-3.64, SIR (unexposed) 
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exposed to ovarian 
stimulating drugs 
1.66, 95% CI 0.86-2.94 
 
Earlier studies suggest that the overall risk for breast cancer after infertility drug 
exposure is not statistically significantly increased (Table 5) but in some studies, 
however, the risk was found to be elevated. According to a study by Lerner-Geva et 
al. (2006) breast cancer risk after clomiphene citrate use was statistically 
significantly elevated. Taking progesterone in turn increased the risk statistically 
significantly but not taking other infertility drugs according to a large cohort study 
by Jensen et al. (2007). Most studies, however, do not report increased breast cancer 
risk after infertility drug treatment (Venn at al. 1995, Rossing et al. 1996, Potashnik 
et al. 1999, Ricci et al. 1999 Venn at al. 1999, Doyle at al. 2002, Burkman et al. 
2003, Brinton et al. 2004 Gauthier et al. 2004, Calderon-Margalit et al. 2009, dos 
Santos Silva et al. 2009). 
 
Table 5. Breast cancer risk after infertility drug use according to previous studies 
STUDY STUDY TYPE N RESULT 
Venn et al. 1995 cohort  10,358 infertile 
women, 5,564 
exposed to infertility 
drugs and 4,794 
unexposed 
Relative risk 
(exposed/unexposed) 1.11, 
95% CI 0.56-2.20 
Rossing et al. 1996 Cohort 3,837 infertile 
women 
RR 0.5, 95% CI 0.2–1.2 for 
clomiphene 
Ricci et al. 1999 case-control 3,415 women with 
breast cancer and 
2,916 controls 
OR 1.2, 95% CI 0.5-2.6 
Venn et al. 1999 Cohort 29,700 women 
infertile women: 
20,656 exposed to 
fertility drugs and 
9,044 unexposed 
SIR (exposed) 0.91, 95% CI 
0.74-1.13 and SIR 
(unexposed) 0.95, 95% CI 
0.73-1.23 
Potashnik et al. 
1999 
Cohort 1,197 infertile 
women 
SIR 1.65, 95% CI 0.94–2.68 
Doyle et al. 2002 cohort 5,556 infertile 
women of whom 
75% exposed to 
RR (exposed/unexposed) 
0.95, 95% CI 0.47-1.92 
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infertility drugs 
Burkman et al. 2003 case–control 4,575 breast cancer 
patients and 4,682 
controls from the 
same area 
OR 1.2, 95% CI, 0.8–1.7 for 
women diagnosed with 
infertility 
Gauthier et al. 2004 questionnaire 92,555 women of 
whom 6,602 were 
treated for infertility 
RR  0.95, 95% CI 0.82–1.11 
Brinton et al. 2004 Cohort  12,193 infertile 
women 
For clomiphene use SIR 
(exposed) 1.29, 95% CI 1.1-
1.6 and SIR (unexposed) 
1.28, 95% CI 1.1-1.5.  
For gonadotrophin use SIR 
(exposed) 1.4,0 95% CI 0.9-
2.0 and SIR (unexposed) 
1.28, 95% CI 1.1-1.4 
Lerner-Geva et al. 
2006 
cohort and nested 
case–control study 
cohort of 5,788 
infertile women, 61 
cases of women with 
breast cancer and 
120 controls 
For clomiphene SIR 1.4, 
95% CI 1.0–1.8 (cohort) and 
OR 2.7, 95% CI 1.3–5.7 
(case-control) 
Jensen et al. 2007 cohort 54,362 infertile 
women 
For use of gonadotrophins 
RR 1.20, 95% CI 0.82-1.78, 
clomiphene RR 1.08, 95% 
CI 0.85-1.39, hCG RR 0.94, 
95% CI 0.73-1.21, GnRH 
RR 1.28, 95% CI 0.75-2.19, 
progesterone RR 3.36, 95% 
CI 1.60-7.07 
Calderon-Margalit 
et al. 2009 
cohort 15,030 women who 
gave birth 1974-
1976 
HR 1.42, 95% CI 0.99-2.05 
dos Santos Silva et 
al. 2009 
cohort 7,355 infertile 
women of whom 
43% exposed to 
ovarian stimulating 
drugs 
SIR (exposed) 1.26, 95 % 
CI 1.03-1.33 and SIR 
(unexposed) 0.99, 95 % CI 
0.78-1.25 
 
Studies indicate that overall ovarian cancer risk after infertility drug use is not 
statistically significantly increased (Venn et al. 1995, Mosgaard et al. 1997, 
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Parazzini et al. 1997, Modan et al. 1998, Venn et al. 1999, Parazzini et al. 2001, 
Doyle et al. 2002, Ness et al. 2002, Brinton et al. 2004, Calderon-Margalit et al. 
2009, Sanner et al. 2009, Jensen et al. 2009, dos Santos Silva et al. 2009) A recent 
Swedish study, however, found statistically significantly elevated risk after use of 
gonadotrophins (Sanner et al. 2009) (Table 6). 
 
Table 6. Ovarian cancer risk after infertility drug use according to previous studies 
STUDY STUDY TYPE N RESULT 
Venn et al. 1995 cohort  10,358 infertile 
women, 5,564 
exposed to infertility 
drugs and 4,794 
unexposed 
Relative risk 
(exposed/unexposed) 1.45, 
95% CI 0.28-7.55 
Parazzini et al. 1997  Case-control 971 women with 
ovarian cancer and 
2,758 controls 
OR 1.1 (0.4-3.3) 
Mosgaard et al. 1997 case-control 684 women with 
ovarian cancer and 
1,721 controls 
OR (treated nulliparous/non-
treated nulliparous infertile 
women) 0.8, 95% CI 0.4-2.0 
and OR (treated parous/non-
treated parous infertile 
women) 0.6 (0.2-1.3) 
Modan et al. 1998 cohort 2,496 infertile 
women 
SIR (exposed) 1.7 and SIR 
(unexposed) 1.6 
Venn at al. 1999 cohort 29,700 women 
infertile women: 
20,656 exposed to 
fertility drugs and 
9,044 unexposed 
SIR (exposed) 0.88, 95% CI 
0.42-1.84 and SIR 
(unexposed) 1.16, 95% CI 
0.52-2.59 
Parazzini et al. 2001 case-control 1,031 women with 
ovarian cancer and 
2,411 controls  
OR 1.3 (0.7-2.5) 
Doyle et al. 2002 cohort 5,556 infertile 
women of whom 
75% exposed to 
infertility drugs 
RR (exposed/unexposed) 
0.59, 95% CI 0.12-3.0) 
Ness et al. 2002 pooled analysis of 
eight case-control 
studies conducted 
5,207 women with 
ovarian cancer and 
7,705 controls 
OR for nulliparous subfertile 
women 1.60, 95% CI 0.90-
2.87 
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between 1989 and 
1999 
Brinton et al. 2004 cohort  12,193 infertile 
women 
For clomiphene RR 0.82, 
95% CI 0.4-1.5) and  for 
gonadotrophins RR 1.09, 
95% CI 0.4- 2.8)  
Calderon-Margalit et 
al. 2009 
cohort 15,030 women who 
gave birth 1974-1976 
HR 0.61, 95% CI 0.08-4.42 
Jensen et al. 2009 cohort 54,362 infertile 
women  
For use of gonadotrophins 
RR 0.83, 95% CI 0.50-1.37, 
clomifene RR 1.14, 95 % CI 
0.79 -1.64), hCG RR 0.89, 
95% CI 0.62-1.29, 
gonadotrophin releasing 
hormone  RR 0.80, 95% CI 
0.42-1.51) 
Sanner et al. 2009 cohort  2,768 infertile 
women 
SIR 1.19, 95% CI 0.54-2.25, 
for gonadotrophins RR 5.28, 
95% CI 1.70-16.45 
dos Santos Silva et 
al. 2009 
cohort 7,355 infertile 
women of whom 
43% exposed to 
ovarian stimulating 
drugs 
SIR (exposed) 1.10, 95 % CI 
0.57-1.93 and SIR 
(unexposed) 0.78, 95 % CI 
0.34-1.53 
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2.4 Summary 
The prevalence of infertility varies depending on definition and population studied. 
Previous findings suggest that it may differ by time and socio-demographic and 
ethnic factors. The results of different studies on the subject are, however, somewhat 
inconsistent. Not all infertile couples seek medical help. It has been estimated that 
there are also significant differences in treatment seeking depending on the 
background characteristics of infertile couples. 
 
Infertility is practically always a serious crisis and has negative effects on life. It 
may also predispose to actual psychiatric disorders that are common among couples 
treated for infertility. There is, however, significant variation in the prevalence of 
psychiatric diagnoses among couples receiving infertility treatments. Some of this 
variation is likely to be explained by different background characteristics of infertile 
couples, regarding, for example, duration of childlessness and possible previous 
unsuccessful infertility treatments, or different diagnostic tools to diagnose the 
conditions.  
 
For many women suffering from infertility the cause of impaired fertility is a 
gynaecological condition such as endometriosis or polycystic ovaries syndrome that 
causes significant systemic hormonal or inflammatory effects that could also 
enhance cancer development. As hormonal infertility treatments affect the body’s 
hormonal balance, it has been questioned whether cancer risk after these treatments 
is increased. There has been a great deal of research on this subject but the results 
for some cancer types between studies are still contradictory.  
49 
3. Aims of the study 
To study the prevalence of infertility and use of infertility treatments over time and 
socio-demographic factors, success of infertility treatments and health of treated 
women. 
 
1. Does prevalence of infertility and use of infertility treatments differ over time 
and socio-demographic determinants in Finland? (I) 
 
2. What is the success rate of infertility treatments with different indicators? What 
is the influence of the causes of infertility, maternal age or care site on success 
rates? (II) 
 
3. Did women undergoing IVF, ICSI or FET have more hospitalizations for 
psychiatric diagnosis than control women before and after treatments? Does the 
outcome of treatments affect the number of hospitalizations after treatments? 
Who will provide mental support for infertile women and is this support 
considered sufficient? (III) 
 
4. Have women undergoing IVF, ICSI or FET more cancers 6-8 years after 
infertility treatments than control women? (IV) 
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4. Materials and methods 
The materials used in this study included two nationally representative cross-
sectional surveys, FINRISK 1997 (I) and FINRISK 2002 (I, II, and adequacy of 
mental support during infertility and infertility treatments – data not previously 
published), aggregate IVF Statistics (I, II) and the cohort of 9,175 women receiving 
IVF, ICSI or FET treatments 1996-1998 and their age and residence matched 
controls (III, IV). This IVF cohort and the controls were linked to the Hospital 
Discharge Register to identify hospitalizations for psychiatric diagnoses (III), to 
Finnish Cancer Registry (IV) and to the Central Population Register to collect 
background information on marital status and socio-economic position. For Paper 
III the IVF cohort females were also linked to The Medical Birth Register to obtain 
information about births after infertility treatments. 
4.1 FINRISK 1997 and FINRISK 2002 surveys 
FINRISK 1997 and 2002 surveys form part of the large cross-sectional population 
surveys conducted in Finland every five years since 1972 (THL, 
http://www.ktl.fi/attachments/finriski/2008b34.pdf). The aim of these studies is to 
monitor public health and the risk factors of chronic diseases but they include 
questions on reproductive health. A specific questionnaire for women was included 
in FINRISK 2002 survey and it contained questions about the menstrual cycle, use 
of contraception and hormone replacement therapy, pregnancies and births, 
pregnancy complications and infertility and infertility treatments. In FINRISK 1997 
only one question on the use of hormone therapy to treat infertility was included in 
the questionnaire. FINRISK 2002 included questions about the adequacy and 
sources of mental support for infertility. 
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Six areas in Finland were included in the survey in 2002: the cities of Helsinki and 
Vantaa, South-Western Finland, North Karelia and Kuopio, Oulu and Lapland 
provinces. Lapland region was not included in FINRISK 1997 survey and therefore 
was excluded from the present study. FINRISK surveys used a random population 
sample consisting of subjects aged 25 to 64. The response rate among women 
(N=3,763) was 76.5% in the FINRISK 1997 survey and 75.8% (N=4,729) in the 
FINRISK 2002 survey. 
 
Data from FINRISK 2002 survey were used to study the life-time prevalence of 
infertility by age and education and the participation rate in infertility treatments 
among females who had suffered from infertility by age, education, residence and 
household income. Socio-demographic differences in likelyhood to seek treatment 
were compared in 1997 (FINRISK 1997) and 2002 (FINRISK 2002) in the case of 
hormone treatments. Life-time birth rates among women who had participated in 
infertility treatments were studied by age, cause of infertility and type of infertility 
treatment. Adequacy of mental support during treatments and the source of support 
were elicited in FINRISK 2002 survey. The following options were given for the 
adequacy of support 1) enough support, 2) some support but not enough and, 3) no 
support. The sources of mental support were: 1) spouse, 2) psychiatrist or 
psychologist, 3) infertility clinic personnel 4) health centre or antenatal clinic, 5) 
infertility support group, 6) other organizational activity, 7) relatives and 8) friends. 
Each woman could choose several options. 
4.2 Aggregate IVF Statistics 
Aggregate IVF statistics are gathered annually from all public and private Finnish 
infertility clinics using a specific questionnaire originally designed by the 
International Working Group for Registers on Assisted Reproduction (de Mouzon & 
Lacaster 1997). The clinics are asked about total number of infertility treatment 
cycles, pregnancies started, number of embryos transferred, ages of patients, causes 
of infertility, pregnancy, birth and newborn outcomes, complications and congenital 
anomalies. The statistics are maintained by National Institute for Health and 
Welfare (THL).  
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From this data source number of IVF, ICSI and FET treatments by time, cause of 
infertility and age of women treated with IVF and ICSI were studied. Success of 
infertility treatments over time was studied using several different indicators 
(clinical pregnancies, live births, term singletons and singletons weighing at least 
2,500 grams). Pregnancy rates after IVF, ICSI and FET separately, number of 
embryos transferred and clinical pregnancy rates after single and double embryo 
transfers were calculated and success of treatments in private and public clinics was 
compared. 
4.3 IVF cohort and controls 
The IVF cohort consisted of 9,175 Finnish women who had IVF, ICSI or FET 
treatment during the period 1996-1998. Each woman was recorded once regardless 
the number of drug purchases. The control population for these women (N=9175) 
was selected randomly from the Social Insurance Institution’s population record that 
includes the entirel population of Finland. The controls were matched by age and 
residence. 
 
The IVF cohort was selected using data on infertility drug prescriptions. In Finland 
the Social Insurance Institution offers reimbursement for most drugs prescribed by 
public and private sector’s physicians. In most cases reimbursement is deducted 
from the price already during the drug delivery. When supplying drugs pharmacies 
collect data on recipient’s personal identity number, residence, name and class of 
drug, the size and number of packages, the dose recommended, the dates prescribed 
and purchased and the code of the prescribing physician and record this to the Drug 
Register of the Social Insurance Institution.  
 
In order to generate the IVF cohort information on reimbursements for specific 
drugs or drug combinations was utilized. This enabled the identification of virtually 
all IVF, ICSI or FET cycles as they all start with drug therapy (with the exception of 
FET treatments in the natural cycle). The drugs or drug combinations recorded were 
clomiphene citrate, gonadotrophins, GnRH agonists and progesterone. These could 
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additionally be combined with human chorionic gonadotrophin, estradiol and 
dydrogesterone (Hemminki et al. 2003).  
4.4 Finnish Cancer Registry 
The Finnish Cancer Registry was founded in 1952 and collects information about 
cancer cases diagnosed in Finland since 1953. Since 1961 it has been compulsory 
for all physicians, hospitals and laboratories to report all diagnosed and suspected 
cancer cases to the registry using a specific notification. In addition, Statistics 
Finland sends information on all death certificates where cancer is mentioned, to the 
registry (Cancer Registry, 2011). The coverage of the registry has been estimated to 
be very good, 99% for solid tumours (Teppo et al. 1994). 
 
For this study all cancer cases among the women in the IVF cohort and controls 
1996-2004 were collected. For the IVF cohort cancer cases diagnosed before IVF 
treatments were excluded from the study. For the controls, the beginning of IVF 
treatments of the matching treated women was used. The Finnish Cancer registry 
uses a specific classification for cancer. For the study the cancer cases were 
classified again according to ICD-10 criteria and divided into 11 categories (ICD-10 
code in brackets): breast (C50); ovarian (C56); cervical (C53); thyroid (C73); 
uterine (C54); pulmonary cancers (C34); melanoma (C43); other skin cancers 
(C44); tumours of the central nervous system (C70, C71, C72); leukaemia and 
lymphoma (C81-C96) and gastrointestinal track tumours, including duodenal 
(C17.0), jejunal (C17.1), ileal (C17.2), colon (C18), splenic (C26), pancreatic (C25) 
and hepatic cancers (C22), tumours in the gallbladder (C23) and bile ducts (C22.1).  
4.5 The Central Population Register 
In Finland there is a national register (Population Information System) that contains 
basic information on all Finnish citizens and foreign nationals who permanently live 
in Finland. The register is maintained by the Population Register Centre and local 
registry offices. The data collected in the register contain for example name, 
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personal identity code, address, municipality of residence, citizenship, family 
relations, birth (and death) date, first language, occupation, membership of religious 
community and also possible guardianship, restrictions on legal competence and 
continuing power of attorney.  
 
The data for the register is obtained from the people themselves and from various 
public authorities such as local parishes, courts of law, hospitals, health centres, 
marriage authorities and municipal social services authorities (Population Register 
Centre, 2011) 
 
The cohort receiving IVF, ICSI and FET and their controls were linked to this 
register in order to obtain background information on marital status and occupation. 
The occupation was classified into five categories: upper white-collar worker, lower 
white-collar worker, blue-collar worker, other (student, entrepreneur, pensioner, 
housewife, unemployed) and unknown. 
4.6 The Hospital Discharge Register 
The Hospital Discharge Register contains information on all inpatient care in 
hospitals and outpatient care in clinics including operations. The register is 
maintained by National Institute for Health and Welfare. The register contains 
general information on patients and their illnesses, care site and duration of 
hospitalization. Possible operations and need for follow-up treatment are registered. 
If hospitalization is due to a psychiatric diagnosis or severe cardiac disease specific 
data is also recorded (THL, http://www.stakes.fi/FI/tilastot/tausta/Rekisteriselosteet/ 
terveydenhuollonhoitoilmoitukset.htm). 
  
The IVF cohort and their controls were linked to the Hospital Discharge Register in 
order to analyse hospitalizations for psychiatric diagnoses before and after infertility 
treatments from 1 January 1969 until 31 December 2006. For the newest 
hospitalizations ICD-10 criteria were used and for the older ones ICD-9 (1987–
1995) and ICD-8 (1969–1986) were used. In the present study, the diagnoses were 
divided into eight categories: psychotic disorders, depression, bipolar disorder or 
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mania, anxiety disorders, personality disorders, eating disorders, alcohol or other 
intoxicant abuse and adjustment disorder..  
4.7 The Medical Birth Register 
For the Medical Birth Register, maintained by the National Institute for Health and 
Welfare, information on the births of all infants is recorded. The data are obtained 
from the delivery hospitals and from the Population Information System and Cause-
of-Death Register. The health of infants is recorded in the register until the age of 
seven days. Background information about mother is also included in the register 
(THL, http://www.stakes.fi/FI/tilastot/tausta/Laatuselosteet/syntymarekisteri.htm). 
4.8 Study permissions and ethics 
The IVF cohort used also in this study was originally created as a part of large study 
exploring targeting and health effects of infertility treatments. This study was started 
by STAKES in the late 1990s (study number 827/402/99). For the original study, 
permissions were obtained from the Hospital Discharge Register in 2000 
(827/402/99), the Social Insurance Institution in 1999 (827/402/99) and the Central 
Population Register in 2000 (299/40/00). The STAKES research ethics committee 
and The National Data Protection Authority approved the study plan and register 
linkages in 2000. For this study further permission for the use of the IVF cohort was 
applied for to allow register linkages to Finnish Cancer Register and The Hospital 
Discharge Register in 2006. 
 
During years 1992-2007 it was voluntary for the infertility clinics to report 
aggregate data to IVF Statistics. However, since an act on assisted fertility 
treatments came into force, this has been mandatory. As the data is aggregate and 
patients cannot be identified, additional permissions for data collection are not 
needed. For this study STAKES granted permission to use this data in 2006. 
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FINRISK surveys are established cross-sectional population surveys that are 
conducted every five years. As identification of respondents is not possible from the 
data obtained for this study, no specific permissions for data use were needed. 
4.9 Statistical analysis 
In Paper I Chi square test and Odds ratios with 95% confidence intervals were used 
to measure statistical significance. Odds ratios were age adjusted. In Paper II odds 
ratios with 95% confidence intervals and a test for relative proportions were used in 
data calculations.  
 
During the data collection for cohort used as study material in Papers III and IV IVF 
women and their cohorts were matched for age and residence. Thus in Paper III 
logistic regression and conditional logistic regression were used for analysis. Odds 
ratios had 95% confidence intervals. Adjustment for socio-economic position and 
marital status at the time of infertility treatments was performed due to statistically 
significant differences with respect to marital status and socio-economic position 
between IVF cohort and the controls. 
 
In Paper IV odds ratios with 95% confidence intervals for given cancer type 
between IVF cohort and the controls were calculated with conditional logistic 
regression analysis after adjustment for socio-economic position and marital status. 
There were situations when no cancers were observed for some diagnosis among 
either IVF women or controls and then Fisher's exact test was used. Chi square
 
test 
was used when comparing possible differences in occurrence time for a cancer after 
infertility treatments among IVF women and controls. 
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5. Results 
5.1 Prevalence and causes of infertility (I) 
Prevalence of infertility 
  
Sixteen percent of women responding to the FINRISK 2002 survey had suffered 
from infertility. The proportions of infertile women were the smallest among the 
youngest age group (24-29 years) and among women with least formal education 
(15% versus 18% among the most educated group). Self-reported infertility differed 
significantly by education in the different age groups. Among the youngest 
respondents infertility was more common among the least educated women (12% 
versus 6% among the most educated ones) However, when older age groups were 
studied the probability of infertility was the greatest among the most educated group 
(24% versus 14% among the least educated females) suggesting that women with 
lower education try to conceive earlier than women with more formal education 
(Figure 1).  
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Figure 1. Self-reported infertility in different age classes by low, medium and high 
education in 2002 (all respondents) 
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Causes of infertility among couples receiving IVF, ICSI or FET 
 
In the early 1990s tubal infertility was the most common diagnosis among couples 
receiving IVF or FET (in 35% of all treatments). The next most common was the 
infertility caused by multiple causes (18%) and male infertility (17%). Over time the 
role of tubal infertility decreased hugely both in relative and absolute numbers and 
the proportions of male and unexplained infertility among couples treated increased. 
In 2004 the most common diagnosis for IVF, ICSI or FET was male infertility (in 
28% of all treatments). Tubal infertility as a sole diagnosis was the reason for these 
treatments for only one of ten couples treated. 
5.2 Infertility treatments (I, II) 
5.2.1 Use and practices of infertility treatments 
Number of IVF, ICSI and FET treatments provided in Finland over time  
 
In 1992, 2,499 IVF and FET cycles were given in Finland. At that time ICSI was not 
yet available. During the time period 1992-2004, the increase in the number of 
treatments was over threefold as 8,229 IVF, ICSI and FET cycles were started in 
2004. The treatment rate per 1,000 women in fertile age (15-49 years) in turn was 
1.8 in 1992 and 7.0 in 2004. 
  
Probability of seeking help for infertility  
 
Of the infertile respondents of FINSRISK 2002 survey 57% had sought medical 
help. The proportion was smallest among the youngest age group (36%) and largest 
among oldest women (66%) and among women aged 30-34 (61%). Of the most 
educated women suffering from infertility 65% sought help whereas the proportion 
was smallest (55 %) among the least educated women. This difference was not 
statistically significant (p=0.2). The share of treatment-seeking varied by education 
in different age groups. Among the youngest respondents treatment-seeking 
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probability was low in all educational groups. Among women aged 30-34 treatment 
seeking was most likely among the women with the least formal education but in 
older age groups the probability was the highest among the most educated ones. 
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Figure 2. Self-reported participation rate in infertility treatments or medical 
examinations because of infertility by age in 2002 (all respondents) according to 
education (low, medium, high). 
 
Use of infertility treatments by age, education, region and household income 
 
In 1997 the oldest respondents to FINRISK survey were statistically significantly 
less likely to have received hormonal infertility treatments than all other age groups. 
The difference was greatest when compared with women aged 35-39 (OR 2.8, 95% 
CI 1.8-4.4). In 1997 the utilization of hormonal infertility treatments was 
statistically significantly more common among the most educated women and 
among those with the highest household incomes. The utilization rate was lowest in 
North Karelia and highest in Helsinki. In all other regions studied the use of 
hormonal infertility treatments was statistically significantly higher than in North 
Karelia.  
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In 2002 when the use of hormone treatments and all infertility treatments were 
studied the socio-demographic differences persisted but in case of hormone 
treatments the differences were smaller than in 1997. Changes in the use of all 
treatments could not be studied over time as they were not elicited in FINRISK 
1997 survey. In 2002 the utilization of hormone treatments as well as any infertility 
treatments was least common among the youngest respondents and statistically 
significantly more common among all other age groups. In this study the utilization 
of treatments was also statistically significantly more common among the most 
educated and the wealthiest ones. Regional differences in use of infertility 
treatments persisted but were smaller than in 1997 as use of hormonal infertility 
treatments in 2002 was statistically more common only in Helsinki and Kuopio 
compared to North Karelia. 
 
Embryo transfers by the number of embryos in 1992-2005 in IVF, ICSI and FET 
treatments  
 
In 1994 in the majority of the treatment cycles (41%) two embryos were transferred. 
Three embryo transfers were almost equally common: 37% of all cycles. Single 
embryo transfers accounted for only 14% of all cycles and in 7% of cycles four 
embryos were transferred. Over time the proportions of two embryos transferred 
increased up to 70% in 2000 and started to decrease thereafter being 49% in 2005. 
The proportion of four and three embryo transfers decreased in the 1990s and after 
2000 no four embryo transfers were performed. In 2005 three embryos were 
transferred in only 0.3% of cycles. The proportion of single embryo transfers in turn 
increased significantly: in 1999, 21% of transfers were single embryo transfers and 
in 2005 the share was 51%. 
5.2.2 Success of infertility treatments 
Success of IVF, ICSI and FET treatments 1994-2005  
 
Success of infertility treatments was measured as clinical pregnancy rate, live birth 
rate, rate of term singletons and rate of singletons weighing at least 2,500 grams. 
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The clinical pregnancy rate was 21% in 1994. This rate remained stable between 21-
25% in spite of huge increase in elective single embryo transfers. The life birth rate 
remained quite constant throughout the study period: 15-18%. Instead success rates 
improved steadily when measuring the rate of term singletons and rate of singletons 
weighing at least 2,500 grams. Term singleton rate and rate of singletons weighing 
at least 2,500 grams rose from 9% to 14% per treatment cycle.  
 
Life-time birth rate after infertility treatments  
 
Self-reported life-time birth rate after any infertility treatment was estimated from 
FINRISK 2002 survey. The rate was highest among women reporting ovulation 
problems as a cause of infertility: 70%. Among the infertile women with 
endometriosis the life-time birth rate was 55%. The rate was 42% among the 
couples suffering from male infertility and 41% among women with tubal failure. 
The lowest life-time birth rates were reported among women with unexplained 
infertility (40%) or other causes of infertility (40%). Best self-reported life-time 
birth rates were achieved with hormone treatments (59%) and with ICSI (58%). For 
IVF and FET the rate was 47% and for insemination 45%. 
 
Life-time birth rate also differed by age (at time when interviewed), but this 
difference was not statistically significant (p=0.13). Life-time birth rate for women 
aged 24-29 years was 67%, for 30-34 years 70%, for 35-39 years 47%, for 40-45 
years 56%, for 45-54 years 62% and for women aged 55 years or more 60%. 
 
Clinical pregnancy rates after single and two embryo transfers 1995-2005 
 
In the early 1990s the clinical pregnancy rate after single embryo transfers was 
notably lower (10%) than after transfer of two embryos (27%). However, over time 
the clinical pregnancy rate after single embryo transfers increased dramatically 
being 24% in 2005. In 2005 the clinical pregnancy rate after two-embryo transfers 
was only slightly better (28%) than after single embryo transfers (24%). 
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Clinical pregnancy rate by maternal age and cause of infertility and outcome of 
pregnancies 1995 and 2005 in the public and the private sector 
 
Clinical pregnancy rate in both 1995 and 2005 was statistically significantly better 
in the private sector than in the public sector among women aged less than 34 years. 
In 1995 clinical pregnancy rate among women aged less than 30 years was 20.4% in 
the public sector and 35% in the private sector (p<0.001) and among women aged 
30-34 years 20% in the public and 32% in the private sector care. Among older 
women clinical pregnancy rate was somewhat better in the private sector but this 
difference was not statistically significant. Among women aged 35-39 years clinical 
pregnancy rate in the public sector was 20% and in the private sector 24% (p=0.13) 
and among women aged more than 39 years the rate was 3% in the public sector and 
7% in the private sector (p=0.16). In 1995 clinical pregnancy rate among women 
aged 35-39 was 4.4-fold better (95% CI 2.9-7.4) and among women aged less than 
30 years even 6.1-fold better (95% CI 3.8-9.8) than among women aged 40 or more. 
In 1995 clinical pregnancy rates in the public sector did not differ by age among 
women aged less than 39 years (20%). In the private sector women aged less than 
35 years had significantly better pregnancy rates (32-35%) than women aged 35-39 
(24%) or same aged women in the public sector. 
 
In 2005 the clinical pregnancy rate was still better in the private sector among the 
youngest age groups. Among women aged less than 30 years the rate was 24% in 
the public sector and 31% in the private sector (p=0.02) and among women aged 30-
34 the rate was 24% in the public sector and 31% in the private sector (p<0.01). 
Among older women the rates did not differ significantly: among women aged 35-
39 the rate was 24% in the public sector and 25% in the private sector (p=0.70). 
Among women aged 40 or more the clinical pregnancy rate was 12% in the public 
sector and 14% in the private sector (p=0.70). In 2005 the clinical pregnancy rate 
among women aged 40 or more had improved significantly. The clinical pregnancy 
rate among women aged 35-39 was 2-fold (95% CI 1.5-2.6) and among women 
aged less than 35 years 2.3-fold (95 % CI 1.8-3.0) compared to the oldest women. 
 
In 1995 the clinical pregnancy rates were significantly better in the private sector 
when treating tubal failure (19% in the public sector and 25% in the private sector, 
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p=0.05) and unexplained infertility (13% in the public sector and 27% in the private 
sector, p<0.001). For male, other female and multiple causes of infertility the 
clinical pregnancy rate was slightly better in the private sector than in the public 
sector but the difference was not statistically significant. In 2005 the differences by 
care site were not so big: the clinical pregnancy rate was slightly but statistically 
insignificantly better in the public sector for male and tubal infertility and in the 
private sector for unexplained fertility and for infertility with multiple causes. Only 
for other female infertility was the clinical pregnancy rate statistically significantly 
better in the private sector care sites (22% at the public and 29% at the private care 
sites, p<0.01). 
5.3 Health of women before and after infertility 
treatments (III, IV) 
Background characteristics of IVF cohort and controls  
 
When studying the health of treated women, IVF cohorts and their age and 
residence matched controls were used as study subjects. Background characteristics 
of the IVF cohort and controls are presented in Table 7. Statistically significantly 
more women in the IVF cohort had higher education and were married than among 
the controls (p<0.001). For the analysis adjustment for marital status and socio-
economic position was made. 
 
Table 7: Socioeconomic and marital status of IVF women and their controls  
(at the time of infertility treatments) 
 IVF women in register study 
(N=9,175), % 
Control women in  
register (N=9,175), % 
P 
Socioeconomic position    
Upper white-collar worker 25.3 16.3  
Lower white-collar worker 48.5 45.6  
Blue-collar worker 16.2 19.3  
Student, self-employed, 
unemployed, housewives 
7.9 12.3  
Unknown 2.1 6.4  
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   <0.001 
Marital status    
Married 69.4 45.3  
Unmarried 22.3 32.7  
Divorced 7.9 8.9  
Widow 0.4 0  
Unknown 0 13  
   <0.001 
 
Psychiatric hospitalizations among the women with the infertility treatments 
 
Hospitalizations for psychiatric diagnoses among the women with infertility 
treatments were studied before and after infertility treatments. Before infertility 
treatments the infertile women had fewer hospitalizations than the controls for each 
category studied (psychotic disorders, depression, bipolar disorder or mania, anxiety 
disorders, personality disorders, eating disorders, alcohol or other intoxicant abuse 
and adjustment disorder). Among the infertile women the most common diagnoses 
for hospitalizations were depression (63 out of 9,175 women), alcohol and other 
intoxicant use (36 out of 9,175 women), psychotic disorders (33 out of 9,175 
women) and personality disorders (30 out of 9,175 women). Depresson was also the 
most common diagnosis for hospitalizations among the controls (106 out of 9,175 
women). Ninety-four control women had hospitalizations for psychotic disorders, 65 
for alcohol and other intoxicant abuse and 63 for personality disorders. Even though 
the number of hospitalizations was smaller among the infertile women than among 
the controls  in each category, the difference was statistically significant only for 
psychotic disorders (OR 0.38, 95% CI 0.20–0.72). 
 
After infertility treatments depression was the most common reason for 
hospitalizations among both the women with infertility treatments (101 out of 9,175 
women) and the controls (121 out of 9,175 women). The women with infertility 
treatments had again statistically significantly fewer hospitalizations than controls 
for psychotic disorders (OR 0.45, 95% CI 0.28–0.73). Hospitalizations because of 
alcohol and other intoxicant abuse were also statistically more common among the 
control women after infertility treatments (OR 0.44, 95% CI 0.25–0.75). 
Interestingly, the women with infertility treatments had after treatments statistically 
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significantly more hospitalizations for adjustment disorders than did the control 
women (OR 3.43, 95% CI 1.03–11.4). Hospitalizations because of eating disorders 
were equally common in the both groups. The women with infertility treatments had 
fewer hospitalizations for anxiety disorders, bipolar disorder or mania and 
personality disorders than the controls but these differences were not statistically 
significant.  
 
The infertile women who had a baby after treatments had fewer hospitalizations for 
all diagnoses than those infertile women who did not. The difference was significant 
for anxiety disorders (OR 0.38, 95% CI 0.18-0.81), depression (OR 0.63, 95% CI 
0.41-0.96) and alcohol and other intoxicant abuse (OR 0.38, 95% CI 0.18-0.80). 
When comparing those infertile women who did not give birth to the controls the 
numbers of hospitalizations did not differ significantly with the exception of more 
hospitalizations or psychotic disorders (OR 0.38, 95% CI 0.19-0.77) among the 
control women. 
 
Mental support provided for the infertile women (data not previously published) 
 
In total, 45% of women receiving infertility treatments reported that they had 
received enough psychological support. About 33% reported that they had received 
no support, and 22% felt that the support had been insufficient. There was a 
statistically significant (p<0.001) difference in the reported adequacy of support 
between women whose infertility treatment had been successful and those whose 
had not, as significantly more women with unsuccessful treatments found support 
inadequate.  
 
Most women (85%) had received support from their spouse. Friends (54% of 
women), relatives (40%), and personnel at the infertility clinic (31%) were also 
commonly mentioned. Very few women had received help from a psychiatrist or a 
psychologist (2.1%). Peer groups were also an uncommon source of support (0.6%). 
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Cancer morbidity after infertility treatments  
 
In the cohort of 9,175 women with previous infertility treatment 178 cancers were 
diagnosed by the end of year 2004. Cancer incidence among the controls was 193 
out of 9,175 women. The incidence of cancers per 1,000 persons per year among the 
women with infertility treatments was 2.18 and among the controls 2.36. Among the 
controls cancer cases occurred somewhat earlier than among the women with 
infertility treatments but this difference was not statistically significant (p=0.10)  
 
The number of cancer cases is presented in Table 8. For most cancer types the 
differences in incidences between the infertile women and the controls were not 
statistically significant. However, the controls had statistically significantly more 
cervical cancer (OR 0.51, 95% CI 0.30-0.85) and the women with infertility 
treatments had statistically significantly more skin cancers other than melanoma 
(OR 3.11, 95% 1.02-9.6). The women with infertility treatments were also 
diagnosed with more ovarian cancer (13 cases) than the controls (7 cases) but the 
difference was not statistically significant (OR 2.99, 95% CI 0.50-17.8). All 
pulmonary cancer cases occurred among the controls (p=0.03).  
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Table 8. Cancer cases of infertile women and controls (matched for age and residence) after 
infertility treatments: odds ratios (95% confidence intervals) are adjusted for marital status and 
socio-economic position. 
   
 IVF women 
(N=9175) 
Control women 
(N=9175) 
OR (95%CI)    
Any cancer 178 193 1.01 (0.80-1.27)    
Breast cancer 55 60 0.93 (0.62-1.40)    
Ovarian cancer 13 7 2.99 (0.50-17.8)    
Cervical cancer 34 67 0.51 (0.30-0.85)    
Uterine cancer 4 2 2.0 (0.37-10.9)
a 
  
 
Pulmonary cancer 0 5  NC
b 
  
 
Thyroid cancer 10 8 1.27 (0.31-5.2)    
Melanoma 12 9 1.27 (0.34-4.8)    
Other skin cancer 24 10 3.11 (1.02-9.6)    
Tumours in central nervous 
system 
9 7 9.4 (0.56-159.5)    
Gastrointestinal track tumours 12 10 1.88 (0.52-6.8)    
Leukaemia or lymphoma 4 5 0.34 (0.04-3.06)   
 
 
a
Crude Odds Ratio due to small case number 
b
Non Calculable 
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6. Discussion 
Infertility is a common problem. It directly affects couples desiring a child but in 
many cases their parents, siblings, friends and work community. According to the 
sociologist Maili Malin impaired fertility is a medical problem whose social 
equivalent is involuntary childlessness. Involuntary childlessness can be considered 
primarily as social problem as the pain caused by the lack of a child is experienced 
with respect to the other people and the surrounding world. Infertility treatments can 
be used to artificially overcome the medical problems causing impaired fertility 
(Lindfors 2011). 
 
According to the most used definition, a couple is regarded as infertile when the 
woman has not become pregnant after one year of unprotected sexual intercourse 
(Evers 2002, Gnoth 2005). In Finland around one out of six couples meets these 
criteria. In addition to these couples there are people who voluntarily choose not to 
have children and people who would want to have a child but cannot try to conceive 
due, for example, to sexual orientation or lack of a partnership.  
 
In 2008, 20 % of Finnish females aged 42-43 years old, thus approaching end of 
their fertile period, did not have biological children. However, only four percent of 
women and six percent of men think that it is ideal not to have children. The ideal 
number of children has remained constant among Finnish women 1971-2007 being 
on average 2.38-2.55 children. According to a population survey 40 % of females 
and males also thought that the ideal number of children is more than their own 
actualized number of children (Miettinen & Rotkirch 2008). 
 
This study aimed to explore reduced fertility from various different perspectives 
without even trying to cover most of them. The extent of the infertility problem and 
use of infertility treatments were estimated from a population survey FINRISK 2002 
on grounds of socio-demographic factors. Absolute numbers in IVF, ICSI and FET 
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treatments by time and causes of infertility were also explored from aggregate IVF 
Statistics. The second article aimed to estimate the success of infertility treatments 
by time, cause of infertility and care site. This subject is naturally very important for 
couples suffering from infertility but for health care systems as infertility treatments 
are relatively expensive and time-consuming requiring the help of gynaecologists, 
nurses, midwives, cell-biologists and laboratory technicians. 
 
Two articles in this study concentrated on important health questions associated 
with infertility. Reduced fertility and fear of not having children typically cause 
significant stress and negative emotions and may expose people to mental illness. 
Our study aimed to compare hospitalizations due to psychiatric diagnoses among 
women receiving infertility treatments to those of controls before and after infertility 
treatments. After treatments hospitalizations were also compared between those 
treated women who gave birth after treatments and those who did not. Due to the 
severe psychological burden caused by infertility and possible infertility treatments 
mental support received was also studied. 
 
In various conditions causing infertility hormonal or inflammational balance in the 
body is disturbed and during hormonal infertility treatments exogenous drugs 
affecting the hormonal system are administered. Thus it is important to know 
whether either infertility itself or its treatments can via these hormonal changes 
predispose to increased risk for cancer. The last article in this study aimed to 
compare the cancer morbidity of cohort of women treated with IVF, ICSI or FET 
and cohort women. 
6.1 Prevalence of infertility and use of infertility 
treatments 
The present study demonstrated that 16% of females responding to FINRISK 2002 
survey met the criteria of infertility. True estimates of the prevalence of infertility 
can, however, be made only among women who have already passed menopause. 
Among the female respondents to FINRISK 2002 survey aged 50 or more 14 % 
reported infertility.  
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In the present study the prevalence of infertility was more common among the most 
educated women than among the women with less formal education. However, 
when the prevalence of infertility was studied separately in different age groups by 
education it was clearly perceived that among females under 34 years infertility was 
however more often reported among least educated women. This finding strongly 
supports current view in our society that highly educated women tend to postpone 
having children and thus they discover their possible infertility later. 
 
Miettinen and Rotkirch studied in a population survey opinions about the timing of 
having children (Perhebarometri 2008). Their results showed that Finnish women 
and men think that the ideal age to become a mother is on average 25.6 years and 
become a farther 27.4 years. This ideal age was smaller elicited from women who 
themselves had less formal education (on average 24.9 years) than from the most 
educated ones (26.8 years). However, the ideal age of motherhood among the most 
educated women was actually on average two years younger than their own age at 
becoming a mother (Miettinen & Rotkirch 2008). 
 
In 2005, 85% of Finnish women and men aged 25-34 years had completed a higher 
education degree after compulsory school. (Statistics Finland, 2011) and 31% of 
women in this age group and 25% of men had a degree from a university (Ministry 
of Education and Culture, Kehittämissuunnitelma, 2007). The average age to start 
studies at university in Finland is 21 years (Saarenmaa et al. 2010) and usually it 
takes at least 5-6 years to graduate. Becoming pregnant during university studies is 
relative rare as only 13% of university students have children (Saarenmaa et al. 
2010). Thus young adults graduating from university or polytechnic have to choose 
whether trying to start their professional career or to try to become parents. 
 
According to a population survey Perhebarometri 2008, one third of women who did 
not have children believed that having a child would diminish their work prospects. 
The prevalence of this view increased as educational level increased. Thirty percent 
of females aged 25-34 having a permanent employment contract also thought that 
uncertainty in their career was their reason to postpone having children. The 
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proportion was even larger, 40%, among childless women on temporary 
employment contracts (Miettinen & Rotkirch 2008). 
 
The ability to achieve high-quality education and the desired career is naturally a 
great and desirable goal for most people. Many people also find their spouse later in 
life and therefore postpone having children for this reason. Natural fertility, 
however, starts to decline from the late 20´s onwards (Dunson 2002). In order not to 
increase the prevalence of reduced fertility and need for infertility treatments it 
would be important to encourage young educated women to dare to become 
pregnant without significantly compromising their careers. Possible renovations to 
achieve this would, for example, be to share the employer’s cost due to maternity 
leaves more equally and to create more encouraging atmosphere for fathers to use 
parental leaves. 
 
The present study also showed that the use of infertility services differed by socio-
demographic factors. The use was statistically significantly more common among 
the most affluent and the most educated women and in the metropolitan area 
followed by other large cities. In Finland it is possible to be treated for infertility in 
either public or private infertility clinics. In public clinics patients treated pay only a 
taken clinic visit fee, in Tampere University Hospital, for example, 27.40 euros per 
visit (Pirkanmaa Hospital District, 2011). In the private sector patients pay for visits 
and treatments themselves but the Social Insurance Institute (SII) reimburses part of 
costs directly for women aged less than 43 years treated for medical reasons (The 
Social Insurance Institute, http://www.kela.fi/in/internet/suomi.nsf/NET/ 
020411112121MH?OpenDocument). However, even after this reimbursement, 
infertility treatments in private sector typically cost several hundred or thousand 
Euros. Regardless of the care site patients have to pay for the medications used in 
infertility treatments themselves after reimbursements from The Social Insurance 
Institution usually deducted in drug stores. However, the annual costs of reimbursed 
drugs exceeding 675.39 Euros (in 2011) are reimbursed totally and patients only pay 
1.5 Euros per item purchased (Ministry of Social Affairs and Health, 
http://www.stm.fi/sosiaali_ja_terveyspalvelut/asiakasmaksut/terveydenhuollon_mak
sukatto).  
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The costs of infertility treatments may affect low-income couples’ chances to obtain 
infertility services especially in the private sector. However, fortunately in Finland 
there are seven qualified public infertility clinics whose treatments provided, even 
combined with medication expenses, are quite affordable. 
 
According to the present study the use of infertility treatments was clearly least 
common in North Karelia and most common in the metropolitan area. Oulu was the 
northern most region covered in the study and thus utilization by people living up to 
675 kilometres (Utsjoki) further north cannot be discussed. Even though there are 20 
clinics providing infertility services they are located in large cities, typically in 
Southern Finland. Thus infertile people living far from these clinics may have to 
travel several hundred kilometres to their nearest care site. This, of course, causes 
significant loss of time but may be a reason why more rural infertile couples do not 
participate as often in treatments as urban infertile couples even though equally 
aware of treatment options. Intensive infertility treatments, such as IVF require 5-7 
visits to an infertility clinic during one treatment cycle. Regardless of the distance to 
the care site, this may be difficult for working infertile women to arrange. When 
travelling to the infertility clinic takes hours usually a whole working day is needed 
to arrange one visit. Thus it may be necessary to tell about infertility and the need 
for these treatments at work and to the relatives and friends wondering about these 
visits. This may significantly decrease willingness to participate in infertility 
treatments. 
 
During the follow-up period of Paper I (1992-2004) the absolute number of IVF, 
ICSI and FET treatments given in Finland more than tripled and the shares of 
diagnoses for treatments changed significantly. In 1992 over one third of couples 
treated with IVF or FET had tubal infertility as a reason for need for infertility 
treatments. However, as the incidence of Chlamydia trachomatis infections started 
to decrease from the late 1980’s onwards the number of females with significant 
tubal infertility decreased. However, from 1995 onwards the incidence of these 
infections has started to increase again, especially among adolescents under 20 years 
old. (Hiltunen-Back & Reunala 2005). If these infections are not treated early with 
antibiotics the role of tubal infertility is likely to increase as these young people try 
to conceive.  
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ICSI was introduced in Finland in Mid-1990s revolutionising the treatment options 
for couples suffering from severe male infertility. Understandably the proportion 
and absolute numbers of couples treated because of male infertility increased 
significantly thereafter. 
6.2 Success of infertility treatments 
During the study period 1994-2005 a significant change in treatment protocols took 
place in Finland as the number of embryos transferred decreased dramatically and 
elective single embryo transfers became a common protocol: in 2005 in half of IVF, 
ICSI or FET treatments only one embryo was transferred. This proportion has 
remained fairly constant even since: according to the most recent data from 2009, 
46.5% of IVF and ICSI treatments were elective single embryo transfers (THL 
http://www.stakes.fi/tilastot/tilastotiedotteet/2011/Tr15_11.pdf). These shares, 
however, are not totally comparable as in some of the treatment cycles during the 
follow-up only one embryo may have been transferred because no others were 
available.  
 
Despite the huge increase in single embryo transfers clinical pregnancy rates and 
live birth rates remained similar during the study period suggesting that treatment 
protocols are effective and no “extra” embryos are needed to ensure better success 
rates. The shares of term singletons and singletons weighing at least 2500 grams in 
turn increased from 9% to 14%. This improvement was likely largely due to the 
decreased number of multiple pregnancies as the number of embryos transferred 
decreased. 
 
The pregnancy rates after elective single embryo transfers combined with frozen 
embryo transfers from the same treatment cycle are currently similar to those after 
double embryo transfers (Vilska et al. 1999, Thurin et al. 2004, Lundin & Bergh 
2007, Bechoua et al. 2009, Fauque et al. 2009, Veleva et al. 2009, Stillman et al. 
2009). Multiple pregnancies are always risk pregnancies requiring more intense 
monitoring. The risk of pregnancy complications and pre-term birth is also elevated 
compared to singleton pregnancies. Thus it is understandable that many health care 
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professionals want to favour single embryo transfers in order to decrease the risk for 
multiple pregnancies.  
 
However, for couples suffering from infertility a twin pregnancy despite of risks 
may be an even more desired outcome than a singleton pregnancy. Only one percent 
of respondents to the Finnish population survey Perhebarometri 2008 considered 
one child the ideal number of children (Miettinen & Rotkirch 2008). It is 
understandable that some couples who may have suffered from infertility for several 
years and already undergone many previous unsuccessful infertility treatment cycles 
may want to have two children at the same time in order to avoid needing for 
infertility treatments again.  
 
The data indicated that at the beginning of the study period there were statistically 
significant differences in pregnancy rates by care site as the rate was better in the 
private sector especially when young women were treated. However, in 2005 the 
difference was already much smaller. There may have been differences in treatment 
protocols in private and public sector care sites for example in numbers of embryos 
transferred. The results covered IVF, ICSI and FET treatments, so it is possible that 
in the public sector physicians try even more eagerly cut costs and provide, for 
example, more inseminations as first line treatments before using more intense IVF 
or ICSI treatments. Altogether qualified treatments are provided in both public and 
private clinics in Finland. 
 
From FINRISK 2002 survey it was possible to estimate self-reported lifetime 
success rates after different infertility treatments. The highest lifetime birth rate, 
59%, was obtained after hormone treatments followed by ICSI, 58%, IVF and FET, 
47%. However, these success rates cannot be considered actual maximal cumulative 
live birth rates that can be medically obtained with these treatments. Some of the 
couples treated for infertility may have become pregnant naturally after 
unsuccessful infertility treatment cycles and therefore discontinued treatments. 
Some couples may have decided to try to adopt a child and for some couples 
infertility treatment may have been too expensive or mentally too hard and they may 
have abandoned treatments before it was medically suggested.   
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6.3 Health of women receiving IVF, ICSI or FET 
treatments 
Mental health and support during infertility crisis 
 
Research has demonstrated that depressive symptoms and anxiety are common 
among infertile women participating in infertility treatments (Newton et al. 1990, 
Domar et al. 1992, Matsubayashi et al. 2001, Fassino et al. 2002, Lok et al. 2002, 
Chen et al. 2004, Sbaragli et al. 2008, Volgsten et al. 2008). Therefore it was 
interesting to study whether women receiving infertility treatments were more 
vulnerable to psychiatric disorders either before or after treatments than control 
women.  
 
The present data clearly demonstrated that in both before and after infertility 
treatments mental health of treated women was better than or similar to that of 
controls. Only adjustment disorders were slightly but statistically significantly more 
common among women in the cohort of infertile women after infertility treatments. 
These results suggest so-called a healthy patient effect as women planning for 
pregnancy are usually physically and mentally relatively healthy.  
 
This data may not, however, be generalized to all infertile women as it consisted 
only of those infertile women seeking medical help and receiving relatively intense 
infertility treatments. It is thus possible that the results would be somewhat different 
among women suffering from infertility but not participating in infertility 
treatments. A study by Hammarberg et al. (2001) showed that the decision to start 
infertility treatments tends to be difficult and thus it is possible that infertile women 
suffering from mental problems do not have enough strength to make that decision 
or participate in intense infertility treatments. 
 
Adjustment disorders typically evolve in response to stress or grief and according to 
the data only this diagnosis after infertility treatments was more common among 
infertile women than among the controls. This could be explained as a response to 
unsuccessful treatments or stressful childcare, and that is why the number of 
hospitalizations among infertile women regarding whether they gave birth after 
76 
treatments or not was further studied. The results demonstrated that hospitalizations 
for all psychiatric diagnoses were statistically significantly less common among 
those infertility-treated women who gave birth than among those who had 
unsuccessful treatments suggesting that having children does not predispose infertile 
women to severe mental problems. 
 
This view is supported in a study by Klemetti et al. (2010) indicating that risk of 
psychiatric disorders was not increased among formerly infertile women with 
childen even though risk for dysthymia and anxiety disorders were elevated among 
infertile women without a child. A Finnish study by Repokari et al. (2007) 
demonstrated that among 367 couples with IVF or ICSI singletons and control 
couples with singletons successful infertility treatment was not a risk for marital 
adjustment of infertile couples. Neither severe fear of childbirth nor pregnancy-
related anxiety seemed to be more common among previously infertile women than 
among spontaneously conceived controls (Poikkeus et al. 2006). 
 
It was found that less than half of infertile women participating in infertility 
treatments found the mental support received sufficient. Only one third of treated 
women reported having received mental support from their infertility clinic. In most 
cases infertility is a severe crisis and emotional distress during infertility and its 
treatments can be expected. Yet the proportion of women who had consulted a 
psychiatrist or a psychologist was very small. Earlier studies suggest that the risk for 
severe emotional distress is greater in the case of pre-existing psychiatric illness 
(Burns 2007), previous unsuccessful treatment cycles, low socioeconomic status and 
a lack of support from a spouse (Beutel et al. 1999). Protective factors for distress 
are conversely good self-esteem, satisfactory job and good relationship (Bringhenti 
et al. 1997).  
 
In the study women reported that own spouse was the most important supporter. 
Friends and relatives were more common supporters than health care professionals. 
Similar findings have been reported from a Dutch infertility clinic where treated 
women named friends, siblings and their own mothers as the most important support 
givers (Oddens et al. 1999). According to that study, 46% of women found it hard to 
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talk about infertility and over half thought that other people were reluctant to discuss 
the issue with them. 
 
In Finland the Family Federation (Väestöliitto) and infertility clinics of Hospital 
District of Helsinki and Uusimaa and Oulu University Hospital have conducted a 
study among 450 patients treated for infertility. Of these couples 15% had not told 
anyone about their participation in infertility treatments and about half had told only 
to a few close friends. Women were more likely to tell about the treatments but only 
a few percent shared their infertility openly. Twenty percent of couples thought that 
they would have needed more mental support. It was also widely acknowledged that 
support received from close family members and friends may influence participation 
in infertility treatments and willingness and strength to continue treatments 
(Miettinen, 2011) 
 
As mental support received during infertility and infertility treatments is commonly 
considered insufficient and it is usual that people are only seldom aware of the 
infertility of their nearest, supporters may also have problems in handling the 
situation. The Finnish Infertility Association Simpukka has published a guide book 
for friends and relatives of infertile couples that can be used in order to better 
support those suffering from infertility (Paasisalo, 2010) 
 
Risk for cancer among infertile women 
 
Up to eight years follow-up overall cancer incidence was similar in both groups 
studied. Infertile women had statistically significantly fewer cervical cancers and 
more skin cancers other than melanoma. All pulmonary cancers were diagnosed 
among control women.  
 
The difference in the incidence of cervical cancer suggest, as the results of Paper III, 
the so called a healthy patient effect. Women participating in infertility treatments 
are used to visiting their gynaecologists regularly and thus papanicolaou smears are 
likely to be taken often, in many cases enabling diagnosis of possible cell atypia 
before they progress to cancer. It is possible that women suffering from infertility 
have learned to automatically monitor their health and due to infertility treatments 
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are used to receiving health care. This may explain the statistically significantly 
larger incidence of other skin cancers than melanoma among infertile women who 
might react to their suspicious moles more vigilantly. A part of this difference may 
also be due to residual socio-economic differences even after adjustment between 
the groups because skin cancers are more common among highly educated persons 
(Hemminki & Li 2004). 
 
It is likely that many women desiring children have stopped smoking already when 
first trying to conceive or at the latest when discovering their difficulties in 
conceiving because smoking impairs fertility. This may explain differences in the 
incidence of pulmonary cancer. Socio-economic factors could also explain this 
difference. More women in the control group had lower socio-economic position 
and in Finland probability of smoking differs by social class (Rahkonen et al. 2003). 
However, due to the statistically significant difference in this factor between the 
cohort and controls, adjustment for socio-economic position was made before data 
analysis. Thus this difference is unlikely to explain the different pulmonary cancer 
incidences between the groups. 
 
Existing data on cancer risk among infertile women is still, despite a great deal of 
research, somewhat inconsistent. One reason is that in most studies infertile women 
have been analysed as one class regardless cause of infertility. Theoretical 
knowledge about the pathogenesis of conditions causing infertility, like ovulatory 
disturbances, endometriosis or PCOS, still suggests different risk potential for 
different cancer types. For example, it is understandable that among women with 
long anovulatory menstrual cycles the risk for uterine cancer can be increased as the 
endometrium is too long exposed to proliferation caused by oestrogen (Goodarzi et 
al. 2011). Among women suffering from endometriosis the risk for ovarian cancer 
may be increased (Kobayashi et al. 2011, Munksgaard & Blaakaer, 2011). The 
numbers of women with these infertility causing conditions is different in different 
studies. In some studies a larger proportion of infertile couples may suffer from 
male infertility or tubal infertility caused by untreated Chlamydia trachomatis 
infections. Among women treated for these conditions the gynaecological cancer 
risk is likely to be similar than that among women without fertility problem with 
similar other risk factors for these cancers. 
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Knowing that certain gynaecological diseases may, in addition to causing infertility, 
also predispose to cancer could change the treatment protocols of these diseases. For 
example, for those endometriosis patients who could manage pain caused by the 
condition with only pain medications, hormonal treatments that also control 
hormonal and inflammatory changes might be indicated to decrease cancer risk. 
Overweight women suffering from polycystic ovary syndrome should also know 
that in addition to increased risk for infertility and cardiovascular disease, their 
disease may also predispose them to uterine cancer and that loosing weight 
decreases this risk significantly. 
 
This study did not find increased risk related to IVF, ICSI or FET treatments. 
Naturally all medical treatments should have a minimal amount of side-effects, 
especially serious ones. In all cases of infertility effective treatments without 
exogenous drugs significantly affecting the body’s hormonal balance cannot be 
provided. IVF and ICSI do have well-recognized potentially dangerous side-effects 
like ovarian hyperstimulation syndrome. The couples participating in these 
treatments should be well aware of the risks. The desire for children is in many 
cases so intense that people are ready to take risks potentially affecting their own 
health in order to have a child. It is unlikely that even in the future, if research data 
on potential cancer risk after infertility treatments increases, the use of these 
treatments would significantly decrease. 
6.4  Methodological considerations 
The materials used in this study were two cross-sectional population surveys, 
aggregate IVF statistics, a cohort of women (N=9,175) who had received IVF, ICSI 
or FET treatment 1996-1998 and their age and residence matched controls. The 
cohort and their controls were linked to several registries. A study setting like this 
has many advantages but also limitations and disadvantages.  
 
The aggregate IVF statistics utilized in the study are generally regarded as reliable. 
It was voluntary to the clinics to report data but the rate of report is high, up to 
100% in the years studied. Even though a specific questionnaire was used for data 
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collection it is still possible that the clinics report data differently for example when 
classifying causes of infertility.  
 
Each year the statistics also collect preliminary data from the previous year which is 
later compared to actual data from that year. As preliminary and actual data are 
usually very similar the reliability of the data can be regarded as good. The greatest 
restriction of the data obtained from IVF Statistics is that it is reported by the clinics 
in aggregate form and thus no identification of patients treated is received. Thus it is 
impossible to link these women to different national registries. 
 
The two population surveys used in this study are based on random population 
sampling and can therefore be considered representative. However, only some 
regions in Finland are covered in these studies which may naturally cause bias, for 
example, when studying regional differences in use of infertility treatments. The 
response rate in these studies was relatively high but it is still possible that the 
differences in non-responders’ by background factors may bias the results. The 
response rate did not however differ significantly by either age (73-79% in 
FINRISK 2002) or residence of respondents (71-79% in FINRISK 2002) and 
therefore the data is probably not significantly biased. 
 
As the survey data is based on self-reported information it is possible that some 
recall or reporting bias occurred. Generally it is reasonable to try to cover several 
important health issues is these studies. Therefore it is impossible to include all 
possible aspects, for example, of reduced fertility to these surveys. In order to 
enable comparisons over time the questions and answer options on a given issue 
should remain similar. This was not the case when comparing questions about 
undergoing infertility treatments in FINRISK 1997 and 2002 surveys and thus no 
really accurate comparison on possible changes over time could be made. 
 
When studying the health of women treated, a cohort of patients who received IVF, 
ICSI or FET treatment 1996-1998 and their controls were used as a data source. 
This cohort was created from the drug reimbursement records. The drug 
combinations used in IVF, ICSI or FET treatments are not used for other purposes 
and thus this cohort is very unlikely to include women not having received these 
81 
treatments. Moreover in IVF and ICSI treatments controlled hyperstimulation of the 
ovaries is required in order to mature several egg cells. This is not possible without 
drugs and therefore all IVF and ICSI treated women are very likely included in this 
cohort. Practically the only possible explanation for provided IVF or ICSI treatment 
not covered in this cohort would be a case when a woman had visited an infertility 
clinic in December 1995 and then bought drugs for treatments started in January 
1996.  
 
Not all frozen embryo transfers were included in the cohort as it is also common to 
transfer frozen embryos utilizing woman’s natural menstrual cycle without 
exogenous support medications. This, however, unlikely to cause significant bias in 
the results. 
 
Hospitalizations among the cohort women and their controls were compared both 
before and after infertility treatments. This comparison does not enable the 
investigation of actual psychiatric morbidity in these groups as only severe cases 
requiring hospitalization were recorded. A much larger group of women suffering 
from milder psychiatric illnesses were probably treated as outpatients. However, 
there is no reason to believe that the proportions of in-patient care and out-patient 
care would be different between the cohort and control women. Thus this data 
source should be reliable for recording severe, psychiatric illnesses requiring 
hospitalization. 
 
The background characteristics of the women in the cohort and control groups 
regarding marital status and socio-economic position were statistically significantly 
different. This could cause significant bias but adjustments for these were made in 
the data analysis and thus any possible residual confounding caused by these 
differences is likely to be slight. 
 
When investigating cancer morbidity, the same cohort of 9175 women who had 
received IVF, ICSI or FET and their controls were used as study material. The 
follow-up time was relatively short 6-8 years, but as the number of women was 
large, almost 200 cancer cases were diagnosed in both groups. These numbers are 
large enough to permit reasonable estimates in most cases of possible differences in 
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cancer incidences between the groups. For example, during this follow-up time the 
incidences of cervical cancers, pulmonary cancers and skin cancers other than 
melanoma were significantly different between the two groups.  
 
In the case of ovarian cancer possible differences in incidence remain unclear: 
according to the data the incidence seems to be larger (13) among the cohort of 
infertile women than among the controls (7). Ovarian cancer is a relatively rare 
cancer and thus larger case numbers are needed to confirm whether this difference 
of six cancer cases is significant or coincidental. Incidences of uterine cancer were 
also so small (4 in the cohort and 2 in controls) that it is impossible to estimate 
accurate differences in incidences. For thyroid cancer, tumours in the central 
nervous system, gastrointestinal track tumours and leukaemia or lymphoma the 
differences in incidences were at most a few cases and the number of these 
diagnoses was large enough to permit the conclusion that clinically significant 
differences in cancer incidences did not exist. 
 
Most cancers are diagnosed in older age and thus it is to be expected that the 
number of cancer cases for each diagnoses will be much larger when follow-up time 
increases. Most women in the cohort (and of course also among the controls) were 
under 40 years old when receiving infertility treatments and thus were still under 50 
years at the end of follow-up. 
 
One significant weakness of the study setting was that the role of infertility itself in 
affecting cancer incidence cannot be distinguished from that of infertility treatments, 
as general population was used as controls. The data enabled matching for age and 
residence and adjustment for marital status and socio-economic position. However, 
many factors affecting cancer risk such as parity, use of oral contraceptives, genetic 
predisposition, possible obesity or smoking cannot be controlled for.  
 
The risk of cancer either because of infertility or use of infertility treatments has 
already been studied in various cohort, case-control and questionnaire studies. For 
many cancer types the existing data is contradictory between the studies. From the 
theoretical point of view it is reasonable to expect that any possible increase in 
cancer risk might differ depending on the cause of infertility. If the infertility drugs 
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affect on cancer risk, it is likely to be different depending on which hormonal 
infertility drug is given. 
 
Thus in future it would be reasonable and important to collect large cohorts enabling 
estimations of cancer risk depending on the cause of infertility instead of analysing 
infertile women as one group. Also the follow-up time should be long enough. 
When estimating cancer risk after taking hormonal infertility treatments, the control 
group should be un-treated infertile women with the same cause of reduced fertility. 
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7. Conclusions 
1) There were differences in the prevalence of infertility by woman’s age and level 
of education. In general infertility was the most common problem among the 
most educated women. However, when ascertaining prevalence of infertility 
among young women, the least educated ones reported problems more often, 
suggesting that more educated young women tend to postpone childbearing. 
 
2) The number of IVF, ICSI and FET treatments provided in Finland more than 
tripled in the period 1992-2004. The proportions of causes of infertility changed 
significantly over time. 
 
3) There were socio-demographic differences in the probability of seeking help for 
infertility: urban, affluent and the most educated women were most likely to 
seek help. However, the data from FINRISK 1997 and 2002 suggested that 
differences in the use of infertility services by these factors may have 
diminished over time. 
 
4) Clinical pregnancy rate and live birth rate after IVF, ICSI or FET remained 
similar in the period 1994-2005 despite a substantial increase in single embryo 
transfers. The term singleton rate and rate of singletons weighing at least 2500 
grams rose during the follow-up period, which is at least partly explained by the 
smaller number of multiple pregnancies as the number of embryos transferred 
has become smaller. 
 
5) Clinical pregnancy rates after single embryo transfers improved significantly 
1994-2005. 
 
6) Success rates were significantly better in the private sector especially when 
treating young women, but the difference diminished over time. 
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7) Before participating in infertility treatments infertile women had fewer 
hospitalizations than controls due to all psychiatric diagnoses. After treatments 
the number of hospitalizations was still smaller for all other diagnoses but 
statistically significantly greater due to adjustment disorders. 
 
8) After infertility treatments those infertile women who gave birth had fewer 
hospitalizations for all psychiatric diagnoses than those who did not give birth. 
 
9) In the cohort of women receiving IVF, ICSI or FET treatments cancer risk was 
not increased. They had statistically fewer cervical cancers and pulmonary 
cancers and more skin cancers other than melanoma suggesting a healthy patient 
effect. 
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Infertility is an important medical and social problem in
both magnitude and impact on well-being. According to an
often-used definition a couple is regarded as subfertile if the
woman has not become pregnant after 1 year of unprotected
sexual intercourse [1]. The definition of World Health Orga-
nization (WHO) requires as much as 2 years of unprotected
intercourse [2]. The prevalence of subfertility is most often
studied as current prevalence or as lifetime prevalence, which
is a cumulative prevalence until the time of study [3].
It is generally estimated that approximately 10–15% of
couples have difficulties in conceiving [1,4]. In their meta-
analysis Schmidt and Mu¨nster reported that the current
prevalence of subfertility in studies published in 1970–1992* Corresponding author. Tel.: +358 405185509; fax: +358 35516057.
E-mail address: anna-niina.terava@uta.fi (A.-N. Tera¨va¨).
0301-2115/$ – see front matter # 2007 Elsevier Ireland Ltd. All rights reserved
doi:10.1016/j.ejogrb.2007.05.009varied from 3.6 to 14.3% and lifetime prevalence from 12.5
to 32.6%. In the 1990s the lifetime prevalence of subfertility
was reported to be 10% in the United States [5], 16% in
Finland [6] and 26% in Denmark [7].
In industrialized countries half of subfertile couples seek
medical help [8]. It has been speculated that reasons why
subfertile couples may not want to use infertility treatments
may be financial, medical, psychosocial, moral or ethical
[9]. According to a Finnish study women who did not seek
medical help for infertility were younger, had fewer years of
formal education and had tried to become pregnant for a
shorter time period than the treatment-seeking women [6]. In
Finland the per capita use of infertility treatments is
approximately the same that in Denmark and Iceland and,
for example, five times greater than in the United States [10].
In the United States the utilisation of infertility treatments
is significantly higher in those states where the treatments
are either partly or completely covered by health insurance.
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women and those with high incomes [12]. According to a
recent study in a state where insurance coverage of the
infertility treatments is mandatory, Caucasian, affluent and
more educated women also use notably more infertility
treatments [13]. African American women also suffer from
subfertility for a longer time period than other ethnic groups
before seeking medical help [14].
In Finland, too, there are socio-demographic differences
in the use of in vitro fertilization (IVF): the age-standardized
IVF incidence per thousand women aged 20–49 was 7.3 in
rural and 8.8 in urban areas [15]. Moreover, women who
receive infertility treatments are more educated [16] or in a
better socio-economic position [17].
The objective of this study was to examine changes in
infertility treatments by time, causes of infertility, lifetime
prevalence of subfertility and use of infertility treatments by
socio-demographic factors.2. Materials and methods
Two different data sources, aggregate IVF statistics and
two cross-sectional surveys (FINRISK 1997 and FINRISK
2002) were utilised.
2.1. Aggregate IVF statistics
IVF statistics are gathered annually by STAKES (the
National Research and Development Centre for Welfare and
Health). For the years 1992, 1995, 2000 and 2004 the data
consist of aggregated data from IVF, ICSI and FET
treatments in the public and private sectors.
For this data source all clinics in Finland were asked
about the number of treatment cycles and pregnancies
started, the cause of infertility, the number of embryos
transferred, pregnancy, birth and newborn outcomes,
complications and congenital anomalies using a specific
questionnaire [18,19]. The clinics report the data themselves
and participation is voluntary. In years 1995 and 2004 all
clinics participated. In 1992 and 2000 one clinic did not
participate as it had already discontinued its operations at the
time of data collection. Infertility treatments were given in
13 locations in 1992 and 18 in 2004.
For this study we used data from IVF statistics
concerning the number of IVF, ICSI and FET cycles, the
age distribution of the women starting IVF or ICSI treatment
and the causes of infertility. The age of women receiving
FET treatment was not elicited from the clinics, due to
different ways of recording the age (age at ovum harvesting
or age at frozen embryo transfer).
2.2. Survey data: FINRISK 1997 and FINRISK 2002
As another data source we used two cross-sectional
surveys (FINRISK 1997 and FINRISK 2002) that werecoordinated and conducted by National Public Health
Institute. These surveys monitor public health and risk
factors of chronic diseases and included questions on
reproductive health. Six regions in Finland were included in
the survey: the cities of Helsinki and Vantaa in the
metropolitan area of Finland, South-Western Finland, North
Karelia and Kuopio, Oulu and Lapland provinces [20].
Lapland region was not included in the FINRISK 1997
survey and was therefore excluded from this study.
FINRISK surveys used a random population sample
consisting of subjects aged 25–64. The response rate among
women (N = 3763) was 76.5% in the FINRISK 1997 survey
and 75.8% (N = 4729) in the FINRISK 2002 survey [20].
In the FINRISK 1997 survey the women were asked
whether they had ever used hormone therapy to treat
infertility either in outpatient or inpatient care. The
FINRISK 2002 survey included a separate questionnaire
on women’s reproductive health including menstruation,
contraception, pregnancies and pregnancy complications,
use of hormone replacement therapy and infertility.
Participants were asked if they had experienced a time
period when they had tried to become pregnant, but had not
conceived or conception took more than 12 months. Medical
examinations because of infertility or use of infertility
treatments were elicited as a combined question: Have you
ever been in medical examinations or been treated for
infertility? Infertility treatments were elicited with the
following alternatives: insemination, in vitro fertilization
(IVF), intracytoplasmic sperm injection (ICSI), frozen
embryo transfer (FET) and other treatment. The number
of pregnancies and births resulting from treatments was
elicited.
The lifetime prevalence of subfertility and the participa-
tion rate in infertility treatments and medical examinations
due to subfertility were available from the FINRISK 2002
survey. Subfertility was analysed among all respondents by
age and education. Use of infertility treatments was studied
among subfertile women by age and education and among
all respondents by residental region, education and house-
hold income. The education of participants was classified
into three classes. In FINRISK 1997 ‘‘low’’ consisted basic
compulsory education, ‘‘medium’’ vocational training,
college and upper secondary school and ‘‘high’’ university.
In the FINRISK 2002 the classes ‘‘low’’ and ‘‘medium’’
were corresponding but the class ‘‘high’’ also included
polytechnic which was not an option in the FINRISK 1997
survey. Household income per year was pre-divided into
nine classes. The highest was in FINRISK 1997 more than
53,800 euros and in FINRISK 2002 more than 67,280 euros.
For this study we further classified income into three
categories ‘‘low’’, ‘‘medium’’ and ‘‘high’’ so that each
category included about one third of the respondents.
Chi-square test and odds ratios with 95% confidence
intervals were used to measure statistical significance. Odds
ratios were age adjusted. SPPS 14.0 for Windows (Chicago,
Illinois, USA) was used to analyse results.
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Fig. 1. Causes of infertility in initiated IVF and ICSI cycles in 1992, 1995,
2000 and 2004 (IVF statistics). Fig. 2. Self-reported subfertility in different age classes by education in
2002 (all respondents).
3. Results
3.1. Aggregate IVF statistics
The use of IVF services increased significantly: in 1992,
2499 IVF and FET cycles were started in Finland: ICSI was
not yet used. In 1995 the total number of IVF, ICSI and FET
cycles initiated was 5193 but the number increased to 7388
in 2000 and to 8229 in 2004. The increase was over threefold
from 1992 to 2004. Treatment rate per 1000 women in fertile
age (15–49 years) increased from 1.8 in 1992 to 7.0 in 2004
(numbers not shown in a table). The number of IVF or ICSI
cycles increased notably over time in every age group except
in the oldest (40 years or more) from 1992 to 2004. The age
of women receiving FET treatment was not available.
The proportions of the causes of infertility changed
notably from 1992 to 2004. The relative incidence of tubal
injuries as the reported cause of infertility treatment has
decreased significantly (Fig. 1), likewise the absolute
numbers (not shown). Another important trend was the rise
of the proportion of male factor in 1992–1995.
3.2. Survey data
Of the women participating in the FINRISK 2002 survey
16.0% reported a history of subfertility at least once in theirTable 1
Proportions of subfertile women by age and education and use of infertility trea
Age N Subfertile respondents (%)
24–29 554 44 (8)
30–34 528 90 (17)
35–39 531 110 (21)
40–44 551 125 (23)
45–49 540 97 (18)
50–64 1667 235 (14)
Total 4371 701 (16)
Education
Low 2049 300 (15)
Medium 1473 251 (17)
High 825 146 (18)
Total 4347 697 (16)
a Calculated from subfertile women.
b Odds ratios are age adjusted.lifetime (Table 1). The proportion of subfertile women was
smallest in the youngest age group and in the least educated
group. Subfertility was proportionally most common women
aged 40–44 years. Of all subfertile women 57% had sought
medical help. The proportion was smallest in the youngest
age group and largest among the age groups 50–64 and 30–
34 ( p = 0.004). More educated women were also more prone
to seek medical help than subfertile women with less formal
education. This difference was, however, not statistically
significant ( p = 0.2).
In the youngest age group the least educated women were
more likely to report subfertility than more educated ones,
but among women in the oldest age group the opposite was
found (Fig. 2). The use of infertility treatments or attendance
at medical examinations because of infertility varied by
education in a similar manner (Fig. 3).
The proportion of women reporting using of hormone
therapy for infertility (5%) remained the same in 1997 and
2002. However, in 2002 nine percent of women reported
infertility treatments or medical examination for subfertility
(Table 2). In 1997, women aged 35–39 had significantly
( p < 0.001) most often received hormone treatments while
women aged over 50 were proportionally most seldom
treated. By comparison, in 2002 women aged 40–44 years
were most often and women aged less than 30 most seldomtments or medical examinations because of infertility in 2002 in Finland
Subfertile respondents been treated (%)a OR (95% CI)b
16 (36) 1.0
54 (61) 2.6 (1.2–5.5)
57 (52) 1.9 (0.9–3.9)
66 (53) 2.0 (1.0–4.0)
54 (56) 2.2 (1.1–4.6)
151 (66) 3.1 (1.6–6.1)
398 (57)
162 (55) 1.0
142 (57) 1.2 (0.9–1.8)
93 (65) 1.7 (1.1–2.6)
397 (58)
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Fig. 3. Self-reported participation rate in infertility treatments or medical
examinations because of infertility by age in 2002 (all respondents).treated ( p < 0.001). The age of women at the time of
treatments was, however, not elicited.
Age-adjusted self-reported use of hormone therapy to
treat subfertility (1997 and 2002) and participation rate in
infertility treatments or medical examinations (2002) varied
among the study population by place of residence,
education and income (Table 2). The most highly educated
women had about twofold use of infertility treatments
compared to women in the lowest education group
( p < 0.01). A similar trend was found by household
income. In 1997 the difference between the highest and the
lowest income groups was almost threefold and in 2002
almost twofold (any treatment) or threefold (hormone
therapy). These results were all statistically significant
( p < 0.001).Table 2
Self-reported use of hormone therapy to treat infertility (1997 and 2002) and partici
by age, education, region and household income (all respondents)
Age 1997 2002
Users
(hormone
therapy, %)
Number of
respondents
in class
OR (95% CI) Users
(hormon
therapy,
24–29 5.0 402 1.7 (1.0–3.0) 2.0
30–34 7.6 459 2.8 (1.7–4.4) 5.2
35–39 7.7 456 2.8 (1.8–4.4) 7.2
40–44 6.9 481 2.5 (1.5–3.9) 8.2
45–49 5.5 489 2.0 (1.2–3.2) 5.2
50–64 2.9 1443 1 4.3
Education
Low 3.1 1273 1.0 3.8
Medium 5.8 1992 1.5 (1.0–2.3) 5.4
High 8.1 445 2.2 (1.3–3.5) 7.3
Region
North Karelia 2.2 742 1.0 3.0
Kuopio 5.4 794 2.6 (1.5–4.7) 5.8
Turku/Loimaa 5.1 746 2.5 (1.4–4.5) 3.9
Helsinki 7.4 715 3.7 (2.1–6.5) 7.0
Oulu 5.7 733 2.8 (1.5–5.0) 5.6
Income
Low 2.7 1367 1.0 3.0
Medium 5.5 1121 2.1 (1.4–3.2) 5.0
High 7.8 1143 3.0 (2.0–4.5) 7.3
Odds ratios are age adjusted.The use of infertility treatments was most common in
large cities and least common in the most eastern county of
North Karelia. However, regional differences in the use of
hormone therapy become smaller over time. The regional
difference in the use of hormone treatments was statistically
significant both in FINRISK 1997 and FINRISK 2002
( p < 0.001). However, difference in use of any treatment in
FINRISK 2002 was not significant ( p = 0.11).4. Discussion
The total number of IVF, ICSI and FET treatments
initiated in Finland more than tripled between 1992 and
2004. In addition to an increased need for infertility
treatments, this may have been caused by an increased
supply of infertility services and improved technology. The
number of clinics offering infertility services rose from 13 in
1992 to 18 in 2004. ICSI was introduced into Finland in
1994, enabling better treatments options for couples
suffering from male infertility.
The use of IVF services is more common in Finland than
in many other industrialized countries. Less than half of
treatments are given in the public sector and mainly covered
by national health insurance. Private services are also partly
reimbursed regardless of the woman’s age if the couple is
treated for medical reasons. However, for women aged 45 or
more (2001–2005) or 40 or more (2005 onwards) this
reimbursement requires a statement from a treatingpation in infertility treatments or medical examinations because of infertility
e
%)
Number of
respondents
in class
OR (95% CI) Users (any
treatment, %)
OR (95% CI)
557 1.0 2.9 1.0
522 2.7 (1.3–5.5) 10.3 3.9 (2.2–6.9)
528 3.8 (1.9–7.6) 11.0 4.2 (2.4–7.4)
547 4.4 (2.3–8.7) 12.8 5.0 (2.8–8.7)
541 2.7 (1.3–5.5) 10.2 3.8 (2.2–6.8)
1664 2.2 (1.2–4.2) 9.3 3.5 (2.1–5.9)
2049 1.0 8.2 1.0
1466 1.5 (1.1–2.1) 10.0 1.4 (1.1–1.7)
822 2.3 (1.6–3.2) 11.4 1.6 (1.2–2.2)
737 1.0 7.2 1.0
765 2.0 (1.2–3.3) 9.9 1.4 (1.0–2.0)
724 1.3 (0.7–2.3) 8.3 1.2 (0.8–1.7)
698 2.5 (1.5–4.1) 11.5 1.7 (1.2–2.4)
726 1.9 (1.1–3.3) 9.6 1.4 (1.0–2,0)
1586 1.0 6.8 1.0
1379 1.7 (1.2–2.5) 9.5 1.4 (1.1–1.9)
1279 2.5 (1.7–3.6) 12.0 1.9 (1.5–2.4)
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affected the treatment rate among older women but not the
rate among all women in fertile age.
The proportion of tubal injuries has decreased notably
and the proportion of other reasons (other female, male,
multiple, unexplained) has increased. Decrease in tubal
injuries may be due to decreased incidence of Chlamydia
trachomatis infections in the late 1980s and early 1990s in
Finland [21] as C. trachomatis causes the majority of pelvic
inflammatory diseases [22]. Over one third of women
infected with C. trachomatis in Finland are less than 20 years
old and they are likely to try become pregnant about 10 years
later. The number of couples treated because of male
infertility increased remarkably in the period 1992–1995 as
ICSI treatments were started in Finland and male infertility
could be treated better.
An American study reported that the ratio of 15–44 years
old women reporting impaired fecundity rose from 8% in
1982 to 10% in 1995. This increase occurred regardless of
age, parity, education, marital status and ethnicity and
according to the writers was probably due to delayed
childbearing [5]. We could not estimate changes in
subfertility as subfertility was not enquired in FINRISK
1997 study.
The overall lifetime prevalence of subfertility observed in
FINRISK 2002 was 16.0%, which is parallel with previously
reported cumulative prevalences [3,5–7]. However, the
prevalence of ever subfertility can only be measured among
postmenopausal women [3]. Women aged 50 years or more
(12.6%) participating in the FINRISK 2002 survey had
suffered from subfertility at some point their lives.
Interestingly, this prevalence is smaller than among younger
women.
Lifetime prevalence of subfertility differs by age and
education: more educated women were more often subfertile.
The opposite was found in an American study, where more
educated women were less likely to be subfertile compared to
less educated women [13]. In the United States this may be
due to a higher prevalence of sexually transmitted diseases
among less educated women [14]. In Finland, by contrast, this
educational difference is largely due to a trend among more
educated women to postpone childbearing.
Both regional (urban/rural) [15] and educational differ-
ences in the use of IVF treatments have been previously
reported for Finland [16,17]. Our results for 2002 are
parallel with earlier studies: self-reported use of infertility
treatments or medical examinations because of infertility is
also more common in urban areas and among women with
high education and high household income. Regional
differences in the use of hormone therapy in Finland,
however, were greater in 1997 than in 2002. The diminished
difference may be due to better awareness of treatments in
rural areas. However, differences in use of hormone therapy
by education or incomes did not change notably.
Ethnicity is another factor producing social differences in
infertility services. In the United States there are significantdifferences in the proportions of subfertility and in the use of
infertility services by ethnicity [13,14]. Lower prevalences
of subfertility have been reported among Caucasian women
than among non-Caucasian [13], and African American and
Hispanic women had significantly more often tubal
infertility [14]. Our data sources did not include information
on ethnicity or race due to a national confidentiality
regulation. The impact of ethnic minorities, however, is
small in Finland since the proportion of first generation
migrant parturients is low, less than 4% in 1999–2001 [23].
The aggregated IVF statistics used in this study cover
IVF, ICSI and FET treatments given in public and private
clinics in Finland. Participation in statistics is voluntary, but
the participation rate was high, up to 100% in the years
studied. The clinics report the data themselves which may
cause bias. The cause of infertility especially may be
reported differentially by different clinics. However, the
statistics are generally regarded as reliable. The statistics
also contain preliminary data from the previous year and in
the next report this data is compared to actual data.
Preliminary data and actual data are very similar and
possible inaccuracies are corrected yearly.
The FINRISK 1997 and 2002 surveys are good in
external validity since they are based on random population
sampling [24]. In addition to this, the response rate was high.
However, data is self-reported which may cause some recall
or reporting bias. The differences in non-participation by
background factors may also potentially bias our results.
However, response rate did not differ significantly by
respondent’s age (73–79% in FINRISK 2002) or place of
residence (71–79% in FINRISK 2002) and therefore it is
very likely that the data is not significantly biased.
It is impossible to know the exact prevalence of infertility
as the respondents to the FINRISK 2002 survey were not
asked if they had tried to become pregnant. Therefore the
prevalence of infertility from this study can be regarded as
the need for infertility treatments at population level.
Moreover, the FINRISK 1997 survey included only one
question concerning the utilisation of hormone treatments to
treat infertility. Therefore only this utilisation rate can be
used when comparing the FINRISK 1997 and FINRISK
2002 surveys.
Monitoring the prevalence of subfertility and the use of
infertility treatments is important, since there are no signs that
the need for treatments will decrease, rather the opposite. As
suggested by the EU-funded REPROSTAT project on
reproductive health indicators, measuring change over time
is a key element in health monitoring [25]. If countries would
use the same indicators, national trend studies and interna-
tional comparisons would become more reliable.5. Conclusions
The use of infertility treatments has more than tripled in
Finland 1992–2004 and the causes for treatments have
A.-N. Tera¨va¨ et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 136 (2008) 61–6666changed. There are socio-demographical differences in the
use of infertility treatments as their use is more common
among urban, affluent and more educated women.Acknowledgement
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A B S T R A C T
Objectives: The objective was to study the success rates of infertility treatments in the period 1992–2005
in public and private clinics.
Study design: Aggregate IVF statistics (1992–2005) and nationally representative cross-sectional survey
(2002).
Results: The success rates of infertility treatments remained stable, despite a substantial increase in
single-embryo transfers. In 2005, the clinical pregnancy rate was 23/100 initiated cycles and a live birth
rate of 17/100 cycles. The proportions of term singletons and singletons weighing at least 2500 g
improved over time and both rates were 14/100 in 2005. Pregnancy rates improved most among older
women during the study period. The success rate in the private sector was signiﬁcantly better than that
in the public sector among women younger than 35 years.
Conclusion: The single-embryo policy has not decreased pregnancy and birth rates. The proportions of
term singletons per initiated cycle and singletons weighing at least 2500 g per initiated cycle have
improved over time. The higher success rate in the private sector may be because of different clientele.
 2009 Elsevier Ireland Ltd. All rights reserved.
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Implantation rate, clinical pregnancies per cycle, and live birth
delivery rate are traditional indicators formeasuring the success of
infertility treatments [1,2]. However, an optimal indicator should
take into account not only the effectiveness of the treatments, but
also their risks [3–5].
While the clinical pregnancy rate measures the quality of care
in clinics, the efﬁciency of care can be measured by the live birth
rate. Other indicators have also been developed. Min et al.
introduced the concept of BESST (Birth Emphasizing a Successful
Singleton at Term) to measure the success of infertility treatments
[5]. The European IVFMonitoring consortiumhas also introduced a
similar outline of ‘‘singleton delivery rate per embryo transfer’’ [6].
Tiitinen et al. suggested utilization of the cumulative delivery rate
per stimulated cycle after all fresh or frozen embryo transfers. This
indicator would take into account the role of elective one-embryo
transfers and the later utilization of frozen embryos from same
oocyte retrieval [4]. It has also been suggested that instead of one
indicator, several endpoints should be considered simultaneously
[1,2]. Pinborg et al. suggested the use of three parameters to
measure the success of infertility treatments: the number of* Corresponding author. Tel.: +358 405105509; fax: +358 35516057.
E-mail address: anna-niina.terava@uta.ﬁ (A.-N. Yli-Kuha).
0301-2115/$ – see front matter  2009 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.ejogrb.2008.12.017oocytes per aspiration as a pre-in vitro parameter, the number of
ongoing implantations per embryo transfer as an in vitro
parameter, and the number of deliveries per embryo transfer as
a post-in vitro parameter [3].
Women’s age and the duration of childlessness are the most
important single factors to determine the outcome of infertility
treatments [7,8]. According to registry data from the United States,
women under 27 years of age have a live birth rate of over 40%,
whereas the rate is only 6% for women over 43 years of age.
Reduced pregnancy rates in older women are mainly because of
the diminished ovarian function and poor egg quality [9]. Older
women also have poorer implantation rates and are at an increased
risk of miscarriages [10].
In general, the cause of infertility has only a limited effect on
pregnancy rates. Low-ovarian response to gonadotropins inde-
pendently decreases pregnancy rates. Women with polycystic
ovaries (PCOS), hydrosalpinges, leiomyomata or endometriosis
have even poorer success rates [8,10], likewise overweight women
or smokers [11].
In Finland, the use of elective single-embryo transfers has
increased notably and the twin delivery rate is now 10% [4]. In
general, the implantation rate is 10–12% per embryo [12]. Elective
one-embryo transfers still have good success rates. In a Finnish
study based on data from a large university clinic in 1998–1999,
the pregnancy rate was 40.0% after double-embryo transfer. After
elective single-embryo transfer, the rate was 39% and the
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oocyte retrieval was 53% [13]. According to CDC data from the
United States, women under the age of 35 years had a pregnancy
rate of 47/100 after single-embryo transfer and 52/100 after
double-embryo transfer [9].
In this study, we report the outcomes and trends of infertility
treatments in Finland over the period 1992–2005. We also study
the success of infertility treatments by using pregnancy rates in
relation to women’s age, the number of embryos transferred, and
the cause of infertility, and calculated alternative success rates
taking into account infant outcome.
2. Materials and methods
In this study we utilized two different data sources: national
aggregate IVF statistics and a cross-sectional population study,
FINRISK 2002.
2.1. Aggregate IVF statistics
Aggregate IVF statistics have been collected annually since
1992. The data were ﬁrst gathered by Helsinki Central University
Hospital and since 1994 by STAKES (the National Research and
Development Centre for Welfare and Health). The IVF statistics
used in this study consist of data on IVF, ICSI, and FET treatments
(excluding donor cycles) in both the public and private sectors.
Infertility treatments were given in 13 locations in 1992 and 18 in
2004. Six clinics are public.
For IVF statistics all Finnish clinics report the number of
treatment cycles and pregnancies, causes of infertility, the number
of embryos transferred, pregnancy, birth and newborn outcomes,
complications, and congenital anomalies [14,15]. For data collec-
tion a speciﬁc questionnaire, originally designed by the Interna-
tional Working Group for Registers on Assisted Reproduction [16],
has been in use since 1994, with minor changes in 2001 and 2005.
The clinics report the aggregated data themselves. Identiﬁcation
numbers of the patients are not required. Two thousand ﬁve
hundred treatment cycles were started in 1992 and 8200 cycles in
2005. Participation in IVF statistics was voluntary during the study
period. In 1995 and 2004 all clinics participated in data collection.
In 1992 and 2000, data from one clinic each year is missing as they
discontinued operation during the study year.
2.2. Survey data: FINRISK 2002
FINRISK 2002 is a cross-sectional population survey gathered by
the National Public Health Institute. The self-report questionnaireFig. 1. Success rates after IVF, ICSI, and FETincluded questions on subfertility and the use of infertility
treatments. Alternative causes of infertility given in the ques-
tionnaire were tubal injury, ovulation problems, endometriosis,
male infertility, unexplained, and other. The infertility treatments
elicitedwere hormone treatments, insemination, IVF, ICSI, FET, and
other. Pregnancies and births were elicited as a treatment
outcome. This data source was used to estimate lifetime success
rates, which cannot be achieved using aggregate IVF statistics.
The participants of the FINRISK 2002 survey are from six areas
in Finland: (1) the cities of Helsinki and Vantaa in themetropolitan
area, (2) southwest Finland, (3) North Karelia, (4) Kuopio, (5) Oulu,
and (6) Lapland. The population sample is random and consists of
subjects aged 25–64. The response rate among women was 75.8%
(N = 4729).
The statistical comparisons were made using a test for relative
proportions and odds ratios with 95% conﬁdence intervals.
3. Results
3.1. Aggregate IVF statistics
Fig. 1 gives the success rates calculated by different endpoints.
The proportions were calculated per initiated IVF, ICSI, and FET
cycle. The clinical pregnancy rate and live birth rate increased
slightly. The more signiﬁcant increase is in the proportion of term
singletons and singletons weighing at least 2500 g. In 1992 the
rates of term singletons and singletons weighing at least 2500 g
were both 9 per 100 initiated cycles. In 2004 these success rates
were both 14/100.
We calculated the live birth rate after IVF, ICSI, and FET
separately over the time period 1994–2005 (ICSI was introduced in
Finland in 1994). The live birth rate after IVF and ICSI increased
slightly in the mid-1990s and remained stable thereafter. The live
birth rate after FET in turn increased evenly over the period 1995–
2005 and was 11% in 1995 and 17% in 2006.
The number of embryos transferred decreased notably over
time. In 1992, in 14% of treatment cycles one embryo, in 41% two
embryos, in 37% three embryos, and in 7% four embryos were
transferred. The number of cycles with four embryos transferred
decreased rapidly and after 2000 no such cycles were carried out.
The ratio of single-embryo transfers also increased drastically: 51%
of treatments were single-embryo transfers in 2005 (Fig. 2).
The pregnancy rates after a single-embryo transfer also
increased notably in 1995–2005 (p < 0.001) from 10% to 24%.
The pregnancy rate after two-embryo transfers remained stable
(26%) over the study period. Pregnancy rates after two-embryo
transfers are in 2005 even better than after single-embryotreatments over the period 1994–2005.
Fig. 2. Embryo transfers according to the number of embryos over the period 1992–2005.
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Overall pregnancy rates remained stable during the study period
(1992–2005) despite the substantial increase in single-embryo
transfers (Fig. 1).
We compared success rates between the public and private
sectors by calculating the clinical pregnancy rate in 1995 and 2005.
Therewere some differences according to the cause of infertility. In
1995, the clinical pregnancy rate after all treatments was 18% in
the public sector and 22% in the private sector. In 2005, the rate
was 21% in the public sector and 23% in the private sector. Among
women less than 35 years of age, the clinical pregnancy rate was
statistically signiﬁcantly better in the private sector. Also, life-birth
rates in the private sector were slightly, but statistically
signiﬁcantly better in 2005. In Finland overall, however, care site
does not have a big inﬂuence on success rates (Table 2).
When comparing success rates between the public and private
sectors according to maternal age, it can be perceived that in 1995
clinicalpregnancyratesweresigniﬁcantlybetter foryoungerwomen
in the private sector, and 10 years later these rates in private clinics
were still somewhat better. A more important ﬁnding, however, is
that the difference in success rates according to age has diminished.
In1995, the clinical pregnancyratewas6-fold forwomenagedunder
30 years of age compared with the rate for women aged 40 or more;
in 2005, this difference was only 2.3-fold (Table 2).
3.2. Survey data
Self-reported lifetime success rates were obtained from the
FINRISK 2002 survey. The highest lifetime birth rate was forTable 1
Clinical pregnancy rates after single, two, three and four embryo transfers.
Number of cycles Clinical pregnancies % p
1995
One 656 67 10.2
Two 2707 730 27.0 0.02
Three 779 214 27.5 0.02
Four 42 11 26.2 0.05
2000
One 1803 379 21.0
Two 4099 1067 26.1 0.01
Three 327 84 25.7 0.02
Four 6 1 16.7
2005
One 3632 874 24.1
Two 3476 956 27.5 0.001
Three 19 6 31.6 0.09
Four 1 0 0women reporting ovulation problems (70%). For endometriosis the
rate was 55%, for male infertility it was 42%, for tubal failure it was
41%, and for unexplained infertility it was 40%.
When different treatment optionswere compared, the best self-
reported lifetime birth rates were achieved with hormone
treatments (59%) and with ICSI (58%). For IVF and FET, the rate
was 47% and for insemination 45% (Fig. 3).
The lifetime birth rate also differed according to age (at
interview), but this difference was not statistically signiﬁcant
(p = 0.128). The lifetime birth rate for women aged 24–29 years
was 67%, that for 30–34 years was 70%, that for 35–39 years was
47%, that for 40–45 years 56% was, that for 45–54 years was 62%,
and for women aged 55 years or more it was 60%.
4. Discussion
In this study we demonstrated that, despite a remarkable
decrease in embryos transferred per cycle, pregnancy rates
remained stable. We also found increased pregnancy rates,
especially for women aged 40 years or more. Differences in success
rates between the private and public sectors were small but
statistically signiﬁcant amongwomen less than 35 years of age. The
difference is clinically signiﬁcant, but may be because of the
different clientele. According to our study, the self-reported lifetime
birth rate was, depending on the cause of infertility, 40–70%.
In Finland, the overall clinical pregnancy rate (IVF, ICSI, and FET)
was 23% and the live birth rate 17% in 2005. These success rates are
comparable with European success rates, but poorer than success
rates reported from the United States. The aggregate clinical
pregnancy rate for all European countries in 2001 was 24% and
the live birth rate 17%. In the United States, the clinical pregnancy
rate in 2001 was 33% and the live birth rate 27% [17]. However, it is
noteworthy that inFinland theproportionof frozenembryo transfers
is almost three times greater than that in Europe or in the United
States and the success rates after FET are signiﬁcantly lower than
those after IVFor ICSI. Also, it is commonin theUnitedStates to select
embryos, conduct oocyte donation cycles, and perform genetic
diagnosis prior to implantation [17]. These proceduresmay improve
the quality of embryos transferred and thus also success rates.
These days in Finland, the general method of conducting
infertility treatments is to provide IVF or ICSI treatment and freeze
extra embryos. Subsequent cycles can thus be conducted as FET
cycles as a part of a seamless chain of care. This manner is cost
effective and also easier for the couple treated.
Thus, the role of elective single-embryo transfers has been
strongly emphasized in recent years in Finland. According to this
procedure only a single embryo is transferred and other embryos
are frozen and used in later cycles. Our data show that in 2005, in
Table 2
Clinical pregnancy rate per 100 cycles by maternal age and the cause of infertility and the outcome of pregnancies.
1995 2005
PUBLIC (%) PRIVATE (%) pa ORb (95% CI) PUBLIC (%) PRIVATE (%) pa ORb (95% CI)
Maternal age
<30 20.4 34.7 <0.001 6.1 (3.8–9.8) 24.0 30.6 0.02 2.3 (1.8–3.0)
30–34 20.3 32.3 <0.001 5.5 (3.4–8.7) 23.6 31.1 <0.01 2.3 (1.8–3.0)
34–39 20.0 24.3 0.13 4.4 (2.9–7.4) 24.1 25.1 0.70 2.0 (1.5–2.6)
40 3.3 6.9 0.16 1 12.0 14.3 0.70 1
Cause of infertility
Tubal 19.2 25.3 0.05 25.1 21.6 0.38
Other female 19.0 23.4 0.29 21.5 29.1 <0.01
Male 23.5 25.8 0.46 26.6 26.4 0.80
Multiple 17.3 22.5 0.30 23.9 25.4 0.55
Unexplained 13.3 26.7 <0.001 23.9 26.0 0.46
Outcome of pregnancy
Live birth 74.5 72.7 0.52 75.4 76.1 0.02
Spontaneous abortion (<22 gw) 19.9 23.9 0.13 20.3 20.1 <0.01
Ectopic pregnancy 4.0 2.9 0.34 3.3 2.8 <0.01
Induced abortion 0.3 0.5 0.63 0.7 1.0 <0.01
Stillbirth (22–27 gw) 1.3 0 <0.001 0.1 0 <0.01
Stillbirth (28 gw) 0 0 0 0.1 <0.01
TOTAL 17.5 21.8 <0.001 21.1 23.3 0.02
a When comparing success rates in public and private clinics.
b When comparing overall success rates (both public and private) by maternal age.
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transferred. Hence, it is remarkable that despite a signiﬁcant
decrease in embryos transferred per cycle, pregnancy rates have
remained the same for years. In fact, according to recent studies,
similar pregnancy rates can be achieved after single-embryo
transfer compared with double-embryo transfers [8,13]. In
Finland, 1587 elective single-embryo transfers were conducted
in 2006 (the most recent data at the time of writing) with high-
clinical pregnancy rates (34%) and live birth rates (26%) [18] It has
also been demonstrated that pregnancy rates peak when two
embryos are transferred and onlymultiple gestations are increased
when more than two embryos are transferred [19]. However, twin
pregnancies are also a medical problem. Despite the Finnish
method of strongly emphasizing the role of single-embryo
transfers, 10% of pregnancies after infertility treatments are twin
pregnancies, as the proportion in naturally conceived pregnancies
is only 1.2%.
Therefore, it is paradoxical that despite similar success rates, in
asmany as 32% of American and 6% of European cycles four ormore
embryos are still transferred [17]. In Finland, only sporadic three-
embryo transfers are made and four or more embryos are never
transferred. In the United States, the transfer of multiple embryos
is at least partly caused by the lack of insurance coverage for
infertility treatments: Jain et al. showed that in the United States
there was an association between state-mandated insuranceFig. 3. Self-reported lifetime birth rates according to treatments.coverage and the number of embryos transferred [20]. Thus,
despite higher pregnancy and live birth rates in the countries
conducting three- or four-embryo transfers, the modern success
rates measuring the proportion of term singletons in those
countries are quite poor.
Our data demonstrated that proportions of term singletons per
cycle and singletons weighing at least 2500 g per cycle have
increased. This increase in term singletons is noteworthy, as 57% of
IVF twins are preterm and 55% have low-birth weight [21]. The
infant mortality rate is also 5.3-fold for multiple gestations [21].
Multiple gestations also increase babies’ risk of respiratory distress
syndrome, bronchopulmonary dysplasia, intraventricular bleed-
ing, cerebral palsy, and pneumonia [22]. For women, multiple
gestations in turn increase the risk of hypertension, postpartum
bleeding, cesarean sections, and maternal mortality [8].
It is also remarkable that subfertility itself seems to have a
deleterious effect on pregnancy outcomes. It has been demon-
strated that previously subfertile women delivering singletons are
at increased risk of pre-eclampsia and antepartum bleeding
compared with controls when age and parity are assessed [23].
Moreover, singletons born after infertility treatments are at
increased risk of low-birth rate and prematurity compared with
naturally conceived babies [24].
From the IVF statistics used in this study it is not possible to
calculate cumulative success rates, as data are aggregated and no
single treatment cycle or subfertile woman can be identiﬁed. Thus,
we used the cross-sectional population survey FINRISK 2002 to
estimate the self-reported lifetime birth rate. In our study, the
lifetime birth rate was the lowest, 40%, for women suffering from
unexplained infertility and the highest, 70%, for women with
ovulation problems. Our birth rates were in line with earlier
studies, which have reported cumulative pregnancy rates ranging
from 48% to 87% [25–29].
The aggregated IVF statistics used in this study cover IVF, ICSI,
and FET treatments given in public and private clinics in Finland
1992–2005. Participation in the IVF statistics was high, up to 100%,
despite voluntary reporting. Some bias may, however, occur as the
clinics report data themselves, and, for example, there are no
generally accepted guidelines on how to deﬁne the cause of
infertility, for example. In addition, the live birth rates permaternal
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collected in 2005 for the ﬁrst time, andwewere not able to use this
in our trend comparisons. In general, however, IVF statistics are
regarded as reliable [30]. The response rate to FINRISK 2002 was
high, but it is still possible that the differences in non-participation
according to background factors may cause bias. Moreover, the
data are self-reported, which may have caused some recall or
reporting bias.
5. Conclusion
The single-embryo policy has not decreased pregnancy and
birth rates. Proportions of term singletons per initiated cycles and
singletons weighing at least 2500 g per initiated cycle have
improved over time. The higher success rate in the private sector
may be because of the different clientele.
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background: This study aimed at determining the psychiatric morbidity of women undergoing infertility treatments, before and after
treatment as compared with control women.
methods: The number of women hospitalized because of psychiatric disorders was obtained from the Hospital Discharge Register
(1969–2006) in a cohort of women who purchased drugs for in vitro fertilization, intra-cytoplasmic sperm injection or frozen embryo transfer
treatments (n ¼ 9175) in 1996–1998 in Finland and their controls (n ¼ 9175). The age- and residence-matched controls were further
adjusted in the analysis for socio-economic position and marital status.
results: Women with infertility treatments had fewer hospitalizations due to depression, psychotic disorders, personality disorders,
anxiety disorders, bipolar disorder or mania, eating disorders, adjustment disorders and alcohol or other intoxicant abuse before their treat-
ments than did controls. However, the difference was statistically signiﬁcant only for psychotic disorders [Odds ratios (OR) 0.38, 95% con-
ﬁdence intervals (CI) 0.20–0.72]. Differences in hospitalization remained similar also during the 10-year post-treatment follow-up. The
exceptions were increased risk of hospitalizations due to adjustment disorders (OR 3.43, 95% CI 1.03–11.4) and decreased risk of
alcohol or other intoxicant abuse (OR 0.44, 95% CI 0.25–0.75) among the women with infertility treatments. The infertile women who
gave birth had fewer hospitalizations for all psychiatric diagnoses than did infertile women who did not have a baby. The difference was stat-
istically signiﬁcant for anxiety disorders (OR 0.38, 95% CI 0.18–0.81), depression (OR 0.63, 95% CI 0.41–0.96) and alcohol or other intox-
icant abuse (OR 0.38, 95% CI 0.18–0.80). Hospitalizations among infertile women who did not have a baby and controls were similar, with
the exception of signiﬁcantly more hospitalizations for psychotic disorders among controls (OR 0.38, 95% CI 0.19–0.77).
conclusions: Women treated for infertility had less serious psychiatric morbidity leading to hospitalization than did the controls, both
before and after treatments, suggesting a healthy patient effect. After treatments, the risk of hospitalization due to adjustment disorders was
increased among the infertile women. Having a baby after infertility treatments was associated with fewer hospitalizations following psychia-
tric diagnosis.
Key words: assisted reproduction / epidemiology / infertility
Introduction
Infertility is a common medical and social problem that affects 10–15%
of couples in the course of their lifetime (Evers, 2002; Gnoth et al.,
2005). Grief and emotional distress are understandable and expected
responses to infertility, as it can be regarded as a loss by the couple
(Burns, 2007). Many couples have found infertility the most upsetting
experience of their lives (Guerra et al., 1998).
Even if a person with decreased fertility or infertility does not suffer
from a psychiatric disorder, some emotional distress related to
infertility itself and infertility treatments can be expected. The most
common reactions are shock, anger, guilt, marital distress, lowered
self-esteem, sexual dysfunction and social isolation (Burns, 2007).
The decision whether to start infertility treatments is also a difﬁcult
one, and it may provoke anxiety. Negative emotions and stress also
vary during the course of treatment procedures (Hammarberg et al.,
2001; Verhaak et al., 2007).
Previous studies have reported a high prevalence of depression and
anxiety disorders among women receiving infertility treatments, but
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the estimates vary widely. This can, at least partly, be explained by
variation in diagnostic criteria for the disorders, data collection
methods and differences in the backgrounds of the infertile couples
in regard of matters such as duration of childlessness or number of
prior treatments. These varied within the studies as well as between
them. At least mild depression has been reported in 12–54% of
women during infertility treatments (Newton et al., 1990; Domar
et al., 1992; Matsubayashi et al., 2001; Fassino et al., 2002; Lok
et al., 2002; Chen et al., 2004; Volgsten et al., 2008). Also, 12–23%
of women have been reported to have anxiety disorders (Newton
et al., 1990; Sbaragli et al., 2008; Volgsten et al., 2008).
Previous studies suggest that the prevalence of symptoms of
depression and anxiety disorders among women participating in infer-
tility treatments is relatively high. We wanted to study whether the
psychiatric morbidity of infertility-treatment-seeking women differs
from that of controls both before and after infertility treatments.
The impact of successful infertility treatment was also evaluated; hos-
pitalizations were compared between the infertile women who gave
birth and those who did not.
Materials and Methods
We utilized a cohort of women who had received in vitro fertilization (IVF),
intra-cytoplasmic sperm injection (ICSI) or frozen embryo transfer (FET)
treatments in 1996–1998 (n ¼ 9175) in Finland (Klemetti et al., 2005).
This IVF cohort was identiﬁed from reimbursement ﬁles for women
who had bought drugs or combinations of drugs that are speciﬁc to infer-
tility treatments and typically used at the beginning of treatments. The
cohort covers practically all women who received IVF treatments during
the chosen time period in Finland. The creation of the algorithm has
been previously described (Hemminki et al., 2003).
For the IVF cohort population, controls (n ¼ 9175) matched by age and
municipality were randomly taken from the Social Insurance Institution’s
population register including all Finnish citizens and permanent residents.
The controls were further adjusted for marital status and socio-economic
position for the analysis. The background characteristics of the women
with and without infertility treatments are presented in Table I. The
sample of women having had infertility treatments had a larger proportion
of upper-level white-collar workers and married women than the control
group did.
The hospitalization episodes of the IVF cohort and their controls were
searched for in the Hospital Discharge Register, using the personal identi-
ﬁcation code as the linkage key. This register is currently maintained by
THL (the National Institute for Health and Welfare), previously by
STAKES (the National Development and Research Centre for Welfare
and Health). It contains data on all in-patient care given (since 1969)
and all out-patient visits that involve procedures (since 1994). The
search included all hospitalizations before and after infertility treatments
from 1 January 1969 to 31 December 2006. Since 1996, diagnoses
were reported according to the ICD-10 classiﬁcation (International Classi-
ﬁcation of Diseases, 10th revision). For earlier hospitalizations, ICD-9
(1987–1995) and ICD-8 (1969–1986) were used.
For this study, all psychiatric diagnoses were identiﬁed and the main
diagnosis for each hospitalization was used. Each patient was considered
one case regardless of the number of hospitalizations recorded for the
same diagnosis. If a woman had many hospitalizations for different main
diagnoses, she was counted several times and categorized according to
each main diagnosis. The time of infertility treatments was a cut-off
point for each patient, and if she had post-treatment hospitalizations for
the same diagnoses as before treatments she was counted again for the
same diagnosis. There were 150 hospitalizations among 81 persons
whose main diagnosis was reported according to both ICD-9 and
ICD-10 for the same hospitalization where those diagnoses differed signiﬁ-
cantly. These hospitalizations were excluded from the study.
The diagnoses were divided into eight categories: psychotic disorders,
depression, bipolar disorder or mania, anxiety disorder (including also
obsessive-compulsive disorder, dissociative disorders, somatization dis-
order and other neurotic disorders), personality disorder, eating disorder,
alcohol or other intoxicant abuse and adjustment disorder. The classiﬁ-
cations are presented in Table II. The diagnoses of organic mental dis-
orders (F00–F09), mental retardation (F70–F79), disorders of
psychological development (F80–89) and behavioural or emotional dis-
orders of childhood or adolescence (F90–99) occasionally diagnosed
among controls were excluded from the study.
Among infertile women, data about births after infertility treatments
until the end of 1999 were obtained from the nationwide Medical
Birth Register covering all births in Finland, and by recording women’s
ID numbers.
.............................................................................................................................................................................................
Table I Socio-economic and marital status of IVF women and their controls (at the time of infertility treatments).
IVF women in register
study (n 5 9175), %
Control women in
register (n 5 9175), %
P-value
Socio-economic position ,0.001
Upper white-collar worker 25.3 16.3
Lower white-collar worker 48.5 45.6
Blue-collar worker 16.2 19.3
Student, self-employed, unemployed 7.9 12.3
Unknown 2.1 6.4
Marital status ,0.001
Married 69.4 45.3
Unmarried 22.3 32.7
Divorced 7.9 8.9
Widow 0.4 0
Unknown 0 13
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The statistical comparisons were made by using logistic regressions and
conditional logistic regressions. Odds ratios (OR) were calculated with
95% conﬁdence intervals (CI). We adjusted the number of hospitalizations
for psychiatric diagnoses for the women’s marital status and socio-
economic position at the time of the infertility treatments.
Results
Before infertility treatments, the most common psychiatric disorders
among infertile women were depression and alcohol and other intox-
icant abuse (Table III). Among the controls, the most common diag-
noses were depression and psychotic disorders. The women in the
control group had signiﬁcantly more hospitalizations for psychiatric dis-
orders than the women with infertility treatments. The greatest differ-
ence was found for the prevalence of psychotic disorders (OR 0.38,
95% CI 0.20–0.72). The control population also had more
depression, personality disorders, bipolar disorder or mania, anxiety
disorders and alcohol and other intoxicant abuse, but these differ-
ences were statistically insigniﬁcant after adjustment for socio-
economic position and marital status. The prevalence of adjustment
and eating disorders was similar.
The main ﬁnding was also similar after the treatments (Table III), but
the difference with regard to alcohol and intoxicant abuse was now
statistically signiﬁcant (OR 0.44, 95% CI 0.25–0.75). Adjustment dis-
orders, in turn, were statistically signiﬁcantly more common among
infertile women (OR 3.43, 95% CI 1.03–11.4).
The infertile women who gave birth after infertility treatments had
fewer hospitalizations for all diagnoses than did those infertile women
who did not have a baby (Table IV). The number of hospitalizations
among infertile women without a baby after the treatment and non-
treated controls did not differ signiﬁcantly for any diagnosis with the
exception of psychotic disorders. Infertile women had fewer hospital-
izations due to psychotic disorders when compared with control
women.
.............................................................................................................................................................................................
Table II Classiﬁcation of the diagnoses in different categories (ICD-8, ICD-9, ICD-10).
Category ICD-8 ICD-9 ICD-10
Alcohol or
intoxicant abuse
291.00, 291.10, 291.20, 291.30, 291.98, 291.99, 294.30,
303.00, 303.10, 303.20, 303.98, 303.99, 304.00, 304.10,
304.20, 304.30, 304.40, 304.50, 304.60, 304.70, 304.88,
304.99
2913, 2914, 2918, 2928, 303, 3039, 3040, 3041, 3042,
3043, 3044, 3045, 3046, 3049, 3050, 3051, 3052, 3053,
3054, 3055, 3056, 3057, 3059
F10–19
Psychotic
disorders
295.00–295.99, 297.00, 297.10, 297.98, 299.99, 2951–2959, 297, 298 F20–29
Bipolar disorder
and mania
296.10, 296.20, 296.30, 296.88, 296.99 2962, 2960, 2964, 2967, F30–F31
Depression 296.00, 300.40, 300.41 2961, 2963, 3004, 2968 F32–F39
Anxiety disorders 300.10, 300.20, 300.30, 300.50, 300.60, 300.70, 300.88, 300,
99
3002, 3003, 3007, 3008, 3009 F40–42, F44,
F45, F48
Adjustment
disorders
307.99 309 F43
Eating disorders 3071, 3075 F50
Personality
disorders
301.00, 301.10, 301.20, 301.30, 301.40, 301.50, 301.60,
301.70, 301.80, 301.88, 301.99
3010, 3011, 3012, 3014, 3015, 3016, 3017, 3018, F60–62
................................................................... ...................................................................
.............................................................................................................................................................................................
Table III Number of hospitalizations for psychiatric diagnoses before and after treatments among 9175 women receiving
infertility treatments and 9175 age- and residence-matched controls, with OR (95% CI) adjusted for marital status and
socio-economic position.
Before treatments (1969–1996/8) After treatments (1996/8–2006)
IVF Controls OR CI (95%) IVF Controls OR CI (95%)
Anxiety disorders 26 37 0.70 0.33–1.48 39 55 0.68 0.40–1.55
Depression 63 106 0.73 0.49–1.10 101 121 0.84 0.64–1.16
Bipolar disorder or mania 11 17 1.02 0.26–4.0 20 29 0.75 0.34–1.63
Psychotic disorders 33 94 0.38 0.20–0.72 33 106 0.45 0.28–0.73
Personality disorders 30 63 0.57 0.30–1.04 15 36 0.73 0.31–1.71
Alcohol and other intoxicants 36 65 0.81 0.47–1.41 41 86 0.44 0.25–0.75
Eating disorders 8 10 3.28 0.23–46 4 4 1.0
Adjustment disorders 27 29 1.04 0.52–2.10 20 16 3.43 1.03–11.4
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The number of hospitalizations for adjustment disorders did not
differ in comparison of the formerly infertile women who delivered
multiples to other infertile women (OR 1.12, 95% CI 0.26–4.88).
Discussion
In this study, we found that women receiving infertility treatments had
less psychiatric morbidity leading to hospitalizations than their control
group after matching and adjustment for age, municipality, socio-
economic position and marital status. The results were similar
before and after they entered infertility treatments with the exception
of signiﬁcantly more adjustment disorders arising among the women
with infertility treatments after their treatments. The infertile
women who gave birth after treatments had fewer hospitalizations
for all psychiatric diagnoses than those infertile women who did not.
Furthermore, infertile women not having a baby after the treatment
had fewer hospitalizations than control women did.
We used a cohort of women who had purchased infertility drugs
that are not used for other purposes in these combinations. There-
fore, this cohort very probably includes all Finnish women who
entered IVF, ICSI or FET treatment in 1996–1998. The number of
cases in 1996–1998 was as high as 9175, and, therefore, the
number of women with psychiatric diagnoses was also signiﬁcant.
A limitation of our study was that only severe psychiatric morbidity
was captured, because hospitalization due to the disorder was
required. Many milder cases that are treated in out-patient care
with, for example, medication and/or psychotherapy are therefore
not included in this study. Even though our study underestimates
the incidence of psychiatric disorders, there is no reason to
presume that different proportions of disorders among infertile
women and the controls would be treated differently in terms of
in-patient and out-patient care. This is, therefore, unlikely to cause
any bias due to a difference between the groups.
Probably our results of fewer psychiatric hospitalizations among the
women with infertility treatments can at least partly be explained by
the healthy patient effect. Women planning pregnancy tend to be
physically and mentally quite healthy. The desired number of children
among women with severe psychiatric disorders may be smaller, or
they may be more reluctant to start infertility treatments. The back-
ground information for our subjects supports this, as women partici-
pating in infertility treatments were more often married and
upper-level white-collar workers. In the analysis, we adjusted for
marital status and socio-economic position, but some residual con-
founding may have remained. The healthy patient effect has also
been reported for mortality of IVF patients (Venn et al., 2001).
Our study population consists of those infertile women who sought
medical help. It is possible that these women differ from those infertile
women who do not participate in infertility treatments. A study by
Hammarberg et al. (2001) showed that it may be difﬁcult to make
the decision to start infertility treatments and it is possible that
some infertile women suffering from psychiatric disorders do not
have sufﬁcient strength to make that decision.
In our study, the largest difference in prevalence between the infer-
tile women and the controls was observed for psychotic disorders,
which were three times more prevalent among the control group.
The women with the psychotic disorders have lower fertility than con-
trols do (McGrath et al., 1999; Howard et al., 2002; Howard, 2005;
MacCabe et al., 2009), but this difference has diminished over the
years (Howard, 2005) as a greater proportion of schizophrenia
patients are treated on an out-patient basis. It is not known
whether nulliparous women with schizophrenia do not want to have
children or are actually infertile. Furthermore, it is possible that
women with psychotic disorders willing to get pregnant have to face
more prejudice than other women and they need justify more to
other people that they ‘are allowed’ to get pregnant or to participate
in infertility treatments. Infertility among patients with psychotic dis-
orders may also be elevated, as many neuroleptics cause hyperprolac-
tinaemia and impair ovulation (Dickson et al., 2005).
Mood disorders and fertility are linked to each other in many ways.
A review article by Williams et al. (2007) concludes that women with
.............................................................................................................................................................................................
Table IV Number and proportion of women with hospitalization for psychiatric diagnoses after treatments among
women with infertility treatments with and without births during the study period and non-treated controls (matched for
age and residence), with OR (95% CI), adjusted for age, marital status and socio-economic position.
Infertile women
with births n (%)
Infertile women
without births n (%)
Controls n
(%)
Infertile women with and
without births: OR (95% CI)
Infertile women without births
and controls: OR (95% CI)
Anxiety disorders 9 (0.2) 30 (0.6) 29 (0.6) 0.38 (0.18–0.81) 0.87 (0.45–1.69)
Depression 33 (0.8) 68 (1.4) 57 (1.3) 0.63 (0.41–0.96) 1.22 (0.79–1.89)
Bipolar disorder
or mania
8 (0.2) 12 (0.2) 13 (0.3) 0.90 (0.36–2.25) 0.85 (0.29–2.54)
Psychotic
disorders
13 (0.3) 20 (0.4) 57 (1.2) 0.88 (0.42–1.80) 0.38 (0.19–0.77)
Personality
disorders
5 (0.1) 10 (0.2) 14 (0.4) 0.56 (0.19–1.68) 1.80 (0.35–9.20)
Alcohol and other
intoxicants
9 (0.2) 32 (0.6) 43 (0.9) 0.38 (0.18–0.80) 0.80 (0.40–1.60)
Eating disorders 1 (0) 3 (0.1) 3 (0) 0.30 (0.03–2.92) 1.00
Adjustment
disorders
8 (0.2) 12 (0.2) 9 (0.2) 0.82 (0.33–2.05) 1.01 (0.20–5.09)
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mood disorders had a lower observed number of children as com-
pared with the expected number. However, it cannot be distinguished
whether this is due to infertility, voluntary childlessness or social
factors such as lack of a sexual relationship. With respect to the last
of these, study by Harlow et al. (2003) suggests that depressive
women have an increased risk of divorce and widowhood.
Biological and pharmacological interactions between mood dis-
orders and fertility have also been studied (Williams et al., 2007).
According to two studies, women suffering from bipolar disorder
may have menstrual problems even before use of mood stabilizers
(Rasgon et al., 2005; Joffe et al., 2006). For unipolar depression, the
evidence is inconsistent (Rowland et al., 2002; Harlow et al., 2004;
Joffe et al., 2006). However, the use of selective serotonin re-uptake
inhibitors may potentially inﬂuence fertility, as the medication can
decrease libido and increase the risk of spontaneous miscarriages
(Williams et al., 2007).
Due to this complex interaction, infertility could be more actively
taken into consideration when treating patients with psychiatric pro-
blems. Infertility clinics in turn should pay more attention to previous
history of psychiatric disorders among their patients and provide more
intense support during infertility treatments.
According to our study, adjustment disorders were equally
common among infertile women and controls before treatments
but more common among infertile women after treatments. This
disorder evolves typically in response to stress and grief and is
therefore understandable among infertile females. The larger
numbers of hospitalizations due to adjustment disorders after
infertility treatments could be explained as a result of unsuccessful
treatment, or more stressful child-care, as the number of multiple
births after infertility treatments is elevated. Our results support
the impact of unsuccessful treatments but not that of twins
causing extra stress.
As infertility and participation in infertility treatments often cause
stress and negative emotions, it would be expected that the
outcome of treatments affects the mental health of infertile women.
In a study by Hammarberg et al. (2001), psychological symptoms
among infertile women did not differ by outcome of treatments.
However, in a study by Klemetti et al. (2010), risk of psychiatric dis-
orders was not increased among formerly infertile women with a
child, even though infertile women without a child had an increased
risk of anxiety disorders and dysthymia. Also Verhaak et al. (2007)
reported in their study that infertile women who gave birth had signiﬁ-
cantly less anxiety and depression. In our study, risk of hospitalizations
for psychiatric disorders was higher among those infertile women who
did not give birth than among those who did. Thus, our data suggest
that unsuccessful treatments seem to expose women to psychiatric
disorders whereas formerly infertile women with a child had fewer
hospitalizations.
Conclusions
Women receiving IVF treatments had lower psychiatric morbidity
leading to hospitalization than did women in a control group of
similar age and municipality after socio-economic and marital status
are taken into account. Having a baby after infertility treatments was
associated with fewer hospitalizations for psychiatric diagnosis.
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Abstract 
Background: Results of earlier studies on cancer risk in infertile women are inconsistent for many 
cancer types. Our goal was to study cancer incidence among a cohort of women treated with in vitro 
fertilization (IVF), including intra cytoplasmic sperm injection (ICSI) and frozen embryo transfer 
(FET), compared to that of a control population. 
Methods: A cohort of women who purchased drugs for IVF (including ICSI and FET treatments, 
N=9,175) in the period 1996-1998 in Finland (later called IVF women) and their age and residence 
matched controls, further adjusted for socio-economic position and marital status, were linked to the 
Finnish Cancer Registry 1996-2004.  
Results: The overall cancer incidence and combined incidence of hormonal related breast, uterine 
and invasive ovarian cancers were similar among IVF women and controls. IVF women had 
statistically significantly less cervical cancer (OR 0.51, 95% CI 0.30-0.85), but more skin cancers 
other than melanoma (OR 3.11, 95% 1.02-9.6). IVF women had three times more invasive ovarian 
cancers than controls, but this difference was not statistically significant, possibly due to the small 
number of cases. IVF women had slightly fewer breast cancers but difference was likewise not 
statistically significant.  All cases of pulmonary cancer were diagnosed among controls (p=0.03).  
Conclusions: General cancer risk or risk of hormonal related cancers in IVF women was not 
increased. The differences in certain cancers suggest a healthy patient effect or may be partly 
caused by residual socio-economic differences. More large studies and re-analysis of existing 
studies are needed to evaluate cancer risk among infertile women by sub-groups regarding the cause 
of infertility. When evaluating risk of cancer after drug exposure dosage and the use of different 
medicaments should be taken into consideration. 
 
Key words: infertility, infertility treatments, cancer incidence 
 
 
Introduction 
 
Many gynaecological diseases such as polycystic ovaries syndrome or endometriosis cause 
significant changes in the body’s hormonal or inflammatory balance. These imbalances may 
predispose to fertility problems but could potentially also promote cancer development (Klip et al. 
2000). During hormonal infertility treatments exogenous drugs affecting the hormonal system are 
administered. The risk of cancer among infertile women has been explored in many studies but for 
many cancer types the results are inconsistent and partly contradictory. Much of this is caused by 
methodological weaknesses including too small number of cases weakening the statistical power. 
 
According to three cohort studies the overall cancer incidence among infertile women compared to 
general population was slightly increased. Modan et al. (1998) studied a cohort of 2,496 infertile 
women and reported a standardized incidence ratio (SIR) of 1.20 (95% CI 1.0-1.5) for all cancers. 
In a large Danish cohort study among 54,362 infertile women parity-specific SIR for all cancers 
was 1.04 (95% CI 1.00-1.09) (Jensen et al. 2008) and in an American study among 12,193 infertile 
women SIR was 1.23 (95% CI 1.1-1.3) (Brinton et al. 2005). However, in other cohort studies 
(population size 1,082-5,556 women) the cancer incidence did not differ significantly (Doyle et al. 
2002) (Dor et al. 2002) (Lerner-Geva et al. 2003). 
 
Most studies exploring the risk of cancer in infertile women have focused in hormonal related 
gynaecological and breast cancers. Twenty years ago American researchers combined data from 
several case-control studies and reported that a risk for the borderline tumours of the ovary was 
increased among infertile women and that invasive ovarian cancers were more common among 
women who had taken fertility drugs (Harris et al. 1992, Whittemore et al. 1992). Increased risk for 
borderline tumours of the ovary among infertile women has also been reported in two other studies: 
a cohort study by Rossing et al. (1994), SIR 3.3 (95% CI 1.1-7.8), and a case-control study by 
Shushan et al. (1996) adjusted OR 9,38 (95% CI 1.66-52.08). The results for invasive ovarian 
cancer are inconsistent. Seven earlier cohort studies (population sizes 2,496-29,700) did not report 
elevated risk among infertile women compared to general population (Rossing et al. 1994,Venn et 
al. 1995, Shushan et al. 1996, Parazzini et al. 1997, Modan et al. 1998, Venn et al. 1999, Doyle et 
al. 2002) but two cohort studies (population sizes 12,193 and 54,362) reported statistically 
significantly elevated SIR: Brinton et al. (2004) SIR 1.98 (95% CI 1.4-2.6) and Jensen et al. (2008) 
SIR 1.46 (95% CI 1.24- 1.71). In a case-control study by Mosgaard et al. (1997) SIR 2.7 (95% CI 
1.3-5.5) and in a survey by Tworoger et al. (2007) SIR 1.36 (95% CI 1.07-1.75) was reported.  
 
According to eight studies the risk of breast cancer among infertile women compared to that of 
general population was not significantly increased (Venn et al. 1995, Braga et al. 1996,  Modan et 
al. 1998, Venn et al. 1999, Ricci et al. 1999, Dor et al. 2002, Doyle et al. 2002, Pappo et al. 2008). 
The population size of the cohort studies varied between 2,469 and 10,358 women and in the case-
control studies 2,569-3,415 cases. However, in a cohort study by Brinton et al. (2004) exploring the 
risk among 12,193 infertile women SIR was 1.29 (95% CI 1.1-1.4) and in a study among 54,362 
infertile women SIR 1.08 (95% CI 1.01-1.16) was reported (Jensen et al. 2008).   
 
The risk for uterine cancer among infertile women also varies according to different studies. Three 
cohort studies reported statistically significantly increased risk (Venn et al. 1995, Modan et al. 
1998, dos Santos Silva et al. 2009). In addition, according to two studies the risk was increased 
among females with unexplained infertility (Venn et al. 1995, Venn et al. 1999). However not all 
studies have reported elevated risk. According to two case-control studies (Benshushan et al. 2001, 
Brinton et al. 2007) and three cohort studies (Venn et al. 1999, Doyle et al. 2002, Jensen et al. 2008) 
the risk for uterine cancer did not differ statistically significantly from that of general population. 
 
Cancer risk related to use of infertility drugs has also been studied. According to a study by Doyle 
et al. (2002) the use of infertility drugs did not increase the overall cancer risk compared to the non-
exposed infertile women. However, in a cohort study by Calderon-Margalit et al. (2009) among 
15,030 women the hazard ratio of all cancers among parous women treated with infertility drugs 
compared to other parous women was significantly increased (HR 1.36, 95% CI 1.06-1.74).  
 
According to a cohort study by Calderon-Margalit et al. (2009) the risk for uterine cancer after 
infertility drug use compared to other parous women was increased. A study by Jensen et al. (2008) 
reported elevated risk after exposure for gonadotrophins and more than six cycles of clomiphene 
citrate even though the risk after any infertility drug use was not elevated. In cohort studies by Venn 
et al. (1999), Doyle et al. (2002), Althuis et al. (2009) and dos Santos Silva et al. (2009), however, 
uterine cancer risk after infertility drug use was not increased. 
 
Previous studies exploring the risk of cancer after infertility drug use have suggested that the 
general risk for breast cancer compared to either general population or other un-treated infertile 
women is not statistically significantly increased (Venn et al. 1995, Rossing et al. 1996, Potashnik 
et al. 1999, Ricci et al. 1999 Venn et al. 1999, Doyle et al. 2002, Burkman et al. 2003, Brinton et al. 
2004 Gauthier et al. 2004, Calderon-Margalit et al. 2009, dos Santos Silva et al. 2009). The general  
risk of invasive ovarian cancer after infertility drug exposure is likewise not increased (Venn et al. 
1995, Mosgaard et al. 1997, Parazzini et al. 1997, Modan et al. 1998, Venn et al. 1999, Parazzini et 
al. 2001, Doyle et al. 2002, Ness et al. 2002, Brinton et al. 2004, Calderon-Margalit et al. 2009, 
Sanner et al. 2009, Jensen et al. 2009, dos Santos Silva et al. 2009). Studies by Ness et al. (2002) 
and Sanner et al. (2009), however, reported statistically significantly elevated risk for borderline 
tumours of the ovary, SIR 2.43 (95% CI 1.01-5.80) and SIR 3.61 (95% CI 1.45-7.44), respectively. 
A few studies also suggests, that the risk for breast or invasive ovarian cancers may be elevated 
after certain drug exposure (Lerner-Geva et al. 2006, Jensen et al. 2007, Sanner et al. 2009).  
 
In this study we compared cancer risk among women receiving IVF treatments to that of control 
women drawn from the general population. We studied cancer risk in general and separately for 
different cancer types. 
 
Materials and methods 
 
As the exposed population we used a cohort of women who received in vitro fertilization (IVF, also 
including intra cytoplasmic sperm injection ICSI and frozen embryo transfer FET) treatments 1996-
1998 in Finland (N=9175). In this study these women are called IVF women. The creation of this 
cohort has been described earlier (Hemminki et al. 2003). In brief, the women were identified from 
the reimbursements for drugs or drug combinations that are specific to these infertility treatments. 
Each woman having received one of these treatments was recorded once in the cohort regardless the 
number of drug purchases 1996-1998. It has previously been estimated that the cohort covers 
practically all Finnish women who received IVF, ICSI or FET treatments 1996-1998 (Klemetti et al. 
2005).  
 
The control women were randomly picked from the Population Register maintained by the Social 
Insurance Institution and matched by age and municipality. The information on marital status and 
socio-economic position at the beginning of the study period was collected from the Central 
Population Register. In this national register socio-economic position is self-reported and based on 
occupation. It was further classified into four categories in the National Research and Development 
Centre for Welfare Health (currently National Institution for Health and Welfare): upper white-
collar worker, lower white-collar worker, blue-collar worker and other. For women temporarily at 
home, e.g. on maternity leave, socio-economic position is based on their occupation before the 
leave. Housewives who are permanently at home are included to the class "Other". The socio-
economic position and marital status varied between the groups (Table 1) and thus for the analysis 
we further adjusted women for these determinants.  
 
In order to identify cancer cases, IVF women and their controls were linked to the Finnish Cancer 
Registry. This is a nationwide registry that collects information on all cancers and cancer deaths. 
The coverage of the registry is considered very good: according to an earlier study, it records 99% 
of solid tumours (Teppo et al. 1994). We collected all cancer cases reported among the IVF women 
and controls from 1996 to 2004. Cancers diagnosed before IVF treatments were excluded, for the 
controls, the beginning of IVF treatments of the matched IVF woman was used. 
 
The cancer cases were divided into 12 categories (ICD-10 code in brackets): breast cancer (C50); 
invasive ovarian cancer (C56); borderline tumours of the ovary (C56) cervical (C53); uterine (C54); 
thyroid (C73); pulmonary cancer (C34); melanoma (C43); other skin cancers (C44); tumours of 
central nervous system (C70, C71, C72); leukaemia and lymphoma (C81-C96) and gastrointestinal 
track tumours, including duodenal (C17.0), jejunal (C17.1), ileal (C17.2), colon (C18), splenic 
(C26), pancreatic (C25) and hepatic cancers (C22), tumours in the gallbladder (C23) or bile ducts 
(C22.1). Invasive ovarian cancers and borderline tumours of the ovary were grouped depending on 
the malignancy rate also recorded in the Cancer Registry. Rare cases of other tumours (less than 
three cases per cancer type) were included in the total number of cases, but not reported separately. 
The cancer incidences were calculated first starting from the last IVF treatment (covering the whole 
follow-up time) and secondly starting from twelve months after the last recorded IVF treatment 
(Table 2). There were 11 women who had two cancers registered. Three of them had the same 
cancer type twice and these cases were calculated in the analysis only once. Eight women had two 
independent cancers and these 16 cancers were included twice in the analysis by cancer type, but 
only once in the total number of women with cancer. The follow-up time was until 31 December 
2004, on average seven years and nine months. 
 
During the data collection IVF women and their controls were matched for age and residence. In the 
present study odds ratios with 95% confidence intervals for given cancer type between the two 
groups were calculated with conditional logistic regression analysis after adjustment for socio-
economic position and marital status. If no cancers were observed for some diagnosis among either 
IVF women or controls, Fisher's exact test was used. Χ2 test (in the case of breast cancers) and 
Fisher's exact test (in the case of invasive ovarian cancers and uterine cancers) were used to 
compare possible differences in occurrence time for a cancer after infertility treatments among IVF 
women and controls. 
 
Results 
 
Background characteristics of IVF women and controls are given in Table 1. A larger proportion of 
IVF women were married and upper white-collar workers. Differences with respect to both marital 
status and socio-economic position between the groups were statistically significant and adjustment 
for these factors was done for the analysis. 
 
The total cancer incidence was slightly but statistically insignificantly greater among the control 
women: among IVF women 178 and among the controls 193 cancer cases were reported after 
infertility treatments by the end of 2004. The combined incidences of hormonal related cancers 
(breast cancer, invasive ovarian cancer and uterine cancer) did not differ between the groups.  
 
Cumulative incidences for hormonal related cancers among IVF women and controls are presented 
in Figure 1. Among IVF women five breast cancers were diagnosed within the first year after 
receiving infertility treatments compared to two cases among the controls. Thereafter breast cancer 
incidence between the groups did not differ significantly (p=0.09). For uterine cancer and invasive 
ovarian cancer, too, the differences in time of occurrence were not statistically significant (p=0.467 
and p=0.705 respectively). 
 
As expected, most cancer cases in both groups were diagnosed among women aged 35 years or 
more. Among the IVF women this share was 80.9% and among the controls 76.7%. The difference 
was not statistically significant (p=0.322).  
 
Among IVF women the most common cancers reported after infertility treatments were breast 
cancers (55 cases), cervical cancers (34 cases) and skin cancers other than melanoma (24 cases). 
The most common cancer types among controls were in turn cervical cancers (67 cases), breast 
cancers (60 cases) and skin cancers other than melanoma and gastrointestinal track tumours (10 
cases).  
 
After adjusting for socio-economic position and marital status the differences between IVF and the 
control women with respect to the incidences of most cancer types were statistically insignificant 
(Table 2). However, IVF women had statistically significantly less cervical cancer (OR 0.51, 95% 
CI 0.30-0.85), but more skin cancers other than melanoma (OR 3.11, 95% 1.02-9.6). IVF women 
also had three times more invasive ovarian cancers (9 cases) than the controls (3 cases), but the 
difference was not statistically significant. The incidence of borderline tumours of the ovary was 
similar in the groups. All pulmonary cancers (n= 5) occurred among the control women. This 
difference was statistically significant, p=0.03 (calculated with Fisher’s exact test), but this 
comparison was unadjusted and unmatched due to the small number of cases. 
 
In order to reduce the risk of recording cancers that were already developing when infertility 
treatments were provided, we also studied the number of cancers diagnosed 12 months or more after 
infertility treatments. The differences in cancer incidences between the groups remained unchanged. 
(Table 2). 
 
 
Discussion 
 
According to our study the general cancer incidence or combined incidence of hormonal related  
cancers among the Finnish women treated with IVF (including ICSI and FET) in the period 1996-
1998 did not differ significantly from that among the control population which was matched for age 
and municipality and further adjusted for marital status and socio-economic position. The incidence 
of invasive ovarian cancer was three times greater among IVF women than controls but the case 
number was low which may explain why the difference was statistically insignificant.  
 
IVF women in our study had statistically significantly fewer cervical and pulmonary cancers, but 
more skin cancers other than melanoma. The difference in cervical, skin and pulmonary cancer is 
likely to be explained by the healthy patient effect as women desiring pregnancy tend to be 
relatively healthy. The same effect was also found in another study reporting lower mortality among 
infertile patients (Venn et al. 2001) and in our earlier study according to which IVF women had a 
smaller number of hospitalizations for psychiatric disorders than controls (Yli-Kuha et al. 2010).  
 
A lower insidence of cervical cancer among infertile women attending to infertility clinics has also 
been reported in other studies (Doyle et al. 2002) (Jensen et al. 2008) (dos Santos Silva et al. 2009). 
The incidence of cervical cancer depends on sexual behaviour, and it is possible that infertile 
women or their partners engaged in different sexual behaviour from the control women. 
Furthermore, this difference could be explained by surveillance bias, as it is likely that IVF women 
are used to visiting their gynaecologists regularly and thus more papanicolaou smears are taken, 
which enables earlier treatment of suspicious cell atypia. 
 
It is possible that the greater number of skin cancers diagnosed among IVF women is partly 
explained by the differences in socioeconomic position between the groups even though adjustment 
for this was made. The composition of the class "Other" is likely to be different between IVF 
women and controls which may cause some bias. Also, the share of women in class "unknown" is 
different. Skin cancers are more common among highly educated people (Hemminki & Li 2004) at 
least partly because of more intense exposure to solarium and more frequent holidays. It is also 
possible that IVF women may react to their suspicious moles more vigilantly as they are used to 
monitoring their health. 
 
The probability of smoking is likely to be different between the two groups explaining differences 
in pulmonary cancer incidence. Smoking is significantly more common among people from lower 
than from higher socioeconomic position in Finland (Katainen, 2010). However, for the analysis we 
adjusted for social class. It is also likely that many smokers stop smoking when trying to get 
pregnant or at least when discovering their infertility as smoking may impair fertility. 
 
A strength of our study was the large cohort of 9,175 IVF women and their controls. Because of the 
size of the study population, a significant number of cancer cases occured even during this 
relatively short follow-up time of on average seven years and nine months. The cohort is also 
representative as it is estimated that virtually all Finnish women treated by IVF 1996-1998 are 
included in this cohort (Klemetti et al. 2005). A weakness of this study is that the control group 
consisted of women from general population. 
 
There are also important risk factors that could not be adjusted for in the analysis. Parity between 
groups is likely to be different as the control women probably had more children than IVF women. 
Low parity is a risk factor, for example, for ovarian cancer (Risch 1998) (Riman et al. 2002) 
(Sueblinvong & Carney 2009), breast cancer (Butt et al. 2009) (Kawai et al. 2009) and uterine 
cancer (Parazzini et al. 1998) (Salazar-Martinez et al. 1999) (Reis et al. 2009). On the other hand 
the group of control women may include infertile women not having received these treatments 
1996-1998. Other risk factors not adjusted for are use of oral contraceptives or other hormonal 
treatments, smoking, obesity, and possible genetic predisposition, for which no register-based 
information is available in Finland. 
 
The possibly increased cancer risk among infertile women or after infertility drug exposure has 
been evaluated in several studies with partly inconsistent results. Some of this difference may be 
explained through methodological weaknesses such as too small study material or too short follow-
up time. It is, however, possible that study settings analysing infertile women as a one group cannot 
reliably determine this risk. From a theoretical point of view it is likely that different conditions 
causing impaired fertility have different risk potential for given cancers. For example, earlier 
studies suggest that women with polycystic ovaries syndrome may have increased risk for uterine 
cancer (Goodarzi et al. 2011) and women with endometriosis for ovarian cancer (Kobayashi et al. 
2011). The proportion of women treated for male infertility or suffering from tubal infertility caused 
by untreated Chlamydia trachomatis infection, thus probably not having increased cancer risk 
caused by infertility, may also vary significantly between different studies.  
 
In future it would be reasonable to reanalyse existing data and in future studies collect a large 
number of study subjects enabling analysis in sub-groups depending on the cause of infertility. 
When evaluating if infertility drugs affect cancer risk infertile non-treated women with the same 
cause of impaired fertility should be used as controls. It would also be important to analyse drug 
exposure separately for each drug used, also taking into consideration dosage and number of 
treatment cycles with the given drug. Because cancer development also typically takes several 
years, follow-up time should be long enough. This would also take into consideration the possibility 
that infertility drugs could enhance the growth of already existing tumours as during long follow-up 
the possible differences in time of occurrence of cancers between the groups would be levelled off. 
 
Conclusions: According to this study the risk of cancer among women undergoing IVF, ICSI or 
FET was not increased. Earlier studies report partly contradictory results in the evaluation of cancer 
risk. In future it will be important to reanalyse existing data and collect large study populations 
thereby also enabling analysis among sub-groups with different causes of infertility. The exposure 
and dosage of different drugs should also be taken in to consideration in the analysis when assessing 
if infertility drugs affect cancer risk. 
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Table 1. Age, marital status  and socio-economic position of IVF women (N=9175) and controls 
(N=9175) at the time of infertility treatments (1996-1998) 
 IVF women % Control women % 
Age   
20-24 3.5 3.5 
25-29 20.8 20.8 
30-34 35.2 35.2 
35-39 27.2 27.2 
40-44 10.8 10.8 
45 or more 
 
2.0 2.0 
Marital status 1   
Married 69.4 45.3 
Unmarried 22.3 32.7 
Divorced 7.9 8.9 
Widow 0.4 0.0 
Unknown 
 
0.0 13.0 
Socio-economic position 1   
Upper white-collar worker 25.3 16.3 
Lower white-collar worker 48.5 45.6 
Blue-collar worker 16.2 19.3 
Other 2 
Unknown 
7.9 
2.1 
12.3 
 6.4 
 
1 p < 0.001 
2(Student, entrepreneur, housewife, unemployed) 
 
 
 
 
 
 
Figure 1. Cumulative number of breast cancers, uterine cancers and invasive ovarian cancers 
among IVF women and controls by the time (years) after infertility treatments. 
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Table 2. Cancer cases of IVF women and controls (matched for age and residence) after infertility treatments and one or more years
after treatments: odds ratios (95% confidence intervals) are adjusted for marital status and socio-economic position.
After infertility treatments One or more years after infertility treatments
IVF women
(N=9175)
Control women
(N=9175)
OR CI) IVF women
(N=9175)
Control women
(N=9175)
OR (95% CI)
Any cancer 178 193 1.01 (0.80-1.27) 166 174 1.01 (0.80-1.29)
Breast cancer 55 60 0.93 (0.62-1.40) 50 58 0.86 (0.57-1.30)
Invasive ovarian
cancer
9 3 2.57 (0.69-9.63) 8 3 2.25 (0.59-8.68)
Borderline
tumours of the
ovary
4 4 1.68 (0.31-9.27) 4 3 2.25 (0.59-8.68)
Cervical cancer 34 67 0.51 (0.30-0.85) 32 59 0.54 (0.32-0.91)
Uterine cancer 4 2 2.0 (0.37-10.9)1 4 1 NC2
Pulmonary cancer 0 5 NC2 0 5 NC2
Thyroid cancer 10 8 1.27 (0.31-5.2) 10 7 1.79 (0.38-8.48)
Melanoma 12 9 1.27 (0.34-4.8) 11 6 0.67 (0.11-3.99)
Other skin cancer 24 10 3.11 (1.02-9.6) 23 10 3.20 (1.04-9.87)
Tumours in
central nervous
system
9 7 9.4 (0.56-159.5) 8 7 7.14 (0.69-74.3)
Gastrointestinal
track tumours
12 10 1.88 (0.52-6.8) 11 9 3.9 (0.38-39.8)
Leukaemia or
lymphoma
4 5 0.34 (0.04-3.06) 4 4 0.38 (0.04-3.56)1
1Crude Odds Ratio due to small case number
2Non Calculable
